<SEC-DOCUMENT>0001104659-25-100854.txt : 20251020
<SEC-HEADER>0001104659-25-100854.hdr.sgml : 20251020
<ACCEPTANCE-DATETIME>20251020163118
ACCESSION NUMBER:		0001104659-25-100854
CONFORMED SUBMISSION TYPE:	S-1
PUBLIC DOCUMENT COUNT:		17
FILED AS OF DATE:		20251020
DATE AS OF CHANGE:		20251020

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cellectar Biosciences, Inc.
		CENTRAL INDEX KEY:			0001279704
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				043321804
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-290971
		FILM NUMBER:		251404277

	BUSINESS ADDRESS:	
		STREET 1:		100 CAMPUS DRIVE
		CITY:			FLORHAM PARK
		STATE:			NJ
		ZIP:			07932
		BUSINESS PHONE:		(608) 441-8120

	MAIL ADDRESS:	
		STREET 1:		100 CAMPUS DRIVE
		CITY:			FLORHAM PARK
		STATE:			NJ
		ZIP:			07932

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVELOS THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20050617

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	COMMON HORIZONS INC
		DATE OF NAME CHANGE:	20040211
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1
<SEQUENCE>1
<FILENAME>tm2529020d1_s1.htm
<DESCRIPTION>FORM S-1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>As filed with the Securities and Exchange Commission
on October 20, 2025</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration No.&nbsp;333-</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="border-top: Black 2pt solid; font-size: 1pt; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 3pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM&nbsp;S-1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OF 1933</B></P>

<P STYLE="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CELLECTAR BIOSCIENCES,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</P>

<P STYLE="font: 3pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2834</B></FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>04-3321804</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction of incorporation<BR>
or organization)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Primary Standard Industrial Classification<BR>
Code Number)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S. Employer Identification No.)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 3pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>



<P STYLE="font: 3pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>100 Campus Drive, Florham Park, New Jersey
07932</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Telephone (608) 441-8120</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address, including zip code and telephone number,
including area code, of registrant&rsquo;s principal executive offices)</P>



<P STYLE="font: 3pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 3pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>James
V. Caruso</B></FONT><B><BR>
President and Chief Executive Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Cellectar Biosciences,&nbsp;Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>100 Campus Drive, Florham Park, New Jersey
07932</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Telephone (608) 441-8120</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Name, address, including zip code and telephone
number, including area code, of agent for service)</P>

<P STYLE="font: 4pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 4pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>With copies to:</I></P>

<P STYLE="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Asher M. Rubin, Esq.</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Istvan Hajdu,&nbsp;Esq.</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Nick D. DeAngelis, Esq.</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Sidley Austin LLP</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>787 Seventh Avenue</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>New York, New York 10019</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Telephone (212) 839-5300</B></P></TD>
    </TR>
  </TABLE>
<P STYLE="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>



<P STYLE="font: 4pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 4pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 4pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>From time to time after the effectiveness of this registration statement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">As soon as practicable after this Registration Statement is declared effective.</P>

<P STYLE="font: 4pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 4pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If any of the securities being registered on this
Form&nbsp;are to be offered on a delayed or continuous basis pursuant to Rule&nbsp;415 under the Securities Act of 1933, check the following
box. <FONT STYLE="font-family: Wingdings">&#120;</FONT></P>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Form&nbsp;is filed to register additional
securities for an offering pursuant to Rule&nbsp;462(b)&nbsp;under the Securities Act, please check the following box and list the Securities
Act registration statement number of the earlier effective registration statement for the same offering. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Form&nbsp;is a post-effective amendment
filed pursuant to Rule&nbsp;462(c)&nbsp;under the Securities Act, check the following box and list the Securities Act registration statement
number of the earlier effective registration statement for the same offering. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Form&nbsp;is a post-effective amendment
filed pursuant to Rule&nbsp;462(d)&nbsp;under the Securities Act, check the following box and list the Securities Act registration statement
number of the earlier effective registration statement for the same offering. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.
See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting company,&rdquo;
and &ldquo;emerging growth company&rdquo; in Rule&nbsp;12b-2 of the Exchange Act.</P>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 1.75pt 2pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer <FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="padding: 1.75pt 2pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer <FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="padding: 1.75pt 2pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer&nbsp;<FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></TD>
    <TD STYLE="padding: 1.75pt 2pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
reporting company <FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></TD>
    <TD STYLE="padding: 1.75pt 2pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company <FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section&nbsp;7(a)(2)(B)&nbsp;of the Securities Act. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This registration statement shall hereafter become effective in accordance with the provisions of Section 8(a) of the Securities Act of
1933.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 3pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: red"><B>The information in this prospectus
is not complete and may be changed. The selling stockholders named in this prospectus may not sell these securities or accept an offer
to buy these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus
is not an offer to sell these securities and the selling stockholders named in this prospectus are not soliciting an offer to buy these
securities in any state or jurisdiction where such offer or sale is not permitted.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: red"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: red"><B>Subject to Completion<BR>
Dated October 20, 2025</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: red"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Up to 2,096,188 Shares of Common Stock Offered
by the Selling Stockholders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tm2529020d1_s1img001.jpg" ALT=""><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CELLECTAR BIOSCIENCES,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus relates to
the resale, from time to time by the selling stockholders named in this prospectus (the &ldquo;selling stockholders&rdquo;), of up to
2,096,188 shares of our common stock (the &ldquo;Shares&rdquo;) issuable upon exercise of common stock purchase warrants (the &ldquo;Inducement
Warrants&rdquo;) issued to the selling stockholders in a warrant inducement transaction (the &ldquo;Warrant Inducement&rdquo;) which closed
on October&nbsp;8, 2025. For additional information about the transaction, see &ldquo;Summary-Description of the Warrant Inducement.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our registration of the shares
of common stock covered by this prospectus does not mean that the selling stockholders will offer or sell any such shares. We are registering
the offer and resale of the Shares to fulfill our contractual obligations set forth in the Inducement Letters (as defined below) entered
into on October&nbsp;7, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will not receive any of
the proceeds from the sale of our Shares by the selling stockholders, although we will receive proceeds from the cash exercise of any
Inducement Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any shares of our common stock
subject to resale hereunder will have been issued by us and received by the selling stockholders prior to any resale of such shares pursuant
to this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The selling stockholders,
or their donees, pledgees, transferees or other successors-in-interest may offer or resell the Shares from time to time through public
or private transactions at prevailing market prices, at prices related to prevailing market prices or at privately negotiated prices.
The selling stockholders will bear all commissions and discounts and similar selling expenses, if any, attributable to the sale of Shares.
We will bear all costs, expenses and fees (other than commissions and discounts and similar selling expenses) in connection with the registration
of the Shares. For additional information on the methods of sale that may be used by the selling stockholders, see &ldquo;Plan of Distribution&rdquo;
beginning on page&nbsp;42 of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our common stock is listed
on the Nasdaq Capital Market under the symbol &ldquo;CLRB.&rdquo; On October 17, 2025, the last reported sale price of our common stock
was $4.50.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Investing in our securities
involves significant risks. We strongly recommend that you read carefully the risks we describe in &ldquo;Risk Factors&rdquo; beginning
on page 9 of this prospectus and in any accompanying prospectus supplement, as well
as the risk factors that are incorporated by reference into this prospectus from our filings made with the Securities and Exchange Commission,
before investing in our securities.</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Neither the Securities
and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy
or accuracy of this prospectus. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">The date of this prospectus
is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 90%"><A HREF="#v2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">About This Prospectus</FONT></A></TD>
    <TD STYLE="text-align: right; width: 10%"><A HREF="#v2">1</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#v3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Summary</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#v3">2</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#v4"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selected Financial Data</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#v4">5</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#v5"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Offering</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#v5">6</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#v6"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#v6">9</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#v7"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forward-Looking Statements</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#v7">34</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#v8"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of Proceeds</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#v8">35</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#v9"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend Policy</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#v9">35</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#v10"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determination of Offering Price</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#v10">35</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#v11"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling Stockholders</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#v11">36</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#v12"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Securities to be Registered</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#v12">38</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#v13"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plan of Distribution</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#v13">42</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#v14"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Matters</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#v14">44</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#v15"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Experts</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#v15">44</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#v16"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where You Can Find More Information</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#v16">44</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#v17"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information Incorporated by Reference</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#v17">45</A></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="text-transform: uppercase"><A NAME="v2"></A><B>About This Prospectus</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>You should rely only on
the information contained or incorporated by reference in this prospectus and any applicable prospectus supplement. We have not, and the
selling stockholders have not, authorized any other person to provide you with different or additional information. If anyone provides
you with different or additional information, you should not rely on it. This prospectus is not an offer to sell, nor are the selling
stockholders seeking an offer to buy, the shares offered by this prospectus in any jurisdiction where the offer and sale is not permitted.
No offers or sales of any of the shares of our common stock are to be made in any jurisdiction in which such an offer or sale is not permitted.
You should assume that the information contained in this prospectus or any applicable prospectus supplement is accurate only as of the
date on the front cover thereof or the date of the document incorporated by reference, regardless of the time of delivery of this prospectus
or any applicable prospectus supplement or any sales of the shares of our common stock offered hereby or thereby.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should read the entire
prospectus and any prospectus supplement and any related issuer free writing prospectus, as well as the documents incorporated by reference
into this prospectus or any prospectus supplement or any related issuer free writing prospectus, before making an investment decision.
Neither the delivery of this prospectus or any prospectus supplement or any issuer free writing prospectus nor any sale made hereunder
shall under any circumstances imply that the information contained or incorporated by reference herein or in any prospectus supplement
or issuer free writing prospectus, as applicable. You should assume that the information appearing in this prospectus, any prospectus
supplement or any document incorporated by reference herein or therein is accurate only as of the date of the applicable documents, regardless
of the time of delivery of this prospectus or any sale of securities. Our business, financial condition, results of operation and prospects
may have changed since that date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The terms &ldquo;Cellectar
Biosciences,&rdquo; &ldquo;Cellectar,&rdquo; the &ldquo;Company,&rdquo; &ldquo;our,&rdquo; &ldquo;us&rdquo; and &ldquo;we,&rdquo; as used
in this prospectus, refer to Cellectar Biosciences,&nbsp;Inc., a Delaware corporation, and its subsidiaries unless we state otherwise
or the context indicates otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<DIV STYLE="padding-right: 10pt; padding-left: 10pt; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="text-transform: uppercase"><B><A NAME="v3"></A>Summary</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>This summary highlights
selected information contained elsewhere in this prospectus and does not contain all of the information that you need to consider in making
your investment decision. You should carefully read the entire prospectus, any applicable prospectus supplement and any related free writing
prospectus, including the risks of investing in our securities discussed under the heading &ldquo;Risk Factors&rdquo; contained in this
prospectus, any applicable prospectus supplement and any related free writing prospectus.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Company Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a late-stage clinical
biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer. Our core objective
is to leverage our proprietary phospholipid ether drug conjugate&trade; (PDC&trade;) delivery platform to develop PDCs that are designed
to specifically target cancer cells and deliver improved efficacy and better safety as a result of fewer off-target effects. We believe
that our PDC platform possesses the potential for the discovery and development of the next generation of cancer-targeting treatments,
and we plan to develop PDCs both independently and through research and development collaborations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our principal executive offices
are located at 100&nbsp;Campus Drive, Florham Park, New&nbsp;Jersey 07932 and the telephone number of our principal executive offices
is (608)&nbsp;441-8120. We maintain a website at www.cellectar.com. The information included or referred to on, or accessible through,
our website does not constitute part of, and is not incorporated by reference into, this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Description of the Warrant Inducement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October&nbsp;7, 2025, we
entered into warrant exercise inducement offer letters (the &ldquo;Inducement Letters&rdquo;) with certain holders (each a &ldquo;Holder&rdquo;)
of certain existing warrants (the &ldquo;Existing Warrants&rdquo;), which were originally issued on October&nbsp;25, 2022, July&nbsp;21,
2024, and July&nbsp;2, 2025, pursuant to which the Holders agreed to exercise for cash their Existing Warrants to purchase 1,048,094 shares
of our common stock, at an exercise price of $5.25 per share, and pay $0.125 per new warrant, in exchange for our agreement to issue the
Inducement Warrants. The transactions contemplated by the Inducement Letters closed on October&nbsp;8, 2025, and we received aggregate
gross proceeds of approximately $5.8&nbsp;million from the exercise of the Existing Warrants by the Holders and the sale of the Inducement
Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company also agreed to
file a registration statement covering the resale of the Shares (the &ldquo;Resale Registration Statement&rdquo;). The registration statement
of which this prospectus is a part is being filed pursuant to the Company&rsquo;s contractual obligation under the Inducement Letters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Terms of the Inducement Warrants</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We issued the Inducement Warrants
in two different series: the Series&nbsp;I Inducement Warrants and the Series&nbsp;II Inducement Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Series&nbsp;I Inducement
Warrants are immediately exercisable at an exercise price of $6.00 per share and will expire on October&nbsp;8, 2030. The Series&nbsp;I
Inducement Warrants are exercisable for up to 1,048,094 shares of our common stock, subject to adjustments as described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Series&nbsp;II Inducement
Warrants are immediately exercisable at an exercise price of $6.00 per share and will expire on April&nbsp;8, 2027. The Series&nbsp;II
Inducement Warrants are exercisable for up to 1,048,094 shares of our common stock, subject to adjustments as described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<DIV STYLE="padding-right: 10pt; padding-left: 10pt; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The exercise price and number
of shares of common stock issuable upon exercise of the Inducement Warrants is subject to adjustment in the event of stock dividends,
stock splits, reorganizations or similar events affecting our common stock and the exercise price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Recent Developments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>October&nbsp;2025 Warrant Inducement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On October&nbsp;7, 2025, the Company, entered into
definitive agreements for investors to immediately exercise certain outstanding warrants to purchase an aggregate of 1,048,094 shares
of common stock, issued by the company on October&nbsp;25, 2022, July&nbsp;21, 2024 and July&nbsp;2, 2025 (the October&nbsp;Existing Warrants),
at an exercise price of $5.25 per share. The shares of common stock issuable upon exercise of the October&nbsp;Existing Warrants are all
registered, or their resale is registered, pursuant to effective registration statements. Other than the shares of common stock issued
upon exercise of the Existing Warrants issued on July&nbsp;2, 2025, the issuance of which was registered under an effective registration
statement, the shares of common stock issued upon exercise of the October&nbsp;Existing Warrants were offered pursuant to the exemption
from the registration requirements of the Securities Act available under Section&nbsp;4(a)(2)&nbsp;of the Securities Act. In connection
with the exercise of the October&nbsp;Existing Warrants, the Company issued new warrants (the Inducement Warrants) in two different series:
the Series&nbsp;I Inducement Warrants and the Series&nbsp;II Inducement Warrants. Each Inducement Warrant is immediately exercisable at
an exercise price of $6.00 per share. The Series&nbsp;I Inducement Warrants will expire on October&nbsp;8, 2030 and the Series&nbsp;II
Inducement Warrants will expire on April&nbsp;8, 2027. The investors paid $0.125 per Inducement Warrant. The Company issued the Inducement
Warrants pursuant to the exemption from the registration requirements of the Securities Act available under Section&nbsp;4(a)(2)&nbsp;of
the Securities Act and intends to issue the shares underlying the Inducement Warrants pursuant to the same exemption or pursuant to the
exemption provided by Section&nbsp;3(a)(9)&nbsp;of the Securities Act. The Company agreed to file a registration statement on Form&nbsp;S-1
covering the resale of such shares within 15 calendar days of the date of closing of the transaction. The gross proceeds to the Company
from the exercise of the October&nbsp;Existing Warrants and the issuance of the Inducement Warrants was approximately $5.8 million, prior
to deducting placement agent fees and offering expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Regulatory Pathway - EMA</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October&nbsp;6, 2025, the
Company announced that after a scientific advice procedure, SAWP advised that filing for a CMA for iopofosine I 131 as a treatment for
post- BTKi refractory patients with WM could be acceptable for a CMA. While there is no guarantee of CMA approval, if iopofosine I 131
is granted CMA, it could potentially begin to be commercially available in the 30 countries represented by the EMA as early as 2027.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&rsquo;s decision
to file for CMA in Europe follows SAWP&rsquo;s advice on the patient population for which iopofosine I 131 is acceptable for a CMA, particularly
a discussion on a post BTKi patient population, consistent with the majority of the patients (&gt;70%) enrolled in the CLOVER WaM Phase
2 study. The Company&rsquo;s briefing document to the SAWP included iopofosine I 131&rsquo;s safety database, CLOVER WaM clinical study
results, subset analyses, and manufacturing information. It is not within the remit of the SAWP to determine whether the data shows the
sufficiency of safety and efficacy for a CMA; however, the SAWP advised that iopofosine I 131 met the eligibility requirements for a CMA
submission for the proposed patient population. As in the U.S., there remains a significant unmet medical need for the treatment of WM
in Europe, where the condition affects an estimated 35,000 to 45,000 patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>July&nbsp;Public Offering</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July&nbsp;2, 2025, we closed
our underwritten public offering for gross proceeds of approximately $6.9&nbsp;million prior to deducting underwriting commissions and
offering expenses. The offering was composed of (i)&nbsp;1,045,000 class&nbsp;A units (which included 180,000 class&nbsp;A units issued
pursuant to Ladenburg Thalmann&nbsp;&amp; Co. Inc.&rsquo;s, the sole bookrunner, exercise of the over-allotment option in full) with each
class&nbsp;A unit consisting of (a)&nbsp;one share of common stock and (b)&nbsp;one common warrant to purchase one share of common stock,
and (ii)&nbsp;335,000 class&nbsp;B units with each class&nbsp;B unit consisting of (a)&nbsp;one pre-funded common stock purchase warrant
to purchase one share of common stock and (b)&nbsp;one common warrant. The price per class&nbsp;A unit was $5.00 and the price per class&nbsp;B
unit was $4.99999 (collectively, the July&nbsp;Offering). The common warrants have an exercise price of $5.25 per share, are exercisable
upon issuance, and have a term expiring five years from issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<DIV STYLE="padding-right: 10pt; padding-left: 10pt; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the July&nbsp;Offering,
we agreed to issue representative warrants to the underwriter, or its designees, which entitled it to purchase up to 82,800 shares of
common stock. The representative warrants have an exercise price equal to $7.75 per share of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The securities described in
the July&nbsp;Offering were sold pursuant to a registration statement on Form&nbsp;S-1 (File No.&nbsp;333-288333), which was declared
effective by the SEC on July&nbsp;1, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>June&nbsp;2025 Warrant Inducement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June&nbsp;5, 2025, the
Company, entered into definitive agreements for investors to immediately exercise certain outstanding warrants to purchase an aggregate
of 276,044 shares of common stock, issued by the company on June&nbsp;5, 2020, October&nbsp;25, 2022 and July&nbsp;21, 2024 (the June&nbsp;Existing
Warrants), at a reduced exercise price of $9.123 per share. The shares of common stock issuable upon exercise of the June&nbsp;Existing
Warrants are all registered, or their resale is registered, pursuant to effective registration statements. Other than the shares of common
stock issued upon exercise of the June&nbsp;Existing Warrants issued on June&nbsp;5, 2020, the issuance of which was registered under
an effective registration statement, the shares of common stock issued upon exercise of the June&nbsp;Existing Warrants were offered pursuant
to the exemption from the registration requirements of the Securities Act available under Section&nbsp;4(a)(2)&nbsp;of the Securities
Act. The Company did not issue any new warrants as part of the agreements. The gross proceeds to the company from the exercise of the
June&nbsp;Existing Warrants was approximately $2.5 million, prior to deducting placement agent fees and offering expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Breakthrough Designation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June&nbsp;4, 2025, we announced
that the FDA has granted Breakthrough Therapy Designation for iopofosine I&nbsp;131, as a radioconjugate monotherapy for the treatment
of relapsed/refractory Waldenstrom macroglobulinemia (r/r&nbsp;WM).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Regulatory Pathway - FDA</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We plan to submit an NDA to
the FDA for accelerated approval of iopofosine I&nbsp;131 as a treatment for WM&nbsp;subject to sufficient funding and once a confirmatory
trial is underway. The submission would be supported by data from the Phase&nbsp;2b CLOVER WaM clinical trial demonstrating a statistically
significant major response rate compared to a null hypothesis of 20% and meaningful duration of response. The data set now includes the
FDA-requested 12-month follow-up results on all patients from the trial and new subset analysis of data from patients immediately following
Bruton Tyrosine Kinase inhibitor (BTKi) treatment failures regardless of line of therapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<DIV STYLE="padding-right: 10pt; padding-left: 10pt; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><A NAME="v4"></A><B>Selected
Financial Data</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Reverse Stock Split</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As previously disclosed, on
June&nbsp;24, 2025 we effected a reverse stock split of our outstanding shares of common stock at a ratio of one-for-thirty (the Reverse
Stock Split).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our periodic and current reports
that are incorporated by reference, and all other documents that were filed prior to June&nbsp;24, 2025, do not give effect to the Reverse
Stock Split. The following selected &ldquo;previously reported&rdquo; information has been derived from our audited financial statements
included in our <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1279704/000141057825000329/clrb-20241231x10k.htm" STYLE="-sec-extract: exhibit">Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2024, filed with the SEC on March&nbsp;13, 2025</A>.
The &ldquo;post Reverse Split&rdquo; information below recasts the &ldquo;previously reported&rdquo; share and per share information to
reflect the June&nbsp;24, 2025 one-for-thirty Reverse Stock Split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Twelve Months Ended December&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Three Months Ended<BR>
 March&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2024</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2023</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2025</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Weighted-average common shares outstanding, basic - previously reported</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">36,622,474</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">12,221,571</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">46,079,875</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Weighted-average common shares outstanding, diluted - previously reported</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">37,143,769</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">12,221,571</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">46,079,875</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Weighted-average common shares outstanding, basic - post-Reverse Split</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,220,749</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">407,386</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,535,996</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Weighted-average common shares outstanding, diluted - post-Reverse Split</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,238,126</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">407,386</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,535,996</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net loss per share, basic - previously reported</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(1.22</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(3.50</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.14</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net loss per share, diluted - previously reported</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(1.40</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(3.50</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.14</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net loss per share, basic - post-Reverse Split</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(36.52</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(104.99</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(4.20</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net loss per share, diluted - post-Reverse Split</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(41.89</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(104.99</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(4.20</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">As of</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">As of</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Dec 31, 2024</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Dec 31, 2023</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Common stock - previously reported</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">461</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">207</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Additional paid-in capital - previously reported</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">261,115,905</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">182,924,210</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Common stock issued and outstanding - previously reported</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">46,079,875</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">20,744,110</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Common stock - post-Reverse Split</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">15</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">7</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Additional paid-in capital - post-Reverse Split</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">261,116,351</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">182,924,410</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Common stock issued and outstanding - post-Reverse Split</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,535,996</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">691,470</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<DIV STYLE="padding-right: 10pt; padding-left: 10pt; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="v5"></A>The
Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares of common stock offered by us</FONT></TD>
    <TD STYLE="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares of common stock offered by the selling stockholders (assuming full exercise of Inducement Warrants and excluding any other anti-dilution or similar adjustments)</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,096,188 Shares</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares of common stock outstanding after completion of this offering (assuming full exercise of Inducement Warrants and excluding any other anti-dilution or similar adjustments)</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,336,322 Shares</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling stockholders</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All of the shares of our common stock are being offered by the selling stockholders. See &ldquo;Selling Stockholders&rdquo; beginning on page&nbsp;36 for additional information on the selling stockholders.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of Proceeds</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We will not receive any proceeds from the resale of the shares of common stock by the selling stockholders. See &ldquo;Use of Proceeds&rdquo; beginning on page&nbsp;35 for additional information on the use of proceeds.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See &ldquo;Risk Factors&rdquo; on page 9 and the other information included in this prospectus for a discussion of factors you should carefully consider before deciding whether to purchase our securities.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq symbol for common stock</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;CLRB&rdquo;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The number of shares of our
common stock outstanding before and after this offering is based on 1,812,040 shares of common stock outstanding as of June&nbsp;30, 2025,
which is adjusted to 4,240,134 to give effect to 1,045,000 shares that were issued pursuant to the July&nbsp;Offering, 335,000 pre-funded
warrants issued pursuant to the July&nbsp;Offering that have been exercised, and 1,048,094 shares that were issued pursuant to the exercise
of the October&nbsp;Existing Warrants, and which excludes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any shares of common stock issuable upon the
exercise of the underwriter&rsquo;s over-allotment option;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any shares of common stock issuable upon the
exercise of Pre-Funded Warrants issued in this offering;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any shares of common stock issuable upon the
exercise of Common Warrants issued in this offering;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any shares of common stock issuable upon the
exercise of the representative warrants issued as compensation to the underwriter in this offering;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">an aggregate of 211,816 shares of common stock
issuable upon the exercise of outstanding stock options issued to employees, directors and consultants;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">an aggregate of 13,040 shares of common stock
issuable upon the conversion of outstanding shares of Series&nbsp;E-2 preferred stock;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">an aggregate of 3,704 shares of common stock
issuable upon the conversion of outstanding shares of Series&nbsp;D preferred stock;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">an aggregate of 417,904 additional shares of
common stock reserved for issuance under outstanding warrants having expiration dates between October&nbsp;2027 and July&nbsp;2029, and
exercise prices ranging from $58.80 to $165.00 per share;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<DIV STYLE="padding-right: 10pt; padding-left: 10pt; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">an aggregate of 436,000 shares of common stock
issuable upon the exercise of common warrants issued in the July&nbsp;Offering; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">an aggregate of 82,800 shares of common stock
issuable upon the exercise of the representative warrants issued as compensation to the underwriter in the July&nbsp;Offering.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">an aggregate of 2,096,188
shares of common stock issuable upon the exercise of common warrants issued in the October&nbsp;Offering</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Summary Risk Factors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An investment in our common
stock involves substantial risk. The occurrence of one or more of the events or circumstances described in the section entitled &ldquo;Risk
Factors,&rdquo; alone or in combination with other events or circumstances, may have a material adverse effect on our business, cash flows,
financial condition and results of operations. Important factors and risks that could cause actual results to differ materially from those
in the forward-looking statements include, among others, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Risks Related to Capital and Our Operations</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our regulatory strategy may not result in the
approval of iopofosine I 131 by the FDA, the European Commission (based on recommendation from the EMA) or any other regulatory authority.
Regulatory authorities have substantial discretion in the approval process and may find that iopofosine I 131 does not meet approval requirements.
In addition, we may not be able to raise additional funds required to execute our regulatory strategy.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Although we have obtained feedback from the EMA
through their scientific advice procedure, this feedback does not guarantee any particular outcome with respect to regulatory approval
of iopofosine I 131.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If the Company&rsquo;s exploration of strategic
alternatives is unsuccessful, its financial condition and results of operations may be materially adversely affected.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We will require additional capital in order to
continue our operations and may have difficulty raising additional capital.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our ability to utilize our net operating loss
carryforwards and certain other tax attributes may be limited.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Risks Related to Manufacturing and Supply</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We rely on a collaborative outsourced business
model, and disruptions with our third-party collaborators may impede our ability to gain marketing approval from the FDA, the European
Commission (based on recommendation from the EMA), or other regulatory authorities and delay or impair commercialization of any products.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Risks Related to Research, Development and
Regulatory Approval of Our Product Candidates</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">All of our product candidates are in clinical
development or in preclinical development. If we are unable to advance our product candidates through clinical development, obtain regulatory
approval and ultimately commercialize our product candidates, or experience significant delays in doing so, our business will be materially
harmed.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Failure to complete the development of our technologies,
obtain government approvals, including required FDA approvals, or comply with ongoing governmental regulations could prevent, delay or
limit introduction or sale of proposed products and result in failure to achieve revenues or maintain our ongoing business.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Risks Related to Legal Compliance and Litigation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Controls we or our third-party collaborators
have in place to ensure compliance with all applicable laws and regulations may not be effective.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We are exposed to product, clinical and preclinical
liability risks that could create a substantial financial burden should we be sued.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<DIV STYLE="padding-right: 10pt; padding-left: 10pt; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Risks Related to Intellectual Property</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We expect to rely on our patents as well as specialized
regulatory designations such as orphan drug classification for our product candidates, but regulatory drug designations may not confer
marketing exclusivity or other expected commercial benefits.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If we are unable to adequately protect or enforce
our rights to intellectual property or to secure rights to third-party patents, we may lose valuable rights, experience reduced market
share, assuming any, or incur costly litigation to protect our intellectual property rights.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Risks Related to Our Employees</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We rely on a small number of key personnel who
may terminate their employment with us at any time, and our success will depend on our ability to hire additional qualified personnel.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Confidentiality agreements with employees and
others may not adequately prevent disclosure of our trade secrets and other proprietary information and may not adequately protect our
intellectual property, which could limit our ability to compete.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Risks Related to Commercialization of our
Products</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Acceptance of our products in the marketplace
is uncertain and failure to achieve market acceptance will prevent or delay our ability to generate revenues.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Regulatory approval for any approved product
is limited by the FDA, the European Commission (based on recommendation from the EMA), and comparable foreign authorities, to those specific
indications and conditions for which clinical safety and efficacy have been demonstrated, and we may incur significant liability if it
is determined that we are promoting the &ldquo;off-label&rdquo; use of any of our future product candidates if approved.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Regulatory legislative reform measures may have
a material adverse effect on our business.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Risks Related to Internal Controls</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We identified certain misstatements to our previously
issued financial statements and have restated the financial statements described below, which has exposed us to additional risks and uncertainties.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We identified material weaknesses in our internal
control over financial reporting. If we are unable to remediate these material weaknesses, or if we identify additional material weaknesses
in the future or otherwise fail to maintain effective internal control over financial reporting, we may not be able to accurately or timely
report our financial condition or results of operations, which may adversely affect our business and share price.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="v6"></A>Risk
Factors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>An investment in our securities involves a high
degree of risk. Prior to making a decision about investing in our securities, prospective investors should consider carefully all of the
information included in this prospectus, including the risk factors set forth herein, as updated by annual, quarterly and other reports
and documents we file with the SEC after the date of this prospectus and that are incorporated by reference herein. Each of these risk
factors could have a material adverse effect on our business, results of operations, financial position or cash flows, which may result
in the loss of all or part of your investment.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Capital and Our Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our regulatory strategy may not result in
the approval of iopofosine I 131 by the FDA, the European Commission (based on recommendation from the EMA) or any other regulatory authority.
Regulatory authorities have substantial discretion in the approval process and may find that iopofosine I 131 does not meet approval requirements.
In addition, we may not be able to raise additional funds required to execute our regulatory strategy.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We plan to submit an NDA to
the FDA for accelerated approval of iopofosine I 131 for the treatment of WM patients that have received two prior lines of therapy, including
a BTKi. FDA, the European Commission (based on recommendation from the EMA) and other regulatory authorities have substantial discretion
in the drug approval process. They may refuse to file, refuse to review, or reject our NDA, or equivalent application, for a variety of
reasons. They may determine that the CLOVER WaM trial or our other clinical trials for iopofosine I 131 did not meet safety and efficacy
endpoints. They may decide that our data, sample size, trial design and other information are insufficient for approval. They may also
disagree with the design of our proposed confirmatory study. They may require additional preclinical, clinical or other studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our existing cash and cash
equivalents are not sufficient to execute our regulatory strategy. We view raising additional funds as a precursor to submission of an
NDA and initiation of our proposed confirmatory study. Additional funds will also be required to continue our potential EMA review process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may not be able to raise
additional funds. If we are able to raise additional funds, such funds may not be sufficient to execute our regulatory strategy. Even
if we raise funds that we believe are sufficient to execute our regulatory strategy, the FDA, the European Commission (based on recommendation
from the EMA) and other regulatory authorities may not approve iopofosine I 131. If we are unable to execute our regulatory strategy,
our business, financial position, results of operations, prospects and stock price may be materially adversely affected and we may be
required to seek other alternatives which may include, among others, the sale of the Company or its assets, discontinuance of certain
operations, a wind-down of operations and/or filing for bankruptcy protection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Although we have obtained feedback from
the EMA through their scientific advice procedure, this feedback does not guarantee any particular outcome with respect to regulatory
approval of iopofosine I 131.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although during the scientific
advice procedure SAWP advised that filing a CMA for iopofosine I 131 as a treatment for post-BTKi refractory patients with WM could be
acceptable, this feedback is not a guarantee of final CMA approval, and we do not know how the EMA will interpret the data and results
from our clinical trials and other elements of our development program. The EMA may raise issues of, for example, safety, efficacy, study
conduct, bias, deviation from the protocol, statistical power and analyses, patient demographics, patient completion rates, changes in
scientific or medical parameters or internal inconsistencies in the data prior to making its final decision. There is no guarantee that
the EMA will not require that we conduct one or more additional clinical trials or nonclinical studies to support potential CMA approval,
or that iopofosine I 131 will receive any regulatory approvals in the EU. Scientific advice is legally non-binding with regard to any
future CMA application and it is beyond the remit of the SAWP to determine whether the data shows sufficient safety and efficacy for a
CMA. Companies which have been provided with positive scientific advice by SAWP have ultimately failed to obtain approval of a CMA or
marketing authorization for their drugs. If we do not obtain approval of a CMA or marketing authorization for iopofosine I 131, our business,
financial position, results of operations, prospects and stock price may be materially adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If the Company&rsquo;s exploration of strategic
alternatives is unsuccessful, its financial condition and results of operations may be materially adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As previously announced, the
Company has engaged a financial advisor to assist it in evaluating potential strategic alternatives to enhance stockholder value. Strategic
alternatives under consideration may include, but are not limited to mergers, acquisitions, business combinations, partnerships, joint
ventures, licensing arrangements or other strategic transactions. The Company and its financial advisor have engaged in preliminary discussions
with potential counterparties but there is no assurance that the potential strategic alternatives will lead to a definitive agreement.
If the Company is unable to consummate a strategic transaction, or if there is any significant delay in closing such a transaction, the
Company&rsquo;s financial condition and results of operations may be materially adversely affected. In addition, the Company may be required
to seek other alternatives which may include, among others, the sale of the Company or its assets, discontinuance of certain operations,
a wind-down of operations and/or filing for bankruptcy protection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We will require additional capital in order
to continue our operations and may have difficulty raising additional capital.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect that we will continue
to generate operating losses for the foreseeable future. As of September&nbsp;30, 2025, our estimated consolidated cash balance was approximately
$12.6 million. We believe our cash balance as of September&nbsp;30, together with net proceeds from the exercise of the Existing Warrants
by the Holders and the sale of the Inducement Warrants of approximately $5.2 million in October&nbsp;2025, but excluding any proceeds
from this offering, will be sufficient to fund the Company&rsquo;s operations into the third quarter of 2026.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&rsquo;s ability
to execute its current operating plan depends on its ability to obtain additional funding via the sale of equity and/or debt securities,
a strategic transaction or other source of capital. The Company plans to continue actively pursuing financing alternatives, however, there
can be no assurance that it will obtain the necessary funding, raising substantial doubt about the Company&rsquo;s ability to continue
as a going concern within one year of the date these financial statements are issued. The accompanying financial statements do not include
any adjustments that might result from the outcome of this uncertainty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our capital requirements and
our ability to meet them depend on many factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the number of potential products and technologies
in development;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">continued progress and cost of our research and
development programs;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">progress with preclinical studies and clinical
studies;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the time and costs involved in obtaining regulatory
clearance;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">costs involved in preparing, filing, prosecuting,
maintaining and enforcing patent claims;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">costs of developing sales, marketing and distribution
channels and our ability to sell our drugs;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">costs involved in establishing manufacturing
capabilities for clinical study and commercial quantities of our drugs;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">competing technological and market developments;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">claims or enforcement actions with respect to
our products or operations;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">market acceptance of our products;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">costs for recruiting and retaining management,
employees and consultants;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our ability to manage computer system failures
or security breaches;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">costs for educating physicians regarding the
application and use of our products;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">whether we are able to maintain our listing on
a national exchange;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">uncertainty and economic instability resulting
from conflicts, military actions, terrorist attacks, natural disasters, public health crises, including the occurrence of a contagious
disease or illness, cyber-attacks and general instability; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the condition of capital markets and the economy
generally, both in the U.S. and globally.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may consume available resources
more rapidly than currently anticipated, resulting in the need for additional funding sooner than expected. We may seek to raise any additional
funds through the issuance of any combination of common stock, preferred stock, warrants and debt financings or by executing collaborative
arrangements with corporate partners or other sources, any of which may be dilutive to existing stockholders or have a material effect
on our current or future business prospects. If we cannot secure adequate financing when needed, we may be required to delay, scale back
or eliminate one or more of our research and development programs or to enter into license or other arrangements with third parties to
commercialize products or technologies that we would otherwise seek to develop and commercialize ourselves. In the event that additional
funds are obtained through arrangements with collaborative partners or other sources, we may have to relinquish economic and/or proprietary
rights to some of our technologies or products under development that we would otherwise seek to develop or commercialize by ourselves.
In such an event, our business, prospects, financial condition and results of operations may be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our ability to utilize our net operating
loss carryforwards and certain other tax attributes may be limited.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ability to utilize our
federal net operating loss and tax credit carryforwards may be limited under Sections&nbsp;382 and 383 of the Internal Revenue Code of
1986, as amended (the Code). The limitations apply if we experience an &ldquo;ownership change&rdquo;, generally defined as a greater
than 50&nbsp;percentage point change in the ownership of our equity by certain stockholders over a rolling three-year period. Similar
provisions of state tax law may also apply. We have not evaluated whether such an ownership change has occurred previously. If we have
experienced an ownership change at any time since our formation, we may already be subject to limitations on our ability to utilize our
existing net operating losses and other tax attributes to offset taxable income. In addition, future changes in our stock ownership, which
may be outside of our control, may trigger an ownership change and, consequently, the limitations under Sections&nbsp;382 and 383 of the
Code. As a result, if or when we earn net taxable income, our ability to use our net operating loss carryforwards and other tax attributes
to offset such taxable income may be subject to limitations, which could adversely affect our future cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Manufacturing and Supply</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We rely on a collaborative outsourced business
model, and disruptions with our third-party collaborators may impede our ability to gain marketing approval from the FDA, the European
Commission (based on recommendation from the EMA), or other regulatory authorities and delay or impair commercialization of any products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are in the preclinical
and clinical study phases of product development and commercialization. We have closed manufacturing operations located at our former
corporate headquarters in Wisconsin and have implemented a collaboration outsourcing model to more efficiently manage costs. We rely significantly
on contracts with third parties to use their facilities to conduct our research, development and manufacturing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have engaged AtomVie and
SpectronRx as sources to supply drug product for our ongoing research and clinical studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we rely exclusively
on contract research organizations to conduct research and development. Any inability of these organizations to fulfill the requirements
of their agreements with us may delay or impair our ability to gain marketing approval from the FDA, European Commission (based on recommendation
from the EMA), or other regulatory authorities and commercialization of our drug delivery technology and products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our reliance on third-party
collaborators exposes us to risks related to not being able to directly oversee the activities of these parties. Furthermore, these collaborators,
whether foreign or domestic, may experience regulatory compliance difficulties, mechanical shutdowns, employee strikes, or other unforeseeable
acts that may delay fulfillment of their agreements with us. This may lead to the stopping or delay of our clinical trials or commercial
manufacturing activity. Failure of any of these collaborators to provide the required services in a timely manner or on commercially reasonable
terms could materially delay the development and approval of our products, increase our expenses, and materially harm our business, prospects,
financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our current and anticipated
future dependence upon these third-party manufacturers may adversely affect our ability to develop and commercialize product candidates
on a timely and competitive basis, which could have an adverse effect on sales, results of operations and financial condition. If we were
required to transfer manufacturing processes to other third-party manufacturers and we were able to identify an alternative manufacturer,
we would still need to satisfy various regulatory requirements. Satisfaction of these requirements could cause us to experience significant
delays in receiving an adequate supply of our products and products in development and could be costly. Moreover, we may not be able to
transfer processes that are proprietary to the manufacturer, if any. These manufacturers may not be able to produce material on a timely
basis or manufacture material at the quality level or in the quantity required to meet our development timelines and applicable regulatory
requirements and may also experience a shortage in qualified personnel. We may not be able to maintain or renew our existing third-party
manufacturing arrangements, or enter into new arrangements, on acceptable terms, or at all. Our third-party manufacturers could terminate
or decline to renew our manufacturing arrangements based on their own business priorities, at a time that is costly or inconvenient for
us. If we are unable to contract for the production of materials in sufficient quantity and of sufficient quality on acceptable terms,
our planned clinical trials may be significantly delayed. Manufacturing delays could postpone the filing of our IND applications and/or
the initiation or completion of clinical trials that we have currently planned or may plan in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Drug manufacturers are subject
to ongoing periodic unannounced inspection by the FDA, the Drug Enforcement Administration, the EU Member States (coordinated by the EMA),
and other comparable foreign regulatory authorities and other federal and state government and regulatory agencies to ensure strict compliance
with cGMP and other government regulations and corresponding foreign standards. We do not have control over third-party manufacturers&rsquo;
compliance with these regulations and standards and they may not be able to comply. Switching manufacturers may be difficult because the
number of potential manufacturers is limited. It may be difficult or impossible for us to find a replacement manufacturer quickly on acceptable
terms, or at all. Additionally, if we are required to enter into new supply arrangements, we may not be able to obtain approval from the
FDA, the European Commission (based on recommendation from the EMA) or other comparable foreign regulatory authorities of any alternate
supplier in a timely manner, or at all, which could delay or prevent the clinical development and commercialization of any related product
candidates. Failure of our third-party manufacturers or us to comply with applicable regulations could result in sanctions being imposed
on us, including fines, civil penalties, delays in or failure to grant marketing approval of our product candidates, injunctions, delays,
suspension or withdrawal of approvals, license revocation, seizures or recalls of products and compounds, operating restrictions and criminal
prosecutions, warning or similar letters or civil, criminal or administrative sanctions against the company, any of which could adversely
affect our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that we have a
good working relationship with our third-party collaborators. However, should the situation change, we may be required to relocate these
activities on short notice, and we do not currently have access to alternate facilities to which we could relocate our research, development
and/or manufacturing activities. The cost and time to establish or locate an alternate research, development and/or manufacturing facility
to develop our technology would be substantial and would delay obtaining FDA or European Commission (based on recommendation from the
EMA) approval and commercializing our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, if our products
are approved for commercial sale, we will need to work with our existing third-party collaborators to ensure sufficient capacity, or engage
additional parties with the capacity, to commercially manufacture our products in accordance with FDA, the European Commission (based
on recommendation from the EMA) and other regulatory requirements. There can be no assurance that we would be able to successfully establish
any such capacity or identify suitable manufacturing partners on acceptable terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Research, Development and Regulatory Approval of
Our Product Candidates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>All of our product candidates are in clinical
development or in preclinical development. If we are unable to advance our product candidates through clinical development, obtain regulatory
approval and ultimately commercialize our product candidates, or experience significant delays in doing so, our business will be materially
harmed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At present, our success is
dependent on one or more of the following to occur: the successful development of iopofosine for the treatment of a hematologic or solid
tumor cancer including Waldenstrom&rsquo;s macroglobulinemia, multiple myeloma and B-Cell lymphomas or the treatment of pediatric solid
tumors and lymphomas; the development of new PDCs, specifically new products developed from our PDC program, and the advancement of our
PDC agents through research and development; and/or commercialization partnerships.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a late-stage clinical
biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer. We leverage
our PDC platform to specifically target cancer cells. The PDC platform possesses the potential for the discovery and development of the
next generation of cancer-targeting agents. The PDC platform features include the capacity to link with almost any molecule, the delivery
of a significant increase in targeted oncologic payload, and the ability to target nearly all tumor cells. As a result, we believe that
we can generate PDCs to treat a broad range of cancers with the potential to improve the therapeutic index of oncologic drug payloads,
enhance or maintain efficacy while reducing adverse events by minimizing drug delivery to healthy cells, and increase delivery to cancerous
cells and cancer stem cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our proposed products and
their potential applications are in clinical and manufacturing/process development and face a variety of risks and uncertainties inherent
in the development of pharmaceutical products, including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The inherent difficulty in selecting the right
drug and drug target and avoiding unwanted side effects, as well as unanticipated problems relating to product development, testing, enrollment,
obtaining regulatory approvals, maintaining regulatory compliance, manufacturing, competition and costs and expenses that may exceed current
estimates;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Future clinical study results may show that our
cancer-targeting and delivery technologies are not well-tolerated by patients at their effective doses or are not efficacious. In future
clinical trials, we or our partners may discover additional side effects and/or a higher frequency of side effects than those observed
in previously completed clinical trials.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Future clinical study results may be inconsistent
with testing results obtained to-date. The results of preliminary and mid-stage clinical trials do not necessarily predict clinical or
commercial success, and larger later-stage clinical trials may fail to confirm the results observed in the previous clinical trials.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A clinical trial may show that a product candidate
is safe and effective for certain patient populations in a particular indication, but other clinical trials may fail to confirm those
results in a subset of that population or in a different patient population, which may limit the potential market for that product candidate.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Even if our cancer-targeting and delivery technologies
are shown to be safe and effective for their intended purposes, we may face significant or unforeseen difficulties in obtaining or manufacturing
sufficient quantities at reasonable prices or at all.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our ability to complete the development and commercialization
of our cancer-targeting and delivery technologies for their intended use is substantially dependent upon our ability to raise sufficient
capital or to obtain and maintain experienced and committed partners to assist us with obtaining clinical and regulatory approvals for,
clinical trial patient enrollment in, and the manufacturing, marketing and distribution of, our products.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Even if our cancer-targeting and delivery technologies
are successfully developed, approved by all necessary regulatory authorities, and commercially produced, there is no guarantee that there
will be market acceptance of our products.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our competitors may develop therapeutics or other
treatments that are superior or less costly than our own with the result that our product candidates, even if they are successfully developed,
manufactured and approved, may not generate sufficient revenues to offset the development and manufacturing costs of our product candidates.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are unsuccessful in
dealing with any of these risks, or if we are unable to successfully advance the development of our cancer-targeting and delivery technologies
for some other reason, our business, prospects, financial condition and results of operations may be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With respect to our own compounds
in development, we have established anticipated timelines with respect to the initiation of clinical trials based on existing knowledge
of the compounds. However, we cannot provide assurance that we will meet any of these timelines for clinical development. Additionally,
the initial results of a completed earlier clinical trial of a product candidate do not necessarily predict final results and the results
may not be repeated in later clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because of the uncertainty
of whether the accumulated preclinical evidence (PK, pharmacodynamic, safety and/or other factors) or early clinical results will be observed
in later clinical trials, we can make no assurances regarding the likely results from our future clinical trials or the impact of those
results on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Failure to complete the development of our
technologies, obtain government approvals, including required FDA approvals, or comply with ongoing governmental regulations could prevent,
delay or limit introduction or sale of proposed products and result in failure to achieve revenues or maintain our ongoing business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our research and development
activities and the manufacture and marketing of our intended products are subject to extensive regulation for safety, efficacy and quality
by numerous government authorities in the U.S. and abroad. Before receiving approval to market our proposed products by the FDA, we will
have to demonstrate that our products are safe and effective for the patient population for the diseases that are to be treated. Clinical
studies, manufacturing and marketing of drugs are subject to the rigorous testing and approval process of the FDA and equivalent foreign
regulatory authorities. The Federal Food, Drug, and Cosmetic Act and other federal, state and foreign statutes and regulations govern
and influence the testing, manufacturing, labeling, advertising, distribution and promotion of drugs and medical devices. As a result,
clinical studies and regulatory approval can take many years to accomplish and require the expenditure of substantial financial, managerial
and other resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot predict whether
regulatory clearance or approval will be obtained for any product that we hope to develop. Of particular significance to us are the requirements
relating to research and development and testing. The activities associated with the research, development and commercialization of CLR&nbsp;121225,
CLR&nbsp;121125, iopofosine and other future candidates in our pipeline must undergo extensive clinical trials, which can take many years
and require substantial expenditures, subject to extensive regulation by the FDA and other regulatory agencies in the U.S. and by comparable
authorities in other countries. The process of obtaining regulatory approvals in the U.S. and other foreign jurisdictions is expensive,
and lengthy, if approval is obtained at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Before commencing clinical
trials in humans, we, or our collaborative partners, will need to submit and receive approval from the FDA of an IND application. Clinical
trials are subject to oversight by institutional review boards and the FDA and:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">must be conducted in conformance with the FDA&rsquo;s
good clinical practices and other applicable regulations;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">must meet requirements for institutional review
board oversight;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">must meet requirements for informed consent;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">are subject to continuing FDA and regulatory
oversight;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">may require large numbers of test subjects; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">may be suspended by us, our collaborators or
the FDA at any time if it is believed that the subjects participating in these trials are being exposed to unacceptable health risks or
if the FDA finds deficiencies in the IND or the conduct of these trials.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not know whether we
will be permitted to undertake clinical trials of potential products beyond the trials already concluded and the trials currently in process.
It will take us or our collaborative partners several years to complete any such testing, and failure can occur at any stage of testing.
Interim results of trials do not necessarily predict final results, and acceptable results in early trials may not be repeated in later
trials. A number of companies in the pharmaceutical industry, including biotechnology companies, have suffered significant setbacks in
advanced clinical trials, even after achieving promising results in earlier trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Before receiving FDA approval
or similar approval in the European Union or other jurisdiction to market a product, we must demonstrate with substantial clinical evidence
that the product is safe and effective in the patient population and the indication that will be treated. Data obtained from preclinical
and clinical activities are susceptible to varying interpretations that could delay, limit or prevent regulatory approvals. Our clinical
trials may fail to produce results satisfactory to the FDA or regulatory authorities in other jurisdictions. The regulatory process also
requires preclinical testing, and data obtained from preclinical and clinical activities are susceptible to varying interpretations. In
connection with clinical trials of our product candidates, we may face the following risks among others:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the product candidate may not prove to be effective;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the product candidate may cause harmful side
effects;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the clinical results may not replicate the results
of earlier, smaller trials;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">we, or the FDA or similar foreign regulatory
authorities, may delay, terminate or suspend the trials;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our results may not be statistically significant;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">patient recruitment and enrollment may be slower
than expected;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">patients may drop out of the trials or otherwise
not enroll; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">regulatory and clinical trial requirements, interpretations
or guidance may change.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA has substantial discretion
in the approval process and may refuse to approve any NDA or sNDA and decide that our data is insufficient for approval and require additional
preclinical, clinical or other studies. Varying interpretations of the data obtained from preclinical and clinical testing could delay,
limit or prevent regulatory approval of our products for any individual, additional indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To be commercially viable,
we must successfully research, develop, manufacture, introduce, and obtain the required regulatory approval described above for our product
candidates, in order to market and distribute our product candidates. This includes meeting a number of critical developmental milestones,
including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">demonstrating benefit from delivery of each specific
drug for specific medical indications;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">demonstrating through preclinical and clinical
studies that each drug is safe and effective; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">demonstrating that we have established viable
FDA cGMPs capable of potential scale-up.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The timeframe necessary to
achieve these developmental milestones may be long and uncertain, and we may not successfully complete these milestones for any of our
intended products in development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the risks previously
discussed, our technology is subject to developmental risks that include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">uncertainties arising from the rapidly growing
scientific aspects of drug therapies and potential treatments;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">uncertainties arising as a result of the broad
array of alternative potential treatments related to cancer and other diseases; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">expense and time associated with the development
and regulatory approval of treatments for cancer and other diseases.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, delays or rejections
may be encountered based upon additional government regulation from future legislation or administrative action or changes in FDA policy
during the period of product development, clinical trials and FDA regulatory review. Failure to comply with applicable FDA or other applicable
regulatory requirements may result in criminal prosecution, civil penalties, recall or seizure of products, total or partial suspension
of production or injunction, adverse publicity, as well as other regulatory action against our potential products or us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To conduct the clinical studies
that are necessary to obtain approval by the FDA to market a product, it is necessary to receive clearance from the FDA to conduct such
clinical studies. The FDA can halt clinical studies at any time for safety reasons or because we or our clinical investigators do not
follow the FDA&rsquo;s requirements for conducting clinical studies. If any of our studies are halted, we will not be able to obtain FDA
approval until and unless we can address the FDA&rsquo;s concerns. If we are unable to receive clearance to conduct clinical studies for
a product, we will not be able to achieve any revenue from that product in the U.S., as it is illegal to sell any drug for use in humans
in the U.S. without FDA approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If regulatory approval of
a product is granted, this approval will be limited to those indications or disease states and conditions for which the product is demonstrated
through clinical trials to be safe and efficacious. We cannot assure you that any compound developed by us, alone or with others, will
prove to be safe and efficacious in clinical trials and will meet all of the applicable regulatory requirements needed to receive marketing
approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There can be no guarantee
that the EMA will grant CMA in the EU for iopofosine for WM&nbsp;patients having received two or more prior treatment regimens. Even if
we are granted a CMA in the EU, we will be required to undergo annual renewal assessments to determine whether the risk-benefit balance
remains positive. During or in between such assessments, it may be determined that we do not meet the conditions, which would mean that
the CMA is revoked, or that there is a need for additional or modified conditions and/or specific obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if we do ultimately receive
FDA approval or approval in the European Union for any of our products, these products will be subject to extensive ongoing regulation,
including regulations governing manufacturing, labeling, packaging, testing, dispensing, prescription and procurement quotas, record keeping,
reporting, handling, shipment and disposal of any such drug. Failure to obtain and maintain required registrations or to comply with any
applicable regulations could further delay or preclude development and commercialization of our drugs and subject us to enforcement action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Outside the US, our ability,
or that of our collaborative partners, to market a product is contingent upon receiving a marketing authorization from the appropriate
regulatory authorities. This foreign regulatory approval process typically includes all of the risks and costs associated with FDA approval
described above and may also include additional risks and costs, such as the risk that such foreign regulatory authorities, which often
have different regulatory and clinical trial requirements, interpretations and guidance from the FDA, may require additional clinical
trials or results for approval of a product candidate, any of which could result in delays, significant additional costs or failure to
obtain such regulatory approval. There can be no assurance, however, that we or our collaborative partners will not have to provide additional
information or analysis, or conduct additional clinical trials, before receiving approval to market product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Fast track designation by the FDA may not
actually lead to a faster development or regulatory review or approval process and does not assure FDA approval of our product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a product candidate is
intended for the treatment of a serious or life-threatening condition and the product candidate demonstrates the potential to address
unmet medical need for this condition, the sponsor may apply for FDA fast track designation. Fast track designation applies to the combination
of the product and the specific indication for which it is being studied. The sponsor of a fast track product has opportunities for more
frequent interactions with the review team during product development, and the FDA may consider for review sections of the NDA on a rolling
basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA,
the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees
upon submission of the first section of the NDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">However, fast track designation
does not change the standards for approval and does not ensure that the product candidate will receive marketing approval or that approval
will be granted within any particular timeframe. As a result, while the FDA has granted fast track designation to iopofosine for WM patients
having received two or more prior treatment regimens and/or we may seek and receive fast track designation for our future product candidates,
we may not experience a faster development process, review or approval compared to conventional FDA procedures. In addition, the FDA may
withdraw fast track designation if it believes that the designation is no longer supported by data from our clinical development program.
Fast track designation alone does not guarantee qualification for the FDA&rsquo;s priority review procedures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The FDA has granted rare pediatric disease
designation, RPDD, to iopofosine for treatment of neuroblastoma, rhabdomyosarcoma, Ewing&rsquo;s sarcoma and osteosarcoma; however, we
may not be able to realize any value from such designation.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Iopofosine has received RPDD
designation from the FDA for the treatment of neuroblastoma, rhabdomyosarcoma, osteosarcoma and Ewing&rsquo;s sarcoma. The FDA defines
a &ldquo;rare pediatric disease&rdquo; as a disease that affects fewer than 200,000 individuals in the U.S. primarily under the age of
18&nbsp;years old, or a patient population greater than 200,000 in the U.S. when there is no reasonable expectation that the cost of developing
and making available the drug in the U.S. will be recovered from sales in the U.S. for that drug or biological product. Under the FDA&rsquo;s
Rare Pediatric Disease Priority Review Voucher Program, upon the approval of an NDA or a BLA for the treatment of a rare pediatric disease,
the sponsor of such application could be eligible for a Rare Pediatric Disease Priority Review Voucher that can be redeemed to obtain
priority review for a subsequent NDA or BLA. The sponsor of a rare pediatric disease drug product receiving a priority review voucher
may transfer (including by sale) the voucher to another sponsor. The voucher may be further transferred any number of times before the
voucher is used, as long as the sponsor making the transfer has not yet submitted the application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA may also revoke any
priority review voucher if the rare pediatric disease drug for which the voucher was awarded is not marketed in the U.S. within one year
following the date of approval. In addition, the priority review voucher is only awarded to an NCE. Thus, if iopofosine is approved first
for an indication that is not a rare pediatric disease, our application may not be eligible to receive the voucher. There is no assurance
we will receive a Rare Pediatric Disease Priority Review Voucher or that it will result in a faster development process, review or approval
for a subsequent marketing application. Also, although Priority Review Vouchers may be sold or transferred to third parties, there is
no guaranty that we will be able to realize any value if we were to sell a Priority Review Voucher. In December&nbsp;2020, the Priority
Review Voucher Program was extended by the FDA permitting additional grants through September&nbsp;2026 for rare pediatric diseases. It
is possible that even if we obtain approval for iopofosine and qualify for a priority review voucher, the program may no longer be in
effect at the time of such approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, due to recent
communications with the FDA regarding a confirmatory study to support accelerated approval and the regulatory submission for iopofosine,
the Company is, in addition to determining the availability of funding for such a study, pursuing strategic options for the further development
and commercialization of this product candidate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Clinical studies involve a lengthy and expensive
process with an uncertain outcome, and results of earlier studies may not be predictive of future study results.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To obtain regulatory approval
for the commercialization of our product candidates, we must conduct, at our own expense, extensive clinical studies to demonstrate safety
and efficacy of these product candidates. Clinical testing is expensive, it can take many years to complete, and its outcome is uncertain.
Failure can occur at any time during the clinical study process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may experience delays in
clinical testing of our product candidates. We do not know whether planned clinical studies will begin on time, need to be redesigned,
or be completed on schedule, if at all. Clinical studies can be delayed for a variety of reasons, including delays in obtaining regulatory
approval to commence a study, reaching agreement on acceptable clinical study terms with prospective sites, obtaining institutional review
board approval to conduct a study at a prospective site, recruiting patients to participate in a study, or obtaining sufficient supplies
of clinical study materials. Many factors affect patient enrollment, including the size of the patient population, the proximity of patients
to clinical sites, the eligibility criteria for the study, competing clinical studies, and new drugs approved for the conditions we are
investigating. Prescribing physicians will also have to decide to use our product candidates over existing drugs that have established
safety and efficacy profiles or other drugs undergoing development in clinical studies. Any delays in completing our clinical studies
will increase our costs, slow down our product development and approval process, and delay our ability to generate revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, the results
of preclinical studies and early clinical studies of our product candidates do not necessarily predict the results of later-stage clinical
studies. Product candidates in later stages of clinical studies may fail to show the desired safety and efficacy traits despite having
progressed through initial clinical testing. The data collected from clinical studies of our product candidates may not be sufficient
to support the submission of an NDA or to obtain regulatory approval in the U.S. or elsewhere. Because of the uncertainties associated
with drug development and regulatory approval, we cannot determine if or when we will have an approved product for commercialization or
will achieve sales or profits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, we typically
rely on third-party clinical investigators to conduct our clinical trials and other third-party organizations to oversee the operations
of such trials and to perform data collection and analysis. The clinical investigators are not our employees, and we cannot control the
amount or timing of resources that they devote to our programs. Failure of the third-party organizations to meet their obligations could
adversely affect clinical development of our products. As a result, we may face additional delaying factors outside our control if these
parties do not perform their obligations in a timely fashion. For example, any number of those issues could arise with our clinical trials
causing a delay. Delays of this sort could occur for the reasons identified above or other reasons. If we have delays in conducting the
clinical trials or obtaining regulatory approvals, our product development costs will increase. For example, we may need to make additional
payments to third-party investigators and organizations to retain their services or we may need to pay recruitment incentives. If the
delays are significant, our financial results and the commercial prospects for our product candidates will be harmed, and our ability
to become profitable will be delayed. Moreover, these third-party investigators and organizations may also have relationships with other
commercial entities, some of which may compete with us. If these third-party investigators and organizations assist our competitors at
our expense, it could harm our competitive position.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our clinical studies may not
demonstrate sufficient levels of efficacy necessary to obtain the requisite regulatory approvals for our drugs, and our proposed drugs
may not be approved for marketing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may not be able to initiate
or continue clinical studies or trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible
patients to participate in these clinical trials as required by the FDA or other regulatory authorities. Even if we are able to enroll
a sufficient number of patients in our clinical trials, if the pace of enrollment is slower than we expect, the development costs for
our product candidates may increase and the completion of our clinical trials may be delayed, or our clinical trials could become too
expensive to complete. Significant delays in clinical testing could negatively impact our product development costs and timing. Our estimates
regarding timing are based on a number of assumptions, including assumptions based on past experience with our other clinical programs.
If we are unable to enroll the patients in these trials at the projected rate, the completion of the clinical program could be delayed
and the costs of conducting the program could increase, either of which could harm our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may be required to suspend or discontinue
clinical studies because of unexpected side effects or other safety risks that could preclude approval of our product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our clinical studies may be
suspended at any time for a number of reasons. For example, we may voluntarily suspend or terminate our clinical studies if at any time
we believe that they present an unacceptable risk to the clinical study patients. In addition, regulatory agencies may order the temporary
or permanent discontinuation of our clinical studies at any time if they believe that the clinical studies are not being conducted in
accordance with applicable regulatory requirements or that they present an unacceptable safety risk to the clinical study patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Administering any product
candidates to humans may produce undesirable side effects. These side effects could interrupt, delay or halt clinical studies of our product
candidates and could result in the FDA or other regulatory authorities denying further development or approval of our product candidates
for any or all targeted indications. Ultimately, some or all of our product candidates may prove to be unsafe for human use. Moreover,
we could be subject to significant liability if any volunteer or patient suffers, or appears to suffer, adverse health effects as a result
of participating in our clinical studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The biopharmaceutical industry is subject
to extensive regulatory obligations and policies that are subject to change, including due to judicial challenges.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June&nbsp;28, 2024, the
U.S.&nbsp;Supreme Court issued an opinion holding that courts reviewing agency action pursuant to the Administrative Procedure Act (APA)
 &ldquo;must exercise their independent judgment&rdquo; and &ldquo;may not defer to an agency interpretation of the law simply because
a statute is ambiguous.&rdquo; The decision will have a significant impact on how lower courts evaluate challenges to agency interpretations
of law, including those by the FDA and other agencies with significant oversight of the biopharmaceutical industry. The new framework
is likely to increase both the frequency of such challenges and their odds of success by eliminating one way in which the government previously
prevailed in such cases. As a result, significant regulatory policies will be subject to increased litigation judicial scrutiny. Any resulting
changes in regulation may result in unexpected delays, increased costs, or other negative impacts on our business that are difficult to
predict.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Legal Compliance and Litigation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Controls we or our third-party collaborators
have in place to ensure compliance with all applicable laws and regulations may not be effective.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We and our third-party collaborators
are subject to federal, state and local laws and regulations governing the storage, use and disposal of hazardous materials and waste
products. Current or future regulations may impair our research, development, manufacturing and commercialization efforts. The inability
of our third-party collaborators to maintain the required licenses and permits for any reason will negatively impact our manufacturing,
and research and development activities. In addition, we may be required to indemnify third-party collaborators against certain liabilities
arising out of any failure by them to comply with such regulations and/or laws. If we or our third-party collaborators fail to comply
with any of these regulations and/or laws, a range of consequences could result, including the suspension or termination of clinical studies,
failure to obtain approval of a product candidate, restrictions on our products or manufacturing processes, withdrawal of our products
from the market, significant fines, exclusion from government healthcare programs, or other sanctions or litigation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are exposed to product, clinical and
preclinical liability risks that could create a substantial financial burden should we be sued.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business exposes us to
potential product liability and other liability risks that are inherent in the testing, manufacturing and marketing of pharmaceutical
products. In addition, the use in our clinical studies of pharmaceutical products that we, or our current or potential collaborators,
may develop and then subsequently sell, may cause us to bear a portion of, or all, product liability risks. While we carry an insurance
policy covering up to $5,000,000 per occurrence and $5,000,000 in the aggregate for liability incurred in connection with such claims
should they arise, there can be no assurance that our insurance will be adequate to cover all situations. Moreover, there can be no assurance
that such insurance, or additional insurance if required, will be available or, if available, will be available on commercially reasonable
terms. Furthermore, our current and potential partners with whom we have collaborative agreements, or our future licensees, may not be
willing to indemnify us against these types of liabilities and may not themselves be sufficiently insured or have a net worth sufficient
to satisfy any product liability claims. A successful product liability claim or series of claims brought against us could have a material
adverse effect on our business, prospects, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Intellectual Property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We expect to rely on our patents as well
as specialized regulatory designations such as orphan drug classification for our product candidates, but regulatory drug designations
may not confer marketing exclusivity or other expected commercial benefits.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect to file for ODD
or other regulatory designations (fast track, break-through, priority review,&nbsp;etc.) as appropriate for our product candidates. We
have been granted ODD in the U.S. for iopofosine as a therapeutic for the treatment of multiple myeloma, neuroblastoma, osteosarcoma,
rhabdomyosarcoma, Ewing&rsquo;s sarcoma and lymphoplasmacytic lymphoma/Waldenstrom&rsquo;s macroglobulinemia. Additionally, we have been
granted ODD in Europe for iopofosine as a therapeutic for the treatment of multiple myeloma and Waldenstrom&rsquo;s macroglobulinemia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Orphan Drug Act,
the FDA may grant orphan drug designation to a drug or biologic intended to treat a rare disease or condition, which is defined as one
occurring in a patient population of fewer than 200,000 in the US, or a patient population greater than 200,000 in the US where there
is no reasonable expectation that the cost of developing the drug will be recovered from sales in the US. In the US, orphan drug designation
entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee
waivers. In addition, if a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which
it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications,
including a full NDA, to market the same drug for the same indication for seven years, except in limited circumstances, such as a showing
of clinical superiority to the product with orphan drug exclusivity or where the manufacturer is unable to assure sufficient product quantity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even though we have received
ODD as described above, we may not be the first to obtain marketing approval for the orphan-designated indication because of the uncertainties
associated with developing pharmaceutical products. For any product candidate for which we have been or will be granted ODD in a particular
indication, it is possible that another company also holding ODD for the same product candidate will receive marketing approval for the
same indication before we do. If that were to happen, our applications for that indication may not be approved until the competing company&rsquo;s
period of exclusivity expires. In addition, exclusive marketing rights in the US for iopofosine for an orphan-designated indication or
any future product candidate may be limited if we seek approval for an indication broader than the orphan-designated indication or may
be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure
sufficient quantities of the product to meet the needs of patients with the rare disease or condition. We will not be able to rely on
it to exclude other companies from manufacturing or selling products using the same principal molecular structural features for the same
indication beyond these timeframes without our patent portfolio. Even if we were the first to obtain marketing authorization for an orphan
drug indication, there are circumstances under which a competing product may be approved for the same indication during the seven-year
period of marketing exclusivity, such as if the later product is shown to be clinically superior to the product with orphan exclusivity.
Even after an orphan product is approved, the FDA can subsequently approve the same drug with the same active moiety for the same condition
if the FDA concludes that the later drug is safer, more effective, or makes a major contribution to patient care. In addition, exclusive
marketing rights in the US for iopofosine or any future product candidate may be limited if we seek approval for an indication broader
than the orphan-designated indication or may be lost if the FDA later determines that the request for designation was materially defective
or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or
condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, even if we obtain
orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs
with different active moieties can be approved for the same condition. Further, the seven-year marketing exclusivity, if granted, would
not prevent competitors from obtaining approval of the same product candidate as ours for indications other than those in which we have
been granted ODD, or for other indications if not for our patent portfolio, or for the use of other types of products in the same indications
as our orphan product. Furthermore, although the ODD and exclusivity are in effect right now, the FDA has the authority to modify this
assessment at any time. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the
drug any advantage in the regulatory review or approval process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, Congress is considering
updates to the orphan drug provisions of the FDCA in response to a recent decision by the U.S. Court of Appeals for the Eleventh Circuit.
Any changes to the orphan drug provisions could change our opportunities for, or likelihood of success in obtaining, orphan drug exclusivity
and would materially adversely affect our business, results of operations, financial condition and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may face litigation from third parties
claiming our products infringe on their intellectual property rights, particularly because there is often substantial uncertainty about
the validity and breadth of medical patents.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may be exposed to future
litigation by third parties based on claims that our technologies, products or activities infringe on the intellectual property rights
of others or that we have misappropriated the trade secrets of others. This risk is exacerbated by the fact that the validity and breadth
of claims covered in medical technology patents, and the breadth and scope of trade-secret protection, involve complex legal and factual
questions for which important legal principles are unresolved. Any litigation or claims against us, whether valid or not, could result
in substantial costs, place a significant strain on our financial and managerial resources, and harm our reputation. License agreements
that we may enter into in the future would likely require that we pay the costs associated with defending this type of litigation. In
addition, intellectual property litigation or claims could force us to do one or more of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">cease selling, incorporating or using any of
our technologies and/or products that incorporate the challenged intellectual property, which would adversely affect our ability to generate
revenue;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">obtain a license from the holder of the infringed
intellectual property right, which license may be costly or may not be available on reasonable terms, if at all; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">redesign our products, which would be costly
and time-consuming.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we are unable to adequately protect or
enforce our rights to intellectual property or to secure rights to third-party patents, we may lose valuable rights, experience reduced
market share, assuming any, or incur costly litigation to protect our intellectual property rights.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ability to obtain licenses
to patents, maintain trade-secret protection, and operate without infringing the proprietary rights of others will be important to commercializing
any products under development. Therefore, any disruption in access to the technology could substantially delay the development of our
technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The patent positions of biotechnology
and pharmaceutical companies, such as ours, for products that involve licensing agreements are frequently uncertain and involve complex
legal and factual questions. In addition, the coverage claimed in a patent application can be significantly reduced before the patent
is issued or in subsequent legal proceedings. Consequently, our patent applications and any issued and licensed patents may not provide
protection against competitive technologies or may be held invalid if challenged or circumvented. To the extent we license patents from
third parties, the early termination of any such license agreement would result in the loss of our rights to use the covered patents,
which could severely delay, inhibit or eliminate our ability to develop and commercialize compounds based on the licensed patents. Our
competitors may also independently develop products similar to ours or design around or otherwise circumvent patents issued or licensed
to us. In addition, the laws of some foreign countries may not protect our proprietary rights to the same extent as U.S.&nbsp;law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also rely on trade secrets,
technical know-how and continuing technological innovation to develop and maintain our competitive position. Although we generally require
our employees, consultants, advisors, and collaborators to execute appropriate confidentiality and assignment-of-inventions agreements,
our competitors may independently develop substantially equivalent proprietary information and techniques, reverse engineer our information
and techniques, or otherwise gain access to our proprietary technology. We may be unable to meaningfully protect our rights in trade secrets,
technical know-how and other non-patented technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may have to resort to litigation
to protect our rights for certain intellectual property or to determine the scope, validity or enforceability of our intellectual property
rights. Enforcing or defending our rights would be expensive, could cause diversion of our resources, and may not prove successful. Any
failure to enforce or protect our rights could cause us to lose the ability to exclude others from using our technology to develop or
sell competing products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Our Employees</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We rely on a small number of key personnel
who may terminate their employment with us at any time, and our success will depend on our ability to hire additional qualified personnel.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our success depends to a significant
degree on the continued services of our executive officers, including our Chief Executive Officer, James&nbsp;V. Caruso. Our management
and other employees may voluntarily terminate their employment with us at any time, and there can be no assurance that these individuals
will continue to provide services to us. Our success will depend on our ability to attract and retain highly skilled personnel. We may
be unable to recruit such personnel on a timely basis, if at all. The loss of services of key personnel, or the inability to attract and
retain additional qualified personnel, could result in delays in development or approval of our products, loss of sales and diversion
of management resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Confidentiality agreements with employees
and others may not adequately prevent disclosure of our trade secrets and other proprietary information and may not adequately protect
our intellectual property, which could limit our ability to compete.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We operate in the highly technical
field of research and development of small-molecule drugs and rely, in part, on trade-secret protection in order to protect our proprietary
trade secrets and unpatented know-how. However, trade secrets are difficult to protect, and we cannot be certain that our competitors
will not develop the same or similar technologies on their own. We have taken steps, including entering into confidentiality agreements
with our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors, to protect our trade secrets
and unpatented know-how. These agreements generally require that the other party keep confidential and not disclose to third parties all
confidential information developed by the party or made known to the party by us during the course of the party&rsquo;s relationship with
us. Also, we typically obtain agreements from these parties that inventions conceived by them in the course of rendering services to us
will be our exclusive property. However, these agreements may not be honored and may not effectively assign intellectual property rights
to us. Enforcing a claim that a party has illegally obtained, and is using our trade secrets or know-how, is difficult, expensive, and
time-consuming, and the outcome is unpredictable. In addition, courts outside the U.S. may be less willing to protect trade secrets or
know-how. The failure to obtain or maintain trade-secret protection could adversely affect our competitive position.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may be subject to claims that our employees
have wrongfully used or disclosed alleged trade secrets of their current or former employers.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As is common in the biotechnology
and pharmaceutical industry, we engage individuals who were previously employed at other biotechnology or pharmaceutical companies, including
our competitors or potential competitors or who are employed by academic research institutions. Although no claims against us are currently
pending, we may be subject to claims that we, or these employees, have used or disclosed trade secrets or other proprietary information
of their current or former employers, either inadvertently or otherwise. Litigation may be necessary to defend against these claims. Even
if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Commercialization of our Products</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Acceptance of our products in the marketplace
is uncertain and failure to achieve market acceptance will prevent or delay our ability to generate revenues.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our future financial performance
will depend, at least in part, on the introduction and customer acceptance of our proposed products. Even if approved for marketing by
the necessary regulatory authorities, our products may not achieve market acceptance. The degree of market acceptance will depend on several
factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">receiving regulatory clearance of marketing claims
for the uses that we are developing;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the timing of market introduction of the product
as well as competitive products;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the clinical indications for which the product
is approved;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">establishing and demonstrating the advantages,
safety and efficacy of our technologies;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">relative convenience and ease of administration,
and the convenience of prescribing, administrating and initiating patients on the product and the length of time the patient is on the
product;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the willingness of the target patient population
to try new therapies and of physicians to prescribe these therapies;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the willingness of physicians to change their
current treatment practices;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the willingness of hospitals and hospital systems
to include our product candidates as treatment options;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">demonstration of efficacy and safety in clinical
trials;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the prevalence and severity of any side effects;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the ability to offer product candidates for sale
at competitive prices;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the price we charge for our product candidates;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the strength of marketing and distribution support;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the ability to distinguish safety and efficacy
from existing, less expensive generic alternative therapies, if any;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the potential and perceived value and advantages
of the product over alternative treatments;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the cost of treatment in relation to alternative
treatments, including any similar generic treatments;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">pricing and reimbursement policies of government
and third-party payors such as insurance companies, health maintenance organizations and other health plan administrators;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">attracting corporate partners, including pharmaceutical
companies, to assist in commercializing our intended products; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">marketing our products.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Physicians, patients, payors,
or the medical community in general, may be unwilling to accept, use, or recommend any of our products. If we are unable to obtain regulatory
approval or commercialize and market our proposed products as planned, we may not achieve any market acceptance or generate revenue. If
we are unable to sustain anticipated levels of sales growth from our products, if approved, we may need to reduce our operating expenses,
access other sources of cash or otherwise modify our business plans, which could have a negative impact on our business, financial condition
and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Regulatory approval for any approved product
is limited by the FDA, the European Commission (based on recommendation from the EMA), and comparable foreign authorities, to those specific
indications and conditions for which clinical safety and efficacy have been demonstrated, and we may incur significant liability if it
is determined that we are promoting the &ldquo;off-label&rdquo; use of any of our future product candidates if approved.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any regulatory approval is
limited to those specific diseases, indications and patient populations for which a product is deemed to be safe and effective by the
FDA, the European Commission (through the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency) and
other regulators. In addition to the FDA approval required for new formulations, any new indication for an approved product also requires
FDA approval. If we are not able to obtain FDA approval for any desired future indications for our products and product candidates, our
ability to effectively market and sell our products may be reduced and our business may be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While physicians may choose
to prescribe drugs for uses that are not described in the product&rsquo;s labeling and for uses that differ from those tested in clinical
studies and approved by the regulatory authorities, our ability to promote the products is limited to those indications and patient populations
that are specifically approved by the FDA or similar regulatory authorities in jurisdictions outside the U.S. These &ldquo;off-label&rdquo;
uses are common across medical specialties and may constitute an appropriate treatment for some patients in varied circumstances. We have
implemented compliance and monitoring policies and procedures, including a process for internal review of promotional materials, to deter
the promotion for off-label uses. We cannot guarantee that these compliance activities will prevent or timely detect off-label promotion
by sales representatives or other personnel in their communications with health care professionals, patients and others, particularly
if these activities are concealed from the Company. Regulatory authorities in the US generally do not regulate the behavior of physicians
in their choice of treatments. Regulatory authorities do, however, restrict communications by pharmaceutical companies on the subject
of off-label use. If our promotional activities fail to comply with the FDA&rsquo;s or other competent national authority&rsquo;s regulations
or guidelines, we may be subject to warnings from, or enforcement action by, these regulatory authorities. In addition, our failure to
follow FDA rules&nbsp;and guidelines relating to promotion and advertising may cause the FDA to issue warning letters or untitled letters,
suspend or withdraw an approved product from the market, require a recall or institute fines, which could result in the disgorgement of
money, operating restrictions, injunctions or civil or criminal enforcement, and other consequences, any of which could harm our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the regulatory
restrictions on off-label promotion, the FDA and other regulatory authorities allow companies to engage in truthful, non-misleading and
non-promotional scientific exchange concerning their products. We engage in medical education activities and communicate with investigators
and potential investigators regarding our clinical trials. If the FDA or other regulatory or enforcement authorities determine that our
communications regarding our marketed product are not in compliance with the relevant regulatory requirements and that we have improperly
promoted off-label uses, or that our communications regarding our investigational products are not in compliance with the relevant regulatory
requirements and that we have improperly engaged in pre-approval promotion, we may be subject to significant liability, including civil
and administrative remedies as well as criminal sanctions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Any product for which we have obtained regulatory
approval, or for which we obtain approval in the future, is subject to, or will be subject to, extensive ongoing regulatory requirements
by the FDA, the European Commission (based on recommendation from the EMA) and other comparable regulatory authorities, and if we fail
to comply with regulatory requirements or if we experience unanticipated problems with our products, we may be subject to penalties, we
may be unable to generate revenue from the sale of such products, our potential for generating positive cash flow may be diminished, and
the capital necessary to fund our operations may be increased.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any product for which we have
obtain regulatory approval in the future, along with the manufacturing processes and practices, post-approval clinical research, product
labeling, advertising and promotional activities for such product, are subject to continual requirements of, and review by, the FDA, the
European Commission (based on recommendation from the EMA) and other comparable international regulatory authorities. These requirements
include submissions of safety and other post-marketing information and reports, registration and listing requirements, current good manufacturing
practices (cGMP) requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and
documents, requirements regarding the distribution of samples to physicians, import and export requirements and recordkeeping. If we or
our suppliers encounter manufacturing, quality or compliance difficulties with respect to any of our product candidates, when and if approved,
we may be unable to obtain or maintain regulatory approval or meet commercial demand for such products, which could adversely affect our
business, financial conditions, results of operations and growth prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the FDA often
requires post-marketing testing and surveillance to monitor the effects of products. The FDA, the European Commission (based on recommendation
from the EMA) and other comparable international regulatory authorities may condition approval of our product candidates on the completion
of such post-marketing clinical studies. These post-marketing studies may suggest that a product causes undesirable side effects or may
present a risk to the patient. Additionally, the FDA may require a REMS to help ensure that the benefits of the drug outweigh its risks.
A REMS may be required to include various elements, such as a medication guide or patient package insert, a communication plan to educate
healthcare providers of the drug&rsquo;s risks, limitations on who may prescribe or dispense the drug, requirements that patients enroll
in a registry or undergo certain health evaluations or other measures that the FDA deems necessary to ensure the safe use of the drug.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Discovery after approval of
previously unknown problems with any of our products, manufacturers or manufacturing processes, or failure to comply with regulatory requirements,
may result in actions such as:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">restrictions on our ability to conduct clinical
trials, including full or partial clinical holds on ongoing or planned trials&#894;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">restrictions on product manufacturing processes;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">restrictions on the marketing of a product;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">restrictions on product distribution;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">requirements to conduct post-marketing clinical
trials;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">untitled or warning letters or other adverse
publicity;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">withdrawal of products from the market;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">refusal to approve pending applications or supplements
to approved applications that we submit;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">recall of products;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">refusal to permit the import or export of our
products;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">product seizure;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">fines, restitution or disgorgement of profits
or revenue;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">refusal to allow us to enter into supply contracts,
including government contracts;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">injunctions; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">imposition of civil or criminal penalties.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If such regulatory actions
are taken, the value of our company and our operating results will be adversely affected. Additionally, if the FDA, the European Commission
(based on a recommendation from the EMA) or any other comparable international regulatory agency withdraws its approval of a product that
is or may be approved, we will be unable to generate revenue from the sale of that product in the relevant jurisdiction, our potential
for generating positive cash flow will be diminished and the capital necessary to fund our operations will be increased. Accordingly,
we continue to expend significant time, money and effort in all areas of regulatory compliance, including manufacturing, production, product
surveillance, post-marketing studies and quality control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If any of our third-party contractors fail
to perform their responsibilities to comply with FDA rules&nbsp;and regulations, the marketing and sales of our products could be delayed
and we may be subject to enforcement action, which could decrease our revenues.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Conducting our business requires
us to manage relationships with third-party contractors. As a result, our success depends partially on the success of these third parties
in performing their responsibilities to comply with FDA rules&nbsp;and regulations. Although we pre-qualify our contractors and we believe
that they are fully capable of performing their contractual obligations, we cannot directly control the adequacy and timeliness of the
resources and expertise that they apply to these activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any of our partners or
contractors fail to fulfil their obligations in an adequate and timely manner or fail to comply with the FDA&rsquo;s rules&nbsp;and regulations,
then the marketing and sales of our products could be delayed. The FDA may also take enforcement actions against us based on compliance
issues identified with our contractors. If any of these events occur, we may incur significant liabilities, which could decrease our revenues.
For example, sales and medical science liaison or MSL personnel, including contractors, must comply with FDA requirements for the advertisement
and promotion of products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If manufacturers obtain approval for generic
versions of our products, once approved, or of products with which we compete, our business may be harmed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the FDCA, the FDA can
approve an abbreviated new drug application (ANDA) for a generic version of a branded drug without the ANDA applicant undertaking the
clinical testing necessary to obtain approval to market a new drug. Generally, in place of such clinical studies, an ANDA applicant usually
needs only to submit data demonstrating that its product has the same active ingredient(s), strength, dosage form and route of administration
and that it is bioequivalent to the branded product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDCA requires that an
applicant for approval of a generic form of a branded drug certify either that its generic product does not infringe any of the patents
listed by the owner of the branded drug in the Orange Book or that those patents are not enforceable. This process is known as a paragraph&nbsp;IV
challenge. Upon notice of a paragraph&nbsp;IV challenge, a patent owner has 45&nbsp;days to bring a patent infringement suit in federal
district court against the company seeking ANDA approval of a product covered by one of the owner&rsquo;s patents. If this type of suit
is commenced, the FDCA provides a 30-month stay on the FDA&rsquo;s approval of the competitor&rsquo;s application. If the litigation is
resolved in favor of the ANDA applicant or the challenged patent expires during the 30-month stay period, the stay is lifted, and the
FDA may thereafter approve the application based on the standards for approval of ANDAs. Once an ANDA is approved by the FDA, the generic
manufacturer may market and sell the generic form of the branded drug in competition with the branded medicine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The ANDA process can result
in generic competition if the patents at issue are not upheld or if the generic competitor is found not to infringe the owner&rsquo;s
patents. If this were to occur with respect to iopofosine or any future products, once approved, with which our products compete, our
business would be harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Unforeseen safety issues could emerge with
our products, once approved, that could require us to change the prescribing information to add warnings, limit use of the product, and/or
result in litigation. Any of these events could have a negative impact on our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Discovery of unforeseen safety
problems or increased focus on a known problem with respect to our products, once approved, could impact our ability to commercialize
our products and could result in restrictions on its permissible uses, including withdrawal of the medicine from the market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we or others identify additional
undesirable side effects caused by our products after approval:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">regulatory authorities may require the addition
of labeling statements, specific warnings, contraindications, or field alerts to physicians and pharmacies;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">regulatory authorities may withdraw their approval
of the product and require us to take our approved drugs off the market;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">we may be required to change the way the product
is administered, conduct additional clinical trials, change the labeling of the product, or implement a Risk Evaluation and Mitigation
Strategy, or REMS;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">we may have limitations on how we promote our
drugs;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">third-party payers may limit coverage or reimbursement
for our products;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">sales of our approved products may decrease significantly;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">we may be subject to litigation or product liability
claims; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our reputation may suffer.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any of these events could
prevent us from achieving or maintaining market acceptance of our products, once approved and could substantially increase our operating
costs and expenses, which in turn could delay or prevent us from generating significant revenue from sale of any products for which we
obtain approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a safety issue emerges
post-approval, we may become subject to costly product liability litigation by our customers, their patients or payers. Product liability
claims could divert management&rsquo;s attention from our core business, be expensive to defend, and result in sizable damage awards against
us that may not be covered by insurance. If we cannot successfully defend ourselves against claims that our approved products caused injuries,
we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">decreased demand for any product candidates or
products that we may develop;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the inability to commercialize any products that
we may develop;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">injury to our reputation and significant negative
media attention;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">withdrawal of patients from clinical studies
or cancellation of studies;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">significant costs to defend the related litigation;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">substantial monetary awards to patients; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">loss of revenue.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The market for our proposed products is
rapidly changing and competitive, and new therapeutics, drugs and treatments that may be developed by others could impair our ability
to develop our business or become competitive.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The pharmaceutical and biotechnology
industries are subject to rapid and substantial technological change. Developments by others may render our technologies and proposed
products noncompetitive or obsolete, or we may be unable to keep pace with technological developments or other market factors. Technological
competition from pharmaceutical and biotechnology companies, universities, governmental entities and others diversifying into the field
is intense and expected to increase. Most of these entities have significantly greater research and development capabilities and budgets
than we do, as well as substantially more marketing, manufacturing, financial and managerial resources. These entities represent significant
competition for us. Acquisitions of, or investments in, competing pharmaceutical or biotechnology companies by large corporations could
increase our competitors&rsquo; financial, marketing, manufacturing and other resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our resources are limited,
and we may experience management, operational or technical challenges inherent in our activities and novel technologies. Competitors have
developed, or are in the process of developing, technologies that are, or in the future may be, the basis for competition. Some of these
technologies may accomplish therapeutic effects similar to those of our technology, but through different means. Our competitors may develop
drugs and drug delivery technologies that are more effective than our intended products and, therefore, present a serious competitive
threat to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The potential widespread acceptance
of therapies that are alternatives to ours may limit market acceptance of our products even if they are commercialized. Many of our targeted
diseases and conditions can also be treated by other medication or drug delivery technologies. These treatments may be widely accepted
in medical communities and have a longer history of use. The established use of these competitive drugs may limit the potential for widespread
acceptance of our technologies and products if commercialized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>As a result of continued changes in marketing,
sales and distribution, we may be unsuccessful in our efforts to sell our proposed products, develop a direct sales organization, or enter
into relationships with third parties.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not established marketing,
sales or distribution capabilities for our proposed products. Until such time as our proposed products are further along in the development
process, we will not devote any meaningful time and resources to this effort. At the appropriate time, we will determine whether we will
develop our own sales and marketing capabilities or enter into agreements with third parties to sell our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have limited experience
in developing, training or managing a sales force. If we choose to establish a direct sales force, we may incur substantial additional
expenses in developing, training and managing such an organization. We may be unable to build a sales force on a cost-effective basis
or at all. In addition, we will compete with many other companies that currently have extensive marketing and sales operations. Our marketing
and sales efforts may be unable to compete against these other companies. We may be unable to establish a sufficient sales and marketing
organization on a cost-effective or timely basis, if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we choose to enter into
agreements with third parties to sell our proposed products, we may be unable to establish or maintain third-party relationships on a
commercially reasonable basis, if at all. In addition, these third parties may have similar or more established relationships with our
competitors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may be unable to engage
qualified distributors. Even if engaged, these distributors may:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">fail to adequately market our products;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">fail to satisfy financial or contractual obligations
to us;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">offer, design, manufacture or promote competing
products; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">cease operations with little or no notice.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we fail to develop sales,
marketing and distribution channels, we would experience delays in product sales and incur increased costs, which would have a material
adverse effect on our business, prospects, financial condition and results of operation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we are unable to convince physicians
of the benefits of our intended products, we may incur delays or additional expense in our attempt to establish market acceptance.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Achieving use of our products
in the target market of cancer diagnosis and treatment may require physicians to be informed regarding these products and their intended
benefits. The time and cost of such an educational process may be substantial. Inability to successfully carry out this physician education
process may adversely affect market acceptance of our proposed products. We may be unable to educate physicians, in sufficient numbers,
in a timely manner regarding our intended proposed products to achieve our marketing plans and product acceptance. Any delay in physician
education may materially delay or reduce demand for our proposed products. In addition, we may expend significant funds towards physician
education before any acceptance or demand for our proposed products is created, if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Efforts to educate the physicians,
patients, healthcare payors and others in the medical community on the benefits of our product candidates may require significant resources
and may not be successful. If any of our product candidates are approved, if at all, but do not achieve an adequate level of acceptance,
we may not generate significant product revenue and we may not become profitable on a sustained basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If our products are unable to obtain adequate
reimbursement from third-party payors, or if additional healthcare reform measures are adopted, it could hinder or prevent the commercial
success of our product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The commercial success of
any product for which we obtain regulatory approval in the future will depend substantially on the extent to which the costs of our product
or product candidates are or will be paid by third-party payors, including government health care programs and private health insurers.
There is a significant trend in the health care industry by public and private payers to contain or reduce their costs, including by taking
the following steps, among others: decreasing the portion of costs payers will cover, ceasing to provide full payment for certain products
depending on outcomes or not covering certain products at all. If payers implement any of the foregoing with respect to our products,
it would have an adverse impact on our revenue and results of operations. If coverage is not available, or reimbursement is limited, we,
or any of our collaborative partners, may not be able to successfully commercialize our product candidates in some jurisdictions. Even
if coverage is provided, the approved reimbursement amount may not be at a rate that covers our costs, including research, development,
manufacture, sale and distribution. In the U.S., no uniform policy of coverage and reimbursement for products exists among third-party
payors; therefore, coverage and reimbursement levels for products can differ significantly from payor to payor. As a result, the coverage
determination process is often a time consuming and costly process that may require us to provide scientific, clinical or other support
for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently
or obtained in the first instance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In both the U.S. and some
foreign jurisdictions, there have been a number of legislative and regulatory proposals to change the healthcare system in ways that could
affect our ability to sell our products profitably. For example, the Affordable Care Act which was passed in March&nbsp;2010 and substantially
changed the way healthcare is financed by both governmental and private insurers, has been subject to judicial, legislative, and regulatory
efforts to replace it or to alter its interpretation or implementation. Congress has considered legislation that would repeal or repeal
and replace all or part of the Affordable Care Act. While Congress has not passed comprehensive repeal legislation, several bills affecting
the implementation of certain taxes under the Affordable Care Act have been enacted. The Tax Cuts and Jobs Act of 2017 included a provision
that repealed the tax-based shared responsibility payment imposed by the Affordable Care Act on certain individuals who fail to maintain
qualifying health coverage for all or part of a year that is commonly referred to as the &ldquo;individual mandate&rdquo;. In addition,
the Consolidated Appropriations Act of 2020 fully repealed the Affordable Care Act&rsquo;s mandated &ldquo;Cadillac&rdquo; tax on high-cost
employer-sponsored health coverage and medical device tax and also eliminated the health insurer tax. On June&nbsp;17, 2021, the U.S.&nbsp;Supreme
Court dismissed the most recent judicial challenge to the Affordable Care Act brought by several states without specifically ruling on
the constitutionality of the law. It is unclear how future actions before the Supreme Court, other such litigation, and any healthcare
reform measures of the Trump administration will impact the Affordable Care Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other legislative changes
have been proposed and adopted in the U.S. since the Affordable Care Act was enacted. In August&nbsp;2011, the Budget Control Act of 2011,
among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending
a targeted deficit reduction of at least $1.2&nbsp;trillion for the years 2013 through 2021, was unable to reach required goals, thereby
triggering the legislation&rsquo;s automatic reduction to several government programs. This includes aggregate reductions of Medicare
payments to providers of 2%&nbsp;per fiscal year, which went into effect in April&nbsp;2013, and, a result of subsequent legislative amendments,
will remain in effect into 2031, unless additional Congressional action is taken. However, COVID-19 relief support legislation suspended
the 2% Medicare sequester from May&nbsp;1, 2020 through March&nbsp;31, 2022 with a subsequent reduction to 1% implemented from April&nbsp;1,
2022 until June&nbsp;30, 2022. To offset the temporary suspension during the COVID-19 pandemic, in 2030, reductions in Medicare payments
will be 2.25% for the first half of the year, and 3% in the second half of the year. In January&nbsp;2013, President Obama signed into
law the American Taxpayer Relief Act of 2012 (ATRA), which, among other things, further reduced Medicare payments to several providers,
including hospitals and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments
to providers from three to five years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There have been, and likely
will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at broadening the availability
of healthcare and containing or lowering the cost of healthcare. We cannot predict the initiatives that may be adopted in the future.
If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements
or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory
approval that may have been obtained and we may not achieve or sustain profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Enacted and future legislation may increase
the difficulty and cost for us to commercialize our product candidates and may affect the prices we may set.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the U.S., there have been
several recent Congressional inquiries and federal legislation designed to, among other things, bring more transparency to drug pricing,
review the relationship between pricing and manufacturer-sponsored patient assistance programs, and reform government program reimbursement
methodologies for drugs. See Part&nbsp;I,&nbsp;Item&nbsp;1, Business-Regulation-Reimbursement and Pricing Controls in our Annual Report
on Form&nbsp;10-K for the year ended December&nbsp;31, 2024 for more information on recent healthcare reform measures that may affect
our ability to operate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot predict the likelihood,
nature, or extent of health reform initiatives that may arise from future legislation or administrative action. However, we expect these
initiatives to increase pressure on drug pricing. Further, certain broader legislation that is not targeted to the health care industry
may nonetheless adversely affect our profitability. Any additional healthcare reform measures could limit the amounts that the U.S.&nbsp;federal
government will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional
pricing pressures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may be subject, directly or indirectly,
to federal and state healthcare fraud and abuse laws, false claims laws and other federal and state healthcare laws, and the failure to
comply with such laws could result in substantial penalties. Our employees, independent contractors, consultants, principal investigators,
CROs, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards
and requirements.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business operations and
current and future arrangements with investigators, healthcare professionals, consultants, third-party payers and customers, may expose
us to broadly applicable federal, state and foreign fraud and abuse and other healthcare laws and regulations including anti-kickback
and false claims laws, data privacy and security laws, and transparency reporting laws. These laws may constrain the business or financial
arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute any product
for which we have obtained regulatory approval, or for which we obtain regulatory approval in the future. In particular, the promotion,
sales and marketing of healthcare items and services, as well as certain business arrangements in the healthcare industry, are subject
to extensive laws and regulations intended to prevent fraud, misconduct, bribery kickbacks, self-dealing and other abusive or inappropriate
practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, including
promoting off-label uses of our products, commission compensation, certain customer incentive programs, certain patient support offerings,
and other business arrangements generally. Activities subject to these laws also involve the improper use or misrepresentation of information
obtained in the course of patient recruitment for clinical trials, creating fraudulent data in our preclinical studies or clinical trials
or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. See
 &ldquo;Part&nbsp;I,&nbsp;Item&nbsp;1, Business - Regulation - Other U.S.&nbsp;Regulatory Requirements&rdquo; of our Annual Report on Form&nbsp;10-K
for more information on the healthcare laws and regulations that may affect our ability to operate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are also exposed to the
risk of fraud, misconduct or other illegal activity by our employees, independent contractors, consultants, principal investigators, CROs,
commercial partners and vendors. Misconduct by these parties could include intentional, reckless and/or negligent conduct that fails to:
comply with the laws of the FDA and other similar foreign regulatory bodies; provide true, complete and accurate information to the FDA
and other similar foreign regulatory bodies; comply with manufacturing standards we have established; comply with federal and state data
privacy, security, fraud and abuse and other healthcare laws and regulations in the US and similar foreign fraudulent misconduct laws;
or report financial information or data accurately or to disclose unauthorized activities to us. It is not always possible to identify
and deter employee misconduct, and the precautions we take to detect and prevent inappropriate conduct may not be effective in controlling
unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a
failure to be in compliance with such laws or regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are also subject to the
risk that a person or government could allege such fraud or other misconduct, even if none occurred. Efforts to ensure that our business
arrangements will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental
and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case
law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against us, and
we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including
the imposition of significant civil, criminal and administrative penalties, damages, disgorgement, monetary fines, imprisonment, additional
reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations
of non-compliance with these laws, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs,
contractual damages, reputational harm, diminished profits and future earnings, and curtailment or restructuring of our operations, any
of which could adversely affect our ability to operate our business and our results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Regulatory legislative reform measures may
have a material adverse effect on our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the EU, the outcomes of
the ongoing review of the existing EU legislation on pharmaceutical products (the EU&nbsp;General Pharmaceutical Legislation or EU&nbsp;GPL)
are uncertain. The GPL will have a major impact on the EU&nbsp;legislation on pharmaceutical products, and could, for example, result
in a reduction of our data protection and market exclusivity periods. The final content of the EU&nbsp;GPL and timing for its adoption
remain unclear, but negotiations could in theory be completed as early as the end of 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Internal Controls</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We identified certain misstatements to our
previously issued financial statements and have restated the financial statements described below, which has exposed us to additional
risks and uncertainties.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have restated our previously
issued audited financial statements as of and for the years ended December&nbsp;31, 2022 and 2023 and our interim financial statements
as of and for the quarterly periods ended March&nbsp;31, 2024, March&nbsp;31, 2023 through September&nbsp;30, 2023 and March&nbsp;31,
2022 through September&nbsp;30, 2022 (Restatement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result of the misstatements
discussed and the Restatement, we have become subject to a number of additional risks and uncertainties and unanticipated costs for accounting,
legal and other fees and expenses, including risks of lawsuits relating to securities offered by us in public and private offerings as
well as claims by purchasers of our shares of common stock in the public market. Any actions, lawsuit or other legal proceedings related
to the misstatements or the Restatement could result in liabilities, reputational harm and defense and other costs, regardless of the
outcome of the lawsuit or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot ensure that litigation
or other claims by stockholders will not be brought in the future arising out of the Restatement. We may also be subject to further examinations,
investigations, proceedings and orders by regulatory authorities as a result of the Restatement. Any such further actions could be expensive
and damaging to our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We identified material weaknesses in our
internal control over financial reporting. If we are unable to remediate these material weaknesses, or if we identify additional material
weaknesses in the future or otherwise fail to maintain effective internal control over financial reporting, we may not be able to accurately
or timely report our financial condition or results of operations, which may adversely affect our business and share price.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are required to establish
and maintain appropriate internal controls over financial reporting. Rules&nbsp;adopted by the SEC pursuant to Section&nbsp;404 of the
Sarbanes-Oxley Act of 2002 require an annual assessment of internal controls over financial reporting and for certain issuers an attestation
of this assessment by the issuer&rsquo;s independent registered public accounting firm. The standards to assess that our internal controls
over financial reporting are effective are evolving and complex, require significant documentation and testing, and may require remediation
if they are not met. We expect to incur significant expenses and to devote resources to Section&nbsp;404 compliance on an ongoing basis.
It is difficult for us to predict how long it will take or costly it will be to complete the assessment of the effectiveness of our internal
control over financial reporting for each year and to remediate any deficiencies in our internal control over financial reporting. As
a result, we may not be able to complete the assessment and remediation process on a timely basis. In addition, although attestation requirements
by our independent registered public accounting firm are not presently applicable to us, we could become subject to these requirements
in the future, and we may encounter problems or delays in completing the implementation of any resulting changes to internal controls
over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Effective internal controls
are necessary for us to provide reasonable assurance with respect to our financial reports and to effectively prevent fraud. Failure to
maintain effective internal controls could adversely affect our public disclosures regarding our business, prospects, financial condition,
or results of operations. In addition, management&rsquo;s assessment of internal controls over financial reporting may identify weaknesses
and conditions that need to be addressed in our internal controls over financial reporting or other matters that may raise concerns for
investors. Any actual or perceived weaknesses and conditions that need to be addressed in our internal control over financial reporting
or disclosure of management&rsquo;s assessment of our internal controls over financial reporting our business and results of operations
could be harmed, we could fail to meet our reporting obligations, and there could be a material adverse effect on our common stock price.
There are identified material weaknesses that are described further in Item&nbsp;9A. of our Annual Report on Form&nbsp;10-K for the year
ended December&nbsp;31, 2024. These material weaknesses resulted in our historical financial statements requiring restatement, as is noted
above, and delayed our required filings with the SEC, a situation that could recur in the event that we do not effectively remediate the
existing material weaknesses and/or experience additional material weaknesses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Our Equity Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Failure to meet Nasdaq&rsquo;s continued
listing requirements could result in the delisting of our common stock, negatively impact the price of our common stock and negatively
impact our ability to raise additional capital.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We must continue to satisfy
Nasdaq continued listing requirements, including, among other things, certain corporate governance requirements, minimum stockholders&rsquo;
equity of $2.5&nbsp;million, and a minimum closing bid price requirement of $1.00&nbsp;per share. If a company fails for 30&nbsp;consecutive
business days to meet the $1.00&nbsp;minimum closing bid price requirement, Nasdaq will send a deficiency notice to the company, advising
that it has been afforded a &ldquo;compliance period&rdquo; of 180&nbsp;calendar days to regain compliance with the applicable requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January&nbsp;30, 2025,
we received a deficiency letter from Nasdaq notifying us that, for the last 30&nbsp;consecutive business days, the closing bid price for
our common stock was below the minimum $1.00&nbsp;per share required for continued listing on Nasdaq pursuant to the minimum closing bid
price requirement. The Nasdaq deficiency letter had no immediate effect on the listing of our common stock. In accordance with Nasdaq
Listing Rule&nbsp;5810(c)(3)(A), we were given 180&nbsp;calendar days, or until July&nbsp;29, 2025, to regain compliance with the minimum
closing bid price requirement by causing our stock to close above $1.00 for a minimum of 10&nbsp;consecutive trading days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June&nbsp;24, 2025, we
effected the 1-for-30&nbsp;Reverse Stock Split to regain compliance with the bid price requirement prior to the July&nbsp;29, 2025 compliance
deadline. On July&nbsp;9, 2025, we received a letter from Nasdaq confirming that we regained compliance with the minimum bid price requirement
in Nasdaq Listing Rule&nbsp;5550(a)(2), as it was determined that for the last 10&nbsp;consecutive business days, from June&nbsp;24, 2025
to July&nbsp;8, 2025, the closing bid price of our common stock was at $1.00 per share or greater. There is no assurance we will maintain
compliance with Nasdaq continued listing requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our common stock becomes
subject to delisting, it would be subject to rules&nbsp;that impose additional sales practice requirements on broker-dealers who sell
our securities. The additional burdens imposed upon broker-dealers by these requirements could discourage broker-dealers from effecting
transactions in our common stock. This would adversely affect the ability of investors to trade our common stock and would adversely affect
the value of our common stock. These factors could contribute to lower prices and larger spreads in the bid and ask prices for our common
stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our common stock could be further diluted
as the result of the issuance of additional shares of common stock, convertible securities, warrants or options.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the past, we have issued
common stock, convertible securities (such as convertible preferred stock and notes payable) and warrants to raise capital. We have also
issued equity as compensation for services and incentive compensation for our employees and directors. We have shares of common stock
reserved for issuance upon the exercise of certain of these securities and may increase the shares reserved for these purposes in the
future. Our issuance of additional common stock, convertible securities, options and warrants could dilute our common stock, affect the
rights of our stockholders, reduce the market price of our common stock, result in adjustments to exercise prices of outstanding warrants
(resulting in these securities becoming exercisable for, as the case may be, a greater number of shares of our common stock), or obligate
us to issue additional shares of common stock to certain of our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Provisions of our certificate of incorporation,
by-laws, and Delaware law may make an acquisition of us or a change in our management more difficult.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain provisions of our
certificate of incorporation and by-laws could discourage, delay or prevent a merger, acquisition or other change in control that stockholders
may consider favorable, including transactions in which an investor might otherwise receive a premium for its shares. These provisions
also could limit the price that investors might be willing to pay in the future for shares of our common stock or warrants, thereby depressing
the market price of our common stock. Stockholders who wish to participate in these transactions may not have the opportunity to do so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, these provisions
could prevent or frustrate attempts by our stockholders to replace or remove our management. These provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">provide for the division of the Board into three
classes as nearly equal in size as possible with staggered three-year terms and further limit the removal of directors and the filling
of vacancies;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">authorize our Board to issue without stockholder
approval blank-check preferred stock that, if issued, could operate as a &ldquo;poison pill&rdquo; to dilute the stock ownership of a
potential hostile acquirer to prevent an acquisition that is not approved by our Board;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">require that stockholder actions must be effected
at a duly called stockholder meeting and prohibit stockholder action by written consent;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">establish advance notice requirements for stockholder
nominations to our Board or for stockholder proposals that can be acted on at stockholder meetings;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">limit who may call stockholder meetings; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">require the approval of the holders of 75% of
the outstanding shares of our capital stock entitled to vote in order to amend certain provisions of our certificate of incorporation.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, because we are
incorporated in Delaware, we are governed by the provisions of Section&nbsp;203 of the Delaware General Corporation Law, which may, unless
certain criteria are met, prohibit large stockholders, in particular those owning&nbsp;15% or more of our outstanding voting stock, from
merging or combining with us for a prescribed period of time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The sale of a substantial number of shares
of our common stock in the public market, including resale of the Shares hereby, could adversely affect the prevailing market price for
our common stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are registering for resale
up to 2,096,188 shares of our common stock to fulfill our contractual obligations in the Inducement Letters. Sales of substantial amounts
of shares of our common stock in the public market, or the perception that such sales might occur, could adversely affect the market price
of our common stock. We cannot predict if and when the selling stockholders may sell such shares in the public markets or if the selling
stockholders will choose to exercise their Inducement Warrants for shares of common stock. In addition, the issuance of shares of common
stock to the selling stockholders pursuant to the exercise of the Inducement Warrants could result in substantial dilution to our existing
stockholders and could cause our stock price to decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>General Risk Factors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Conflicts, military actions, terrorist attacks,
natural disasters. public health crises, including the occurrence of a contagious disease or illness, cyber-attacks and general instability
could adversely affect our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Conflicts, military actions,
terrorist attacks, natural disasters, public health crises and cyber-attacks have precipitated economic instability and turmoil in financial
markets. Instability and turmoil may result in raw material cost increases. In addition, the long-term effects of climate change on general
economic conditions and the pharmaceutical manufacturing and distribution industry in particular are unclear, and changes in the supply,
demand or available sources of energy and the regulatory and other costs associated with energy production and delivery may affect the
availability or cost of goods and services, including raw materials and other natural resources, necessary to run our businesses. The
uncertainty and economic disruption resulting from hostilities, military action, acts of terrorism, natural disasters, public health crises
or cyber-attacks may impact our operations or those of our suppliers. Accordingly, any conflict, military action, terrorist attack, natural
disasters, public health crises or cyber-attack that impacts us or any of our suppliers, could have a material adverse effect on our business,
liquidity, prospects, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>War, terrorism, other acts of violence,
or natural or manmade disasters may affect the markets in which we operate, our patients and resources required in our research and development
activities.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business may be adversely
affected by political instability, disruption or destruction in a geographic region in which we operate, regardless of cause, including
war, terrorism, riot, civil insurrection or social unrest, and natural or manmade disasters, including famine, flood, fire, earthquake,
storm or pandemic events and spread of disease and the significant military action against Ukraine by Russia. Such events may affect our
business by increasing prices for resources required in our research and development activities or limiting our access to patients for
our clinical trials which may delay our progress on one or more of our clinical or preclinical drug product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our business and operations may be materially
adversely affected in the event of computer system failures or security breaches.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Despite the implementation
of security measures, our internal computer systems, and those of our third-party manufacturers, contract research organizations and other
third parties on which we rely, are vulnerable to damage from computer viruses, unauthorized access, cyber-attacks, phishing attempts,
natural disasters, fire, terrorism, war and telecommunication and electrical failures. If such an event were to occur and interrupt our
operations, it could result in a material disruption in our business. For example, the loss of clinical study data from ongoing or planned
clinical studies could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce
the data. To the extent that any disruption or security breach results in a loss of or damage to our data or applications, loss of trade
secrets, inappropriate disclosure of confidential or proprietary information, including protected health information or personal data
of employees or former employees, lack of access to our clinical data, or disruption of the manufacturing process, we could incur liability
and the further development of our drug candidates could be delayed. We may also be vulnerable to cyber-attacks or other malfeasance by
hackers. This type of breach of our cybersecurity may compromise our confidential and financial information, adversely affect our business,
or result in legal proceedings. Further, these cybersecurity breaches may inflict reputational harm upon us that may result in decreased
market value and erode public trust.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Failure to meet investor and stakeholder
expectations regarding environmental, social and corporate governance, or &ldquo;ESG&rdquo; matters may damage our reputation.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is an increasing focus
from certain investors, employees and other stakeholders concerning ESG matters. Additionally, public interest and legislative pressure
related to public companies&rsquo; ESG practices continue to grow. If our ESG practices fail to meet investor, employee or other stakeholders&rsquo;
evolving expectations and standards for responsible corporate citizenship in areas including environmental stewardship, Board of Directors
and employee diversity, human capital management, corporate governance and transparency, our reputation, brand, appeal to investors and
employee retention may be negatively impacted, which could have a material adverse effect on our business or financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><A NAME="v7"></A><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus, together
with any accompanying prospectus supplement, includes and incorporates by reference forward-looking statements within the meaning of Section&nbsp;21E
of the Securities Exchange Act of 1934, as amended, which we refer to as the Exchange Act. Examples of our forward-looking statements
include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our current views with respect to our business
strategy, business plan and research and development activities;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the progress of our product development programs,
including clinical testing and the timing of commencement and results thereof;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our projected operating results, including research
and development expenses;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our ability to identify a strategic partner with
the resources to develop iopofosine I&nbsp;31 (also known as iopofosine or CLR&nbsp;131) or otherwise continue the development or pursue
other strategic options in connection with iopofosine;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our ability to obtain additional funding via
the sale of equity and/or debt securities, a strategic transaction or otherwise;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our ability to initiate a Phase&nbsp;1b dose
finding study for CLR&nbsp;121125 and obtain the necessary additional funding for such study;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our ability to initiate a Phase&nbsp;1 imaging
and dose escalation safety study for CLR&nbsp;121225 and obtain the necessary additional funding for such study;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our ability to continue development plans for
our clinical and preclinical assets;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our ability to continue development plans for
our Phospholipid Drug Conjugates (PDC)&trade;;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our ability to advance our technologies into
product candidates;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our ability to maintain orphan drug designation
in the U.S. for iopofosine as a therapeutic for the treatment of multiple myeloma, neuroblastoma, osteosarcoma, rhabdomyosarcoma, Ewing&rsquo;s
sarcoma and lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia, and the expected benefits of orphan drug status;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any disruptions to our suppliers;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our current view regarding general economic and
market conditions, including our competitive strengths;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">uncertainty and economic instability resulting
from conflicts, military actions, terrorist attacks, natural disasters, public health crises, including the occurrence of a contagious
disease or illness, cyber-attacks and general instability;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the future impacts of legislative and regulatory
developments in the United States on the pricing and reimbursement of our product candidates;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our ability to meet the continued listing standards
of Nasdaq;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">assumptions underlying any of the foregoing;
and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any other statements that address events or developments
that we intend or believe will or may occur in the future.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In some cases, you can identify
forward-looking statements by terminology, such as &ldquo;expects,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;intends,&rdquo; &ldquo;estimates,&rdquo;
 &ldquo;plans,&rdquo; &ldquo;believes,&rdquo; &ldquo;seeks,&rdquo; &ldquo;may,&rdquo; &ldquo;should,&rdquo; &ldquo;could,&rdquo; &ldquo;would&rdquo;
or the negative of such terms or other similar expressions. Accordingly, these statements involve estimates, assumptions and uncertainties
that could cause actual results to differ materially from those expressed in them. Forward-looking statements also involve risks and uncertainties,
many of which are beyond our control. Any forward-looking statements are qualified in their entirety by reference to the factors discussed
throughout this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should read this prospectus
and the documents that we reference herein and therein and have filed as exhibits to the registration statement, of which this prospectus
is part, completely and with the understanding that our actual future results may be materially different from what we expect. You should
assume that the information appearing in this prospectus is accurate only as of the date on the front cover of this prospectus or such
prospectus. Because the risk factors referred to above could cause actual results or outcomes to differ materially from those expressed
in any forward-looking statements made by us or on our behalf, you should not place undue reliance on any forward-looking statements.
Further, any forward-looking statement speaks only as of the date on which it is made, and we undertake no obligation to update any forward-looking
statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated
events. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot
assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results
to differ materially from those contained in any forward-looking statements. We qualify all of the information presented in this prospectus
and any accompanying prospectus supplement, and particularly our forward-looking statements, by these cautionary statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="v8"></A>Use
of Proceeds</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All proceeds from the resale
of the shares of common stock offered by this prospectus will belong to the selling stockholders. We will not receive any proceeds from
the sale or other disposition by the selling stockholders of the shares of our common stock covered by this prospectus. However, we will
receive proceeds upon any cash exercise of the Inducement Warrants. If the Inducement Warrants are all exercised for cash, we will receive
gross proceeds of $12.6&nbsp;million. We intend to use any proceeds from any such exercise for working capital and general corporate purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="v9"></A><FONT STYLE="text-transform: uppercase"><B>Dividend
Policy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have never declared or
paid cash dividends on our capital stock. We intend to retain all available funds and any future earnings, if any, to fund the development
and expansion of our business and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination related
to dividend policy will be made at the discretion of our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="v10"></A>Determination
of Offering Price</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The prices at which the shares
of our common stock covered by this prospectus may actually be sold will be determined by the prevailing market price for shares of our
common stock or by negotiations between the selling stockholders and buyers of the shares in private transactions or as otherwise described
in &ldquo;Plan of Distribution.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="v11"></A>Selling
Stockholders</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Selling Stockholders will
offer or sell the shares of common stock offered by this prospectus at market prices prevailing at the time of sale, at prices related
to prevailing market price or at privately negotiated prices. We are registering the Shares in order to permit the selling stockholders
to offer them for resale from time to time after their issuance. For additional information regarding the Shares being offered by the
selling stockholders pursuant to this prospectus, see &ldquo;Summary-Description of the Warrant Inducement&rdquo; above. Except for the
ownership of our securities, the selling stockholders have not had any material relationship with us within the past three years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The table below lists the
selling stockholders and other information regarding the beneficial ownership of the shares of Common Stock by each of the selling stockholders.
The second column lists the number of shares of common stock beneficially owned by each selling stockholder, based on its ownership of
the shares of common stock as of October&nbsp;15,&nbsp;2025, and assuming full exercise of the Inducement Warrants on that date. The third
column lists the shares of common stock being offered by this prospectus by the selling stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fourth column assumes
the sale of all Shares offered by the selling stockholders pursuant to this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information in the following
table has been provided to us by or on behalf of the selling stockholders and the selling stockholders may have sold, transferred or otherwise
disposed of all or a portion of their securities after the date on which they provided us with information regarding their securities.
The selling stockholders may sell all, some or none of their Shares in this offering. See &ldquo;Plan of Distribution.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ownership Before Offering</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ownership After Offering</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of</B></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Maximum</B></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of</B></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>shares of</B></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>number of</B></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>shares of</B></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Percentage</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>common</B></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>shares of</B></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>common</B></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>of common</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>stock</B></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>common</B></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>stock</B></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>stock</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>beneficially</B></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>stock</B></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>beneficially</B></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>beneficially</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Selling Stockholder</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>owned(1)</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>offered</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>owned</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>owned(2)</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 48%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Armistice Capital, LLC<SUP>(3)&nbsp;</SUP></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,736,000</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,200,000</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">536,000</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.5</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Laurence Lytton<SUP>(4)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">604,170</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">402,780</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">201,390</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intracoastal Capital LLC<SUP>(5)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">363,872</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">300,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63,872</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.4</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Red Hook Fund LP <SUP>(6)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">95,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">60,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lincoln Park Capital Fund, LLC<SUP>(7)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63,848</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">39,086</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24,762</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">District 2 Capital, LP<SUP>(8)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30,791</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26,242</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,549</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bigger Capital Fund, LP<SUP>(9)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29,248</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29,248</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warberg WF XIII LP<SUP>(10)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Boothbay Absolute Return Strategies, LP<SUP>(11)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,176</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,176</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Boothbay Diversified Alpha Master Fund LP<SUP>(12)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,656</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,656</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in">*</TD><TD STYLE="text-align: justify">Represents ownership of less than one percent.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in">(1)</TD><TD STYLE="text-align: justify">&ldquo;Beneficial ownership&rdquo; is a term broadly defined in Rule&nbsp;13d-3 under the Exchange Act,
and includes more than the typical form of stock ownership, that is, stock held in a person&rsquo;s name. The term also includes what
is referred to as &ldquo;indirect ownership,&rdquo; meaning ownership of shares as to which a person has or shares investment power. For
purposes of this column, a person or group of persons is deemed to have &ldquo;beneficial ownership&rdquo; of any shares that such person
or group of persons has the right to acquire within 60&nbsp;days after October&nbsp;15,&nbsp;2025, including through the exercise of a
warrant or the conversion of a security.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in">(2)</TD><TD STYLE="text-align: justify">Based on 6,336,322 shares of Common Stock outstanding, which assumes the issuance of all the Shares upon
exercise of the Inducement Warrants and does not take into account the date of, or any limitations on, the exercise of the Inducement
Warrants.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in">(3)</TD><TD STYLE="text-align: justify">Consists of 290,000 shares of common stock, 246,000 shares of common stock issued or issuable upon exercise
of pre-funded warrants, and 1,200,000 Inducement Warrants. The securities are directly held by Armistice Capital Master Fund Ltd., a Cayman
Islands exempted company (the &ldquo;Master Fund&rdquo;), and may be deemed to be beneficially owned by: (i)&nbsp;Armistice Capital, LLC
(&ldquo;Armistice Capital&rdquo;), as the investment manager of the Master Fund; and (ii)&nbsp;Steven Boyd, as the Managing Member of
Armistice Capital. The warrants are subject to a beneficial ownership limitation of 4.99%, which such limitation restricts the Selling
Stockholder from exercising that portion of the warrants that would result in the Selling Stockholder and its affiliates owning, after
exercise, a number of shares of common stock in excess of the beneficial ownership limitation. The address of Armistice Capital Master
Fund Ltd. is c/o Armistice Capital, LLC, 510 Madison Avenue, 7th Floor, New York, NY 10022.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in">(4)</TD><TD STYLE="text-align: justify">Consists of 201,390 shares of common stock and 402,780 Inducement Warrants. The business address of Mr.&nbsp;Lytton
is 467 Central Park West 17-A New York, NY 10025.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 0.3in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of 63,872 shares of common stock and 300,000 Inducement Warrants. Mitchell P. Kopin (&ldquo;Mr.&nbsp;Kopin&rdquo;) and Daniel B. Asher (&ldquo;Mr.&nbsp;Asher&rdquo;), each of whom are managers of Intracoastal Capital LLC (&ldquo;Intracoastal&rdquo;), have shared voting control and investment discretion over the securities reported herein that are held by Intracoastal. As a result, each of Mr.&nbsp;Kopin and Mr.&nbsp;Asher may be deemed to have beneficial ownership (as determined under Section&nbsp;13(d)&nbsp;of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;)) of the securities reported herein that are held by Intracoastal. The business address of Intracoastal, Mr.&nbsp;Kopin and Mr.&nbsp;Asher is 245 Palm Trail, Delray Beach, FL 33483.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in">(6)</TD><TD STYLE="text-align: justify">Consists of 35,000 shares of common stock and 60,000 Inducement Warrants held by Red Hook Fund LP (the
 &ldquo;Red Hook Fund&rdquo;). Red Hook Asset Management LLC (the &ldquo;Investment Manager&rdquo;), a Delaware limited liability company,
is the investment advisor to the Red Hook Fund and Red Hook Fund GP LLC (&ldquo;General Partner&rdquo;) is the general partner of the
Red Hook Fund. Mathew Lazarus and Jeff Lopatin are the managing members of the Investment Manager and the General Partner, and may each
be deemed to beneficially own the shares beneficially owned by the Red Hook Fund LP. Mathew Lazarus and Jeff Lopatin each disclaims beneficial
ownership of securities beneficially owned by the Red Hook Fund LP. The principal business address of the Red Hook Fund LP is 44 Ball
Road, Mountain Lakes, NJ 07046.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in">(7)</TD><TD STYLE="text-align: justify">Consists of 24,762 shares of common stock and 39,086 Inducement Warrants. Joshua Scheinfeld and Jonathan
Cope, the principals of Lincoln Park Capital Fund, LLC (&ldquo;Lincoln Park&rdquo;) are deemed to be beneficial owner of all the securities
owned by Lincoln Park. Messrs.&nbsp;Scheinfeld and Cope have shared voting and disposition power. The business address of Lincoln Park
and Messrs.&nbsp;Scheinfeld and Cope is 415 N. LaSalle Dr., Suite&nbsp;700B, Chicago,&nbsp;IL 60654</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in">(8)</TD><TD STYLE="text-align: justify">Consists of 4,549 shares of common stock and 26,242 Inducement Warrants. Michael Bigger, managing member
of the general partner of District 2 Capital, LP (&ldquo;District 2&rdquo;) may be deemed to be beneficial owner of the securities owned
by District 2. The business address of District 2 and Mr.&nbsp;Bigger is 14 Wall Street, 2nd Floor, Huntington NY 11743.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in">(9)</TD><TD STYLE="text-align: justify">Consists of 29,248 Inducement Warrants. Michael Bigger, managing member of the general partner of Bigger
Capital Fund, LP (&ldquo;Bigger Capital&rdquo;) may be deemed to be beneficial owner of the securities owned by Bigger Capital. The business
address of Bigger Capital is 11700 W Charleston Blvd 170-659, Las Vegas, NV 89135.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in">(10)</TD><TD STYLE="text-align: justify">Consists of 28,000 Inducement Warrants. Daniel Warsh, manager of Warberg WF XIII LP (&ldquo;Warberg&rdquo;)
may be deemed to be beneficial owner of the securities owned by Warberg. The business address of Warberg and Mr.&nbsp;Warsh is 716 Oak
St., Winnetka,&nbsp;IL 60093.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in">(11)</TD><TD STYLE="text-align: justify">Consists of 7,176 Inducement Warrants. Boothbay Absolute Return Strategies, LP, a Delaware limited partnership
(&ldquo;BBARS&rdquo;), is managed by Boothbay Fund Management, LLC, a Delaware limited liability company (&ldquo;Boothbay&rdquo;). Boothbay,
in its capacity as the investment manager of BBARS, has delegated to Kingsbrook Partners LP, a Delaware limited partnership (&ldquo;Kingsbrook&rdquo;),
the power to vote and the power to direct the disposition of all securities held by BBARS that are being registered hereby. Ari Glass
is the Managing Member of Boothbay. Each of BBARS, Boothbay and Mr.&nbsp;Glass disclaim beneficial ownership of these securities, except
to the extent of any pecuniary interest therein. The business address of each of BBARS, Boothbay and Mr.&nbsp;Glass is c/o Kingsbrook
Partners LP, 689 Fifth Avenue, 12th Floor, New York, NY 10022.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 0.3in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of 3,656 Inducement Warrants. Boothbay Diversified Alpha Master Fund LP, a Cayman Islands limited partnership ( &ldquo;BBDAMF&rdquo;), is managed by Boothbay.&nbsp;&nbsp;Boothbay, in its capacity as the investment manager of BBDAMF, has delegated to Kingsbrook the power to vote and the power to direct the disposition of all securities held by BBDAMF.&nbsp;&nbsp;Ari Glass is the Managing Member of Boothbay.&nbsp;&nbsp;&nbsp;Each of BBDAMF, Boothbay and Mr. Glass disclaim beneficial ownership of these securities, except to the extent of any pecuniary interest therein.&nbsp;&nbsp;The business address of each of BBDAMF, Booothbay and Mr. Glass is c/o Kingsbrook Partners LP, 689 Fifth Avenue, 12th Floor, New York, NY 10022.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="v12"></A>Description
of Securities to be Registered</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>The following summary description
of our common stock is based on the provisions of our Second Amended and Restated Certificate of Incorporation, as amended, which we refer
to as our certificate of incorporation or charter, our by-laws, and the applicable provisions of the Delaware General Corporation Law,
which we refer to as the DGCL. This description may not contain all of the information that is important to you and is subject to, and
is qualified in its entirety by reference to our certificate of incorporation, our by-laws and the applicable provisions of the DGCL.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Authorized Capital Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our authorized capital stock
consists of 170,000,000 shares of common stock, $0.00001 par value per share and 7,000 shares of preferred stock, $0.00001 par value per
share. Our certificate of incorporation authorizes us to issue shares of our preferred stock from time to time in one or more series without
stockholder approval, each such series to have rights and preferences, including voting rights, dividend rights, conversion rights, redemption
privileges and liquidation preferences as our board of directors may determine. The rights of the holders of common stock will be subject
to, and may be adversely affected by, the rights of holders of any preferred stock, including our Series&nbsp;D and Series&nbsp;E Convertible
Preferred Stock and any other series of preferred stock we may issue in the future. The issuance of preferred stock, while providing desirable
flexibility in connection with possible acquisitions and other corporate purposes, could have the effect of making it more difficult for
others to acquire, or of discouraging others from attempting to acquire, a majority of our outstanding voting stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 17, 2025, there
were 12 holders of record of our common stock. This number does not include stockholders for whom shares were held in a &ldquo;nominee&rdquo;
or &ldquo;street&rdquo; name.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Voting</I>. Holders of
our common stock are entitled to one vote per share held of record on all matters to be voted upon by our stockholders. Our common stock
does not have cumulative voting rights. Persons who hold a majority of the outstanding common stock entitled to vote on the election of
directors can elect all of the directors who are eligible for election.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Dividends</I>. Subject
to preferences that may be applicable to the holders of any outstanding shares of our preferred stock, the holders of our common stock
are entitled to receive such lawful dividends as may be declared by our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Liquidation and Dissolution</I>.
In the event of our liquidation, dissolution or winding up, and subject to the rights of the holders of any outstanding shares of our
preferred stock, the holders of shares of our common stock will be entitled to receive pro rata all of our remaining assets available
for distribution to our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Other Rights and Restrictions</I>.
Our charter prohibits us from granting preemptive rights to any of our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Anti-Takeover Effect of Certain Certificate of Incorporation and
By-Law Provisions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Provisions of our Certificate
of Incorporation and our amended and restated by-laws (our By-Laws) could make it more difficult to acquire us by means of a merger, tender
offer, proxy contest, open market purchases, removal of incumbent directors and otherwise. These provisions, which are summarized below,
are expected to discourage types of coercive takeover practices and inadequate takeover bids and to encourage persons seeking to acquire
control of us to first negotiate with us. We believe that the benefits of increased protection of our potential ability to negotiate with
the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging takeover
or acquisition proposals because negotiation of these proposals could result in an improvement of their terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Authorized but Unissued
Stock</I>. We have shares of common stock and preferred stock available for future issuance, in some cases, without stockholder approval.
We may issue these additional shares for a variety of corporate purposes, including public offerings to raise additional capital, corporate
acquisitions, stock dividends on our capital stock or equity compensation plans. The existence of unissued and unreserved common stock
and preferred stock may enable our Board of Directors to issue shares to persons friendly to current management or to issue preferred
stock with terms that could render more difficult or discourage a third-party attempt to obtain control of us, thereby protecting the
continuity of our management. In addition, if we issue preferred stock, the issuance could adversely affect the voting power of holders
of common stock and the likelihood that such holders will receive dividend payments and payments upon liquidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Amendments to By-Laws</I>.
Our By-Laws are subject to alternation or repeal, and new by-laws may be made, by a majority of the voting power of all then outstanding
shares of capital stock entitled to vote generally in the election of directors, voting together a single class. Additionally, our By-Laws
provide the Board of Directors with the power to make, adopt, alter, amend and repeal, from time to time, our By-Laws, provided, however,
that the stockholders entitled to vote with respect to amendments to our By-Laws may alter, amend or repeal By-Laws made by the Board
of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Classification of Board
of Directors&#894; Removal of Directors&#894; Vacancies</I>. Our Certificate of Incorporation provide for the division of the Board of
Directors into three classes as nearly equal in size as possible with staggered three-year terms&#894; that directors may be removed only
for cause by the affirmative vote of the holders of two-thirds of our shares of capital stock entitled to vote&#894; and that any vacancy
on the Board of Directors, however occurring, including a vacancy resulting from an enlargement of the Board of Directors, may be filled
only by the vote of a majority of the directors then in office. The limitations on the removal of directors and the filling of vacancies
could have the effect of making it more difficult for a third party to acquire, or of discouraging a third party from acquiring, control
of us. Our Certificate of Incorporation requires the affirmative vote of the holders of at least 75% of our shares of capital stock issued
and outstanding and entitled to vote to amend or repeal any of these provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Notice Periods for Stockholder
Meetings</I>. Our By-Laws provide that for business to be brought by a stockholder before an annual meeting of stockholders, the stockholder
must give written notice to the corporation not later than the close of business on the 90th day, or earlier than the 120th day prior
to the one year anniversary of the date of the annual meeting of stockholders of the previous year&#894; provided, however, that in the
event that the annual meeting of stockholders is called for a date that is not within 30 days prior to, or more than 60 days after, such
anniversary date, notice by the stockholder must be received not later than 120 days prior to such annual meeting and not later than the
close of business on the 90th day prior to such annual meeting and the 10th day following the day on which the corporation's notice of
the date of the meeting is first given or made to the stockholders or disclosed to the general public. Our By-Laws also provide that the
Board of Directors or the chair of such meeting may postpone, reschedule or cancel any annual meeting of stockholders previously scheduled
by the Board of Directors and in no event shall the adjournment, recess, postponement, judicial stay or rescheduling of an annual meeting
commence a new time period, or extend any time period, for the giving of notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Stockholder Action&#894;
Special Meetings</I>. Our Certificate of Incorporation provides that stockholder action may not be taken by written action in lieu of
a meeting and provides special meetings of the stockholders may only be called by the chair of the Board of Directors, the president or
by our Board of Directors. These provisions could have the effect of delaying until the next stockholders' meeting stockholder actions
that are favored by the holders of a majority of our outstanding voting securities. These provisions may also discourage another person
or entity from making a tender offer for our common stock, because that person or entity, even if it acquired a majority of our outstanding
voting securities, would be able to take action as a stockholder only at a duly called stockholders' meeting, and not by written consent.
Our Certificate of Incorporation requires the affirmative vote of the holders of at least 75% of our shares of capital stock issued and
outstanding and entitled to vote to amend or repeal the provisions relating to prohibition on action by written consent and the calling
of a special meeting of stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Nominations</I>. Our By-Laws
provide that nominations for election of directors may be made only by (i)&nbsp;the Board of Directors or a committee appointed by the
Board of Directors&#894; or (ii)&nbsp;a stockholder entitled to vote on director election, if the stockholder provides notice to the Secretary
of the Company presented not less than 90 days nor more than 120 days prior to the anniversary of the last annual meeting (subject to
the limited exceptions set forth in the bylaws). These provisions may deter takeovers by requiring that any stockholder wishing to conduct
a proxy contest have its position solidified well in advance of the meeting at which directors are to be elected and by providing the
incumbent Board of Directors with sufficient notice to allow them to put an election strategy in place. Our bylaws also provide that stockholders
seeking to present proposals before a meeting of stockholders to nominate candidates for election as directors at a meeting of stockholders
must provide timely advance notice in writing, and specifies requirements as to the form and content of a stockholder&rsquo;s notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Choice of Forum</I>. Our
bylaws provides that the Court of Chancery of the state of Delaware shall be the exclusive forum for the following types of actions or
proceedings under Delaware statutory or common law:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any derivative action or proceeding brought on
our behalf;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any action asserting a breach of fiduciary duty
owed by any current or former director, officer or other employee of the Corporation to the Corporation or the Corporation&rsquo;s stockholders&#894;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any action asserting a claim against us or any
of our directors, officers or other employees arising pursuant to the Delaware General Corporation Law, our restated certificate, or our
amended and restated bylaws&#894;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any action asserting a claim against us that
is governed by the internal affairs doctrine; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">asserting an &ldquo;internal corporate claim,&rdquo;
as defined in Section&nbsp;115 of the Delaware General Corporation Law.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The provision does not apply
to suits brought to enforce a duty or liability created by the Exchange Act. Furthermore, Section&nbsp;22 of the Securities Act creates
concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts
have jurisdiction to entertain such claims.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To prevent having to litigate
claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our
bylaws provide that unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States
shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While the Delaware courts
have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue
other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and
enforceability of the exclusive forum provisions of our Certificate of Incorporation. This may require significant additional costs associated
with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those
other jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These exclusive forum provisions
may limit a stockholder&rsquo;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors,
officers, or other employees, which may discourage lawsuits against us and our directors, officers and other employees. If a court were
to find either exclusive-forum provision in our bylaws to be inapplicable or unenforceable in an action, we may incur further significant
additional costs associated with resolving the dispute in other jurisdictions, all of which could seriously harm our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our bylaws further provides
that the federal district courts of the United States of America shall be the exclusive forum for resolving any complaint asserting a
cause of action arising under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>No Cumulative Voting</I>.
Delaware General Corporation Law provides that stockholders are not entitled to the right to cumulate votes in the election of directors
unless a corporation&rsquo;s certificate of incorporation provides otherwise. Our Certificate of Incorporation and bylaws do not provide
for cumulative voting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Concentration of Ownership</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our executive officers, directors
and holders of five percent or more of our outstanding common stock, together with their respective affiliates, beneficially own or control
a significant portion of the outstanding shares of the Company. Accordingly, these stockholders will have substantial influence over the
outcome of a corporate action of the Company requiring stockholder approval, including the election of directors, any merger, consolidation
or sale of all or substantially all of the Company&rsquo;s assets or any other significant corporate transaction. These stockholders may
also exert influence in delaying or preventing a change in control of the Company, even if such change in control would benefit the other
stockholders of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Listing</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our common stock is currently
traded on the Nasdaq Capital Market under the symbol &ldquo;CLRB.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Transfer Agent and Registrar</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The transfer agent and registrar
for our common stock is Equiniti Trust Company, LLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Inducement Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Inducement Warrants overlying shares offered
for resale under this prospectus were issued in two different series: the Series&nbsp;I Inducement Warrants and the Series&nbsp;II Inducement
Warrants.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Series&nbsp;I Inducement Warrants are immediately
exercisable at an exercise price of $6.00 per share and will expire on October&nbsp;8, 2030. The Series&nbsp;I Inducement Warrants are
exercisable for up to 1,048,094 shares of our common stock, subject to adjustments as described below.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Series&nbsp;II Inducement Warrants are immediately
exercisable at an exercise price of $6.00 per share and will expire on April&nbsp;8, 2027. The Series&nbsp;II Inducement Warrants are
exercisable for up to 1,048,094 shares of our common stock, subject to adjustments as described below.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The exercise price and number
of shares of common stock issuable upon exercise of the Inducement Warrants is subject to adjustment in the event of stock dividends,
stock splits, reorganizations or similar events affecting our common stock and the exercise price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="v13"></A>Plan
of Distribution</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The selling stockholders,
including their pledgees, donees, transferees, distributees, beneficiaries or other successors in interest, may from time to time offer
some or all of the shares of our common stock offered under this prospectus. We will not receive any of the proceeds from the sale of
the shares of our common stock offered under this prospectus by the selling stockholders. We will bear all fees and expenses incident
to our obligation to register the shares of our common stock offered under this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The selling stockholders may
sell all or a portion of the shares of our common stock beneficially owned by them and offered hereby from time to time directly or through
one or more underwriters, broker-dealers or agents. If the shares of our common stock are sold through underwriters or broker-dealers,
the selling stockholders will be responsible for underwriting discounts or commissions or agent&rsquo;s commissions. The shares of our
common stock may be sold on any national securities exchange or quotation service on which the securities may be listed or quoted at the
time of sale, in the over-the-counter market or in transactions otherwise than on these exchanges or systems or in the over-the-counter
market and in one or more transactions at fixed prices, at prevailing market prices at the time of the sale, at varying prices determined
at the time of sale, or at privately negotiated prices. These sales may be effected in transactions, which may involve crosses or block
transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The selling stockholders may
use any one or more of the following methods when disposing of shares of our common stock or interests therein:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">ordinary brokerage transactions and transactions
in which the broker-dealer solicits purchasers;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">block trades in which the broker-dealer will
attempt to sell shares of our common stock as agent, but may position and resell a portion of the block as principal to facilitate the
transaction;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">purchases by a broker-dealer as principal and
resale by the broker-dealer for its account;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">an over-the-counter distribution;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">an exchange distribution in accordance with the
rules&nbsp;of the applicable exchange;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">privately negotiated transactions;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">short sales effected after the effective date
of the registration statement of which this prospectus forms a part;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">through the writing or settlement of options
or other hedging transactions, whether through an options exchange or otherwise;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">broker-dealers may agree with the selling stockholders
to sell a specified number of such shares at a stipulated price per share;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">a combination of any such methods of sale; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any other method permitted pursuant to applicable
law.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The selling stockholders may,
from time to time, pledge or grant a security interest in some or all of the shares of our common stock owned by them and, if they default
in the performance of their secured obligations, the pledgees or secured parties may offer and sell the shares of our common stock, from
time to time, under this prospectus, or under an amendment to this prospectus under Rule&nbsp;424(b)(3)&nbsp;or other applicable provision
of the Securities Act amending the list of selling stockholders to include the pledgee, transferee, or other successors in interest as
selling stockholder under this prospectus. The selling stockholders also may transfer the shares of our common stock in other circumstances,
in which case the transferees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the sale
of shares of our common stock or interests therein, the selling stockholders may enter into hedging transactions with broker-dealers or
other financial institutions, which may in turn engage in short sales of shares of our common stock in the course of hedging the positions
they assume. The selling stockholders may also sell shares of our common stock short and deliver these securities to close out its short
positions, or loan or pledge the shares of our common stock to broker-dealers that in turn may sell these securities. The selling stockholders
may also enter into option or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative
securities which require the delivery to such broker-dealer or other financial institution of shares of our common stock offered under
this prospectus, which shares of our common stock such broker-dealer or other financial institution may resell pursuant to this prospectus
(as supplemented or amended to reflect such transaction).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Broker-dealers engaged by
the selling stockholders may arrange for other broker-dealers to participate in sales. If the selling stockholders effect certain transactions
by selling shares of our common stock to or through underwriters, broker-dealers or agents, such underwriters, broker-dealers or agents
may receive commissions in the form of discounts, concessions or commissions from the selling stockholders or commissions from purchasers
of the shares of our common stock for whom they may act as agent or to whom they may sell as principal. Such commissions will be in amounts
to be negotiated, but, except as set forth in a supplement to this prospectus, in the case of an agency transaction will not be in excess
of a customary brokerage commission in compliance with applicable rules&nbsp;of the Financial Industry Regulatory Authority,&nbsp;Inc.
(&ldquo;FINRA&rdquo;); and in the case of a principal transaction a markup or markdown in compliance with applicable FINRA rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The aggregate proceeds to
the selling stockholders from the sale of the shares of our common stock offered under this prospectus will be the purchase price of the
shares of common stock less discounts or commissions, if any. The selling stockholders reserve the right to accept and, together with
their agents from time to time, to reject, in whole or in part, any proposed purchase of shares of our common stock to be made directly
or through agents. We will not receive any of the proceeds from the offering under this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The selling stockholders also
may resell all or a portion of the shares of our common stock offered under this prospectus in open market transactions in reliance upon
Rule&nbsp;144 under the Securities Act, provided that they meet the criteria and conforms to the requirements of that rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The selling stockholders and
any underwriters, broker-dealers or agents that participate in the sale of the shares of our common stock or interests therein may be
deemed to be &ldquo;underwriters&rdquo; within the meaning of Section&nbsp;2(a)(11) of the Securities Act. Any discounts, commissions,
concessions or profit they earn on any resale of the shares of our common stock may be underwriting discounts and commissions under the
Securities Act. Each selling stockholder has informed us that it does not have any written or oral agreement or understanding, directly
or indirectly, with any person to distribute the securities. The selling stockholders are subject to the prospectus delivery requirements
of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the extent required pursuant
to Rule&nbsp;424(b)&nbsp;under the Securities Act, the shares of our common stock to be sold, the name of the selling stockholders, the
purchase price and public offering price, the names of any agents, dealer or underwriter, and any applicable commissions or discounts
with respect to a particular offer will be set forth in an accompanying prospectus supplement or, if appropriate, a post-effective amendment
to the registration statement that includes this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have agreed to keep this
prospectus effective until the earliest to occur of the following events: (i)&nbsp;the date on which the selling stockholders shall have
resold all the Securities covered hereby; and (ii)&nbsp;the date on which the Securities may be resold by the selling stockholders without
registration and without regard to any volume or manner-of-sale limitations by reason of Rule&nbsp;144, without the requirement for the
Company to be in compliance with the current public information requirement under Rule&nbsp;144 under the Securities Act or any other
rule&nbsp;of similar effect. In order to comply with the securities laws of some states, if applicable, the shares of our common stock
may be sold in these jurisdictions only through registered or licensed brokers or dealers. In addition, in some states the shares of our
common stock may not be sold unless the shares been registered or qualified for sale or an exemption from registration or qualification
requirements is available and is complied with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The selling stockholders and
any other person participating in a sale of shares of our common stock registered under this prospectus will be subject to applicable
provisions of the Exchange Act, and the rules&nbsp;and regulations thereunder, including, without limitation, to the extent applicable,
Regulation&nbsp;M of the Exchange Act, which may limit the timing of purchases and sales of any of the shares of our common stock by the
selling stockholders and any other participating person. All of the foregoing may affect the marketability of the shares of our common
stock and the ability of any person or entity to engage in market-making activities with respect to the shares of our common stock. In
addition, we will make copies of this prospectus (as it may be supplemented or amended from time to time) available to the selling stockholders
for the purpose of satisfying the prospectus delivery requirements of the Securities Act. The selling stockholders may indemnify any broker-dealer
that participates in transactions involving the sale of the shares of our common stock against certain liabilities, including liabilities
arising under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="v14"></A>Legal
Matters</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The validity of the securities
being offered hereby will be passed upon for us by Sidley Austin&nbsp;LLP, New&nbsp;York, New&nbsp;York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="v15"></A>Experts</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The financial statements of
Cellectar Biosciences,&nbsp;Inc. as of December&nbsp;31, 2024 and 2023, and for each of the two years in the period ended December&nbsp;31,
2024, incorporated by reference in this Prospectus, have been audited by Deloitte&nbsp;&amp; Touche LLP, an independent registered public
accounting firm, as stated in their report. Such financial statements are incorporated by reference in reliance upon the report of such
firm given their authority as experts in accounting and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="v16"></A>Where
You Can Find More Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have filed with the SEC
a registration statement on Form&nbsp;S-1 under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), with respect
to the securities offered by this prospectus and any applicable prospectus supplement. This prospectus and any applicable prospectus supplement
do not contain all of the information set forth in the registration statement and its exhibits and schedules in accordance with SEC rules&nbsp;and
regulations. For further information with respect to us and the securities being offered by this prospectus and any applicable prospectus
supplement, you should read the registration statement, including its exhibits and schedules. Statements contained in this prospectus
and any applicable prospectus supplement, including documents that we have incorporated by reference, as to the contents of any contract
or other document referred to are not necessarily complete, and, with respect to any contract or other document filed as an exhibit to
the registration statement or any other such document, each such statement is qualified in all respects by reference to the corresponding
exhibit. You should review the complete contract or other document to evaluate these statements. You may obtain copies of the registration
statement and its exhibits via the SEC&rsquo;s website at http://www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You can read our Securities
and Exchange Commission filings, including the registration statement, over the Internet at the SEC&rsquo;s website at www.sec.gov. You
may also request a copy of these filings, at no cost, by writing us at 100&nbsp;Campus Drive Florham Park, New&nbsp;Jersey&nbsp;07932
or telephoning us at (608)&nbsp;441-8120.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to the information
and periodic reporting requirements of the Exchange Act, and we file periodic reports, proxy statements and other information with the
SEC. These periodic reports, proxy statements and other information are available for inspection and copying at the website of the Securities
and Exchange Commission referred to above. We maintain a website at https://www.cellectar.com. You may access our annual reports on Form&nbsp;10-K,
quarterly reports on Form&nbsp;10-Q, current reports on Form&nbsp;8-K and amendments to those reports filed or furnished pursuant to Section&nbsp;13(a)&nbsp;or
15(d)&nbsp;of the Exchange Act with the Securities and Exchange Commission free of charge at our website as soon as reasonably practicable
after such material is electronically filed with, or furnished to, the Securities and Exchange Commission. The information contained in,
or that can be accessed through, our website is not incorporated by reference in, and is not part of, this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="v17"></A><FONT STYLE="text-transform: uppercase"><B>Information
Incorporated by Reference</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The SEC allows us to &ldquo;incorporate
by reference&rdquo; information into this prospectus. This means that we can disclose important information to you by referring you to
another document filed separately with the SEC. The information incorporated by reference is considered to be a part of this prospectus,
except for any information that is superseded by other information that is included in this prospectus. The information we incorporate
by reference is an important part of this prospectus and information that we subsequently file with the SEC will automatically update
and supersede information in this prospectus and in our other filings with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We incorporate by reference
the documents listed below, which we have already filed with the SEC, and any filings we make with the SEC under Section&nbsp;13(a), 13(c),
14 or 15(d)&nbsp;of the Exchange Act (1)&nbsp;on or after the date of filing of the registration statement of which this prospectus forms
a part and (2)&nbsp;on or after the date of this prospectus until the earlier of the date on which all of the securities registered hereunder
have been sold or the registration statement of which this prospectus is a part has been withdrawn (in each case, other than information
that is deemed, under SEC rules, not to have been filed):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1279704/000141057825000329/clrb-20241231x10k.htm"><FONT STYLE="color: #0000EE">our
Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 13, 2025;</FONT></A></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                            Quarterly Reports on Form 10-Q for the fiscal quarter ended March 31, 2025, filed with the
                                            SEC on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1279704/000141057825001205/clrb-20250331x10q.htm" STYLE="-sec-extract: exhibit">May 13, 2025</A> and the fiscal quarter ended June 30, 2025, filed with the SEC on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1279704/000141057825001778/clrb-20250630x10q.htm" STYLE="-sec-extract: exhibit">August 14, 2025</A>;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the portions of our <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1279704/000110465925040241/tm2512660-4_def14a.htm"><FONT STYLE="color: #0000EE">Definitive
Proxy Statement on Schedule 14A, filed with the SEC on April 28, 2025</FONT></A>, that are incorporated by reference in our <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1279704/000141057825000329/clrb-20241231x10k.htm"><FONT STYLE="color: #0000EE">Annual
Report on Form 10-K for the fiscal year ended December 31, 2024</FONT></A>;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our Current Reports on Form 8-K, filed with the SEC on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1279704/000110465925008127/tm255128d1_8k.htm">January
                                                                                                              31, 2025</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1279704/000110465925024446/tm259506d1_8k.htm">March 17,
                                                                                                              2025</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1279704/000110465925042870/tm2513754d1_8k.htm">May 1, 2025</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1279704/000110465925056697/tm2517243d1_8k.htm">June
                                                                                                              5, 2025</A> (excluding Item 7.01 and the related exhibit 99.1), <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1279704/000110465925059400/tm2517987d1_8k.htm">June
                                                                                                              13, 2025</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1279704/000110465925060661/tm2518341d1_8k.htm">June 18,
                                                                                                              2025</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1279704/000110465925062639/tm2519011d1_8k.htm">June 25,
                                                                                                              2025</A>, <U></U><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1279704/000110465925062837/tm2519054d1_8k.htm">June 26,
                                                                                                              2025</A>, <U><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1279704/000110465925096928/tm2528016d1_8k.htm" STYLE="-sec-extract: exhibit">October
                                                                                                              6, 2025</A> </U>and <U><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1279704/000110465925098725/tm2528473d1_8k.htm" STYLE="-sec-extract: exhibit">October
                                                                                                              10, 2025</A></U>; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the description of our common stock and warrants to purchase common stock included in our registration
statement on <A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000114420414050006/v386743_8a12b.htm"><FONT STYLE="color: #0000EE">Form
8-A filed on August 14, 2014</FONT></A>, as the same may be updated by <A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000110465924041930/tm2410252d1_ex4-3.htm"><FONT STYLE="color: #0000EE">Exhibit
4.3 to Amendment No. 1 to our Annual Report on Form 10-K filed on April 1, 2024</FONT></A>, including all other amendments and reports
filed for the purpose of updating such description.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also incorporate by reference
any future filings (other than current reports furnished under Item 2.02 or Item 7.01 of Form&nbsp;8-K and exhibits filed on such form
that are related to such items unless such Form&nbsp;8-K expressly provides to the contrary) made with the SEC pursuant to Sections 13(a),
13(c), 14 or 15(d)&nbsp;of the Exchange Act, including those made after the date of the initial filing of the registration statement of
which this prospectus is a part and those made after the effectiveness of such registration statement, until the termination of the offering
of the common stock made by this prospectus, and such filings will become a part of this prospectus from the respective dates that such
documents are filed with the SEC. Information in such future filings updates and supplements the information provided in this prospectus.
Any statements in any such future filings will automatically be deemed to modify and supersede any information herein or in any document
we previously filed with the SEC that is incorporated or deemed to be incorporated herein by reference to the extent that statements in
the later filed document modify or replace such earlier statements.You may request and obtain a copy of any of the filings incorporated
herein by reference, at no cost, by writing or telephoning us at the following address or phone number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Cellectar Biosciences,&nbsp;Inc.<BR>
100&nbsp;Campus Drive<BR>
Florham Park, New&nbsp;Jersey 07932<BR>
Attention: Chief Financial Officer<BR>
(608)&nbsp;441-8120</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Up to 2,096,188 Shares of Common Stock Offered
by the Selling Stockholders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tm2529020d1_s1img002.jpg" ALT=""><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not authorized any
dealer, salesperson or other person to give any information or represent anything not contained in this prospectus. You must not rely
on any unauthorized information. If anyone provides you with different or inconsistent information, you should not rely on it. This prospectus
does not offer to sell any securities in any jurisdiction where it is unlawful. Neither the delivery of this prospectus, nor any sale
made hereunder, shall create any implication that the information in this prospectus is correct after the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART&nbsp;II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>INFORMATION NOT REQUIRED IN PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 13. Other Expenses of Issuance and Distribution.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We estimate that expenses
in connection with the distribution described in this registration statement (other than brokerage commissions, discounts or other expenses
relating to the sale of the shares by the selling stockholders) will be as set forth below. We will pay the following expenses with respect
to the distribution, and such amounts, with the exception of the SEC registration fee, are estimates:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 87%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SEC Registration Fee</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,407</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounting Fees and Expenses</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;35,000</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Fees and Expenses</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;65,000</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Miscellaneous Fees and Expenses</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;5,000</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;106,407</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 14. Indemnification of Directors and Officers.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;102 of the Delaware
General Corporation Law (the &ldquo;DGCL&rdquo;) permits a corporation to eliminate the personal liability of its directors for monetary
damages for a breach of fiduciary duty as a director, except where the director breached his or her duty of loyalty, failed to act in
good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase
in violation of Delaware corporate law or obtained an improper personal benefit. Our second amended and restated certificate of incorporation
(our Certificate of Incorporation) provides that none of our directors shall be personally liable to us or our stockholders for monetary
damages for any breach of fiduciary duty as a director, notwithstanding any provision of law imposing such liability, except to the extent
that the DGCL prohibits the elimination or limitation of liability of directors for breaches of fiduciary duty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;145 of the DGCL
provides that a corporation has the power to indemnify a director, officer, employee, or agent of the corporation and certain other persons
serving at the request of the corporation in related capacities against expenses (including attorneys&rsquo; fees), judgments, fines and
amounts paid in settlements actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he
or she is or is threatened to be made a party by reason of such position, if such person acted in good faith and in a manner he or she
reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no
reasonable cause to believe his or her conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation,
no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable
to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication
of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such
expenses which the Court of Chancery or such other court shall deem proper.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Certificate of Incorporation
contains provisions that limit the liability of our directors for monetary damages to the fullest extent permitted by the DGCL. Consequently,
our directors are not personally liable to us or our stockholders for monetary damages for any breach of fiduciary duties as directors,
except liability for:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any breach of the director&rsquo;s duty of loyalty
to us or our stockholders;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any act or omission not in good faith or that
involves intentional misconduct or a knowing violation of law;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">unlawful payments of dividends or unlawful stock
repurchases or redemptions as provided in Section&nbsp;174 of the DGCL; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any transaction from which the director derived
an improper personal benefit.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 51; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Certificate of Incorporation
provides that we shall indemnify any and all persons whom we shall have power to indemnify under Section&nbsp;145 from and against any
and all of the expenses, liabilities or other matters referred to in or covered by Section&nbsp;145. Our Certificate of Incorporation
provides for the advancement of expenses to each of our directors, officers, employees or agents for the defense of any action for which
indemnification is required or permitted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have entered into indemnification
agreements with certain of our directors and our executive officers. These agreements will provide that we will indemnify such directors
and officers to the fullest extent permitted by law and our Certificate of Incorporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also maintain a general
liability insurance policy that covers certain liabilities of our directors and officers arising out of claims based on acts or omissions
in their capacities as directors or officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 15. Recent Sales of Unregistered Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Share and price per amount
below are adjusted to reflect the Reverse Stock Split effectuated on June&nbsp;24, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>October&nbsp;2025 Warrant Inducement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October&nbsp;7, 2025, the
Company entered into definitive agreements for investors to immediately exercise certain outstanding warrants to purchase an aggregate
of 1,048,094 shares of common stock, issued by the company on October&nbsp;25, 2022, July&nbsp;21, 2024 and July&nbsp;2, 2025 (the October&nbsp;Existing
Warrants), at an exercise price of $5.25 per share. The shares of common stock issuable upon exercise of the October&nbsp;Existing Warrants
are all registered, or their resale is registered, pursuant to effective registration statements. Other than the shares of common stock
issued upon exercise of the Existing Warrants issued on July&nbsp;2, 2025, the issuance of which was registered under an effective registration
statement, the shares of common stock issued upon exercise of the October&nbsp;Existing Warrants were offered pursuant to the exemption
from the registration requirements of the Securities Act available under Section&nbsp;4(a)(2)&nbsp;of the Securities Act. In connection
with the exercise of the October&nbsp;Existing Warrants, the Company issued new warrants (the Inducement Warrants) in two different series:
the Series&nbsp;I Inducement Warrants and the Series&nbsp;II Inducement Warrants. Each Inducement Warrant is immediately exercisable at
an exercise price of $6.00 per share. The Series&nbsp;I Inducement Warrants will expire on October&nbsp;8, 2030 and the Series&nbsp;II
Inducement Warrants will expire on April&nbsp;8, 2027. The investors paid $0.125 per Inducement Warrant. The Company issued the Inducement
Warrants pursuant to the exemption from the registration requirements of the Securities Act available under Section&nbsp;4(a)(2)&nbsp;of
the Securities Act and intends to issue the shares underlying the Inducement Warrants pursuant to the same exemption or pursuant to the
exemption provided by Section&nbsp;3(a)(9)&nbsp;of the Securities Act. The gross proceeds to the company from the exercise of the October&nbsp;Existing
Warrants and the issuance of the Inducement Warrants was approximately $5.8 million, prior to deducting placement agent fees and offering
expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>June&nbsp;2025 Warrant Inducement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June&nbsp;5, 2025, the
Company entered into definitive agreements for investors to immediately exercise certain outstanding warrants to purchase an aggregate
of 276,044&nbsp;shares of common stock, issued by the company on June&nbsp;5, 2020, October&nbsp;25, 2022 and July&nbsp;21, 2024 (the
Existing Warrants), at a reduced exercise price of $9.123 per share. The shares of common stock issuable upon exercise of the Existing
Warrants are all registered, or their resale is registered, pursuant to effective registration statements. Other than the shares of common
stock issued upon exercise of the Existing Warrants issued on June&nbsp;5, 2020, the issuance of which was registered under an effective
registration statement, the shares of common stock issued upon exercise of the Existing Warrants were offered pursuant to the exemption
from the registration requirements of the Securities Act available under Section&nbsp;4(a)(2)&nbsp;of the Securities Act. The Company
did not issue any new warrants as part of the agreements. The gross proceeds to the company from the exercise of the Existing Warrants
was approximately $2.5&nbsp;million, prior to deducting placement agent fees and offering expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>2024 Private Placements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July&nbsp;21, 2024, we
entered into warrant exercise inducement letters with certain institutional investors holding Tranche&nbsp;B warrants, pursuant to which
such holders agreed to exercise for cash such Tranche&nbsp;B warrants to purchase an amount of shares of Series&nbsp;E-4 preferred stock
which is convertible to 224,663 shares of common stock, in the aggregate, at a reduced, as-converted common stock exercise price of $75.60
per share, in exchange for our agreement to issue new inducement warrants. We received aggregate gross proceeds of approximately $19.4&nbsp;million
from the exercise of the Tranche&nbsp;B warrants and the sale of the inducement warrants. We issued the inducement warrants in three different
tranches: Tranche&nbsp;A inducement warrants to purchase 224,663 shares of common stock, immediately exercisable at an exercise price
of $75.60 per share; Tranche&nbsp;B inducement warrants to purchase 273,809 shares of common stock, immediately exercisable at an exercise
price of $120.00 per share; and Tranche&nbsp;C inducement warrants to purchase 142,238 shares of common stock, immediately exercisable
at an exercise price of $165.00 per share. In each case, the exercise price and number of shares of common stock issuable upon exercise
is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common
stock and the exercise price. These securities were offered pursuant to the exemption provided in Section&nbsp;4(a)(2)&nbsp;under the
Securities Act and Rule&nbsp;506(b)&nbsp;promulgated thereunder, and we intend to issue shares of common stock upon exercise of the inducement
warrants pursuant to the same exemption or pursuant to the exemption provided in Section&nbsp;3(a)(9)&nbsp;under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>2023 Private Placements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September&nbsp;8, 2023,
in a private placement with certain institutional investors, we issued 1,225 shares of Series&nbsp;E-1 preferred stock, along with Tranche&nbsp;A
warrants to purchase 2,205 shares of Series&nbsp;E-3 preferred stock and Tranche&nbsp;B warrants to purchase 1,715 shares of Series&nbsp;E-4
preferred stock. Shares of Series&nbsp;E preferred stock were issued at a fixed price of $20,000 per share, resulting in gross proceeds
of $24.5&nbsp;million and net proceeds of approximately $22.2&nbsp;million after placement agent fees and other customary expenses. The
conversion prices for the preferred stock are as follows: for the Series&nbsp;E-1 or E-2 preferred stock, $54.60 per share of common stock,
or a total of 448,717 shares of common stock; for the Series&nbsp;E-3 preferred stock, $95.55 per share of common stock, or a total of
461,538 shares of common stock; and for the Series&nbsp;E-4 preferred stock, $143.325 per share of common stock, or a total of 239,316
shares of common stock, in each case subject to appropriate adjustment in the event of any stock dividend, stock split, combination or
other similar recapitalization. These securities were offered pursuant to the exemption provided in Section&nbsp;4(a)(2)&nbsp;under the
Securities Act and Rule&nbsp;506(b)&nbsp;promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>2022 Private Placements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October&nbsp;20, 2022,
we entered into a securities purchase agreement with certain purchasers named therein, pursuant to which we agreed to issue, in a private
placement transaction, common warrants to purchase an aggregate of 109,171 shares of common stock at an exercise price of $58.80 per share.
In a separate concurrent private placement transaction, we entered into a private placement securities purchase agreement with certain
purchasers named therein, pursuant to which we agreed to issue pre-funded warrants to purchase an aggregate of up to 62,531 shares of
common stock, and common warrants to purchase an aggregate of 62,531 shares of common stock at an exercise price of $58.80 per share.
The purchase price of each pre-funded warrant was $62.5497 and they are exercisable at an exercise price of $0.00001 per share. The proceeds
to us in connection with sale of the warrants and pre-funded warrants were approximately $3.9&nbsp;million and we will receive an additional
$10.1&nbsp;million if the warrants and the pre-funded warrants are exercised in full. The common warrants, pre-funded warrants and the
shares of common stock issuable upon the exercise of the common warrants and the pre-funded warrants were offered pursuant to the exemption
provided in Section&nbsp;4(a)(2)&nbsp;under the Securities Act and Rule&nbsp;506(b)&nbsp;promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 16. Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; width: 10%">Exhibit <BR>
No.</TD>
    <TD STYLE="padding-bottom: 1pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 88%; vertical-align: bottom">Description</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>2.1</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000114420411021341/v218100_ex2-1.htm"><FONT STYLE="color: blue">Agreement and Plan of Merger by and among Novelos Therapeutics, Inc., Cell Acquisition Corp. and Cellectar, Inc. dated April 8, 2011 (filed as Exhibit 2.1 on Form 8-K on April 11, 2011)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>3.1</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000114420411021341/v218100_ex3-1.htm"><FONT STYLE="color: blue">Second Amended and Restated Certificate of Incorporation (filed as Exhibit 3.1 on Form 8-K on April 11, 2011)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>3.2</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000114420414008614/v368520_ex3-1.htm"><FONT STYLE="color: blue">Certificate of Ownership and Merger of Cellectar Biosciences, Inc. with and into Novelos Therapeutics, Inc. (filed as Exhibit 3.1 on Form 8-K on February 13, 2014)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>3.3</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000114420414037652/v381468_ex3-1.htm"><FONT STYLE="color: blue">Certificate of Amendment to Second Amended and Restated Certificate of Incorporation (filed as Exhibit 3.1 on Form 8-K on June 13, 2014)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>3.4</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000114420415038136/v413679_ex3-2.htm"><FONT STYLE="color: blue">Certificate of Amendment to Second Amended and Restated Certificate of Incorporation (filed as Exhibit 3.2 on Form 8-K on June 19, 2015)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>3.5</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000114420416086190/v433496_ex3-1.htm"><FONT STYLE="color: blue">Certificate of Amendment to Second Amended and Restated Certificate of Incorporation (filed as Exhibit 3.1 on Form 8-K on March 4, 2016)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>3.6</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000114420417030585/v468188_ex3-2.htm"><FONT STYLE="color: blue">Certificate of Amendment of Second Amended and Restated Certificate of Incorporation (filed as Exhibit 3.2 on Form 8-K on June 1, 2017)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>3.7</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000114420418038343/tv498554_ex3-1.htm"><FONT STYLE="color: blue">Certificate of Amendment of Second Amended and Restated Certificate of Incorporation (filed as Exhibit 3.1 on Form 8-K on July 13, 2018)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>3.8</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000110465921028235/tm218024d1_ex3-1.htm"><FONT STYLE="color: blue">Certificate of Amendment of Second Amended and Restated Certificate of Incorporation (filed as Exhibit 3.1 on Form 8-K on February 25, 2021)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>3.9</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000141057822001231/clrb-20220331xex3d1.htm"><FONT STYLE="color: blue">Certificate of Correction of Certificate of Amendment of Second Amended and Restated Certificate of Incorporation (filed as Exhibit 3.1 on Form 10-Q on May 10, 2022)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>3.10</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000110465922081598/tm2221588d1_ex3-1.htm"><FONT STYLE="color: blue">Certificate of Amendment of Second Amended and Restated Certificate of Incorporation (filed as Exhibit 3.1 on Form 8-K on July 21, 2022)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>3.11</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000110465923112202/tm2329288d1_ex3-1.htm"><FONT STYLE="color: blue">Certificate of Amendment to Second Amended and Restated Certificate of Incorporation (filed as Exhibit 3.1 on Form 8-K on October 27, 2023)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>3.12</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000110465925062639/tm2519011d1_ex3-1.htm"><FONT STYLE="color: blue">Certificate of Amendment of Second Amended and Restated Certificate of Incorporation (filed as Exhibit 3.1 on Form 8-K on June 25, 2025)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>3.13</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000110465925024446/tm259506d1_ex3-1.htm"><FONT STYLE="color: blue">Amended and Restated By-Laws of Cellectar Biosciences, Inc., effective as of March 11, 2025 (filed as Exhibit 3.1 on Form 8-K on March 17, 2025)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>3.14</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000110465920139761/tm2039355d1_ex3-1.htm"><FONT STYLE="color: blue">Form of Certificate of Designation of Series D Preferred Stock certificate (filed as Exhibit 3.1 on Form 8-K on December 28, 2020)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>3.15</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000110465923099368/tm2325751d1_ex3-1.htm"><FONT STYLE="color: blue">Certificate of Elimination of the Series A Convertible Preferred Stock, the Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock (filed as Exhibit 3.1 on Form 8-K on September 8, 2023)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>3.16</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000110465923099368/tm2325751d1_ex3-2.htm"><FONT STYLE="color: blue">Amendment No. 1 to Certificate of Designation of the Series D Preferred Stock (filed as Exhibit 3.2 on Form 8-K on September 8, 2023)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>3.17</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000110465923099368/tm2325751d1_ex3-3.htm"><FONT STYLE="color: blue">Certificate of Designation of Preferences, Rights and Limitations of the Series E Convertible Voting Preferred Stock (filed as Exhibit 3.3 on Form 8-K on September 8, 2023)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>4.1</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000114420411062631/v236909_ex4-1.htm"><FONT STYLE="color: blue">Form of Common Stock Certificate (filed as Exhibit 4.1 to Form S-1/A on November 9, 2011)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>4.2</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000110465925098725/tm2528473d1_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="color: blue"><U>Form of Series I Common Stock Purchase Warrant (filed as Exhibit 4.1 on Form 8-K on October 10, 2025)</U></FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>4.3</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000110465925098725/tm2528473d1_ex4-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="color: blue"><U>Form of Series II Common Stock Purchase Warrant (filed as Exhibit 4.2 on Form 8-K on October 10, 2025)</U></FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>5.1*</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="tm2529020d1_ex5-1.htm" STYLE="-sec-extract: exhibit">Opinion of Sidley Austin LLP</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>10.1**</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000114420417042654/v472296_ex10-1.htm">Form of Restricted Common Stock Agreement (filed as Exhibit 10.1 on Form 10-Q on August 14, 2017)</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>10.2</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000114420417052049/tv476830_ex4-1.htm">Form of Series D Common Stock Purchase Warrant (filed as Exhibit 4.1 on Form 8-K on October 11, 2017)</A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">10.3</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; vertical-align: bottom"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000114420417052049/tv476830_ex10-2.htm">Registration Rights Agreement, dated as of October 10, 2017, by and among Cellectar Biosciences, Inc. and the Purchasers (filed as Exhibit 10.2 on Form 8-K on October 11, 2017)</A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">10.4**</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; vertical-align: bottom"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000114420417057766/tv479041_ex10-2.htm">Form of Non-Statutory Stock Option (filed as Exhibit 10.2 on Form S-8 on November 9, 2017)</A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">10.5**</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; vertical-align: bottom"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000114420417057766/tv479041_ex10-4.htm">Stock Option Agreement with James V. Caruso (filed as Exhibit 10.4 on Form S-8 on November 9, 2017)</A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">10.6**</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; vertical-align: bottom"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000114420417057766/tv479041_ex10-5.htm">Stock Option Agreement with Jarrod Longcor (filed as Exhibit 10.5 on Form S-8 on November 9, 2017)</A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">10.7</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; vertical-align: bottom"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000114420418038716/tv498621_ex4-5.htm">Series E Common Stock Purchase Warrant (filed as Exhibit 4.5 on Form S-1/A on July 18, 2018)</A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">10.8</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; vertical-align: bottom"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000114420418038716/tv498621_ex4-7.htm">Form of Warrant Agency Agreement (filed as Exhibit 4.7 on Form S-1/A on July 18, 2018)</A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">10.9</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; vertical-align: bottom"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000114420418038716/tv498621_ex10-35.htm">Agreement of Lease between the Company and KBS II 100-200 Campus Drive, LLC (filed as Exhibit 10.35 on Form S-1/A on July 18, 2018)</A></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; width: 10%">Exhibit <BR>
No.</TD>
    <TD STYLE="padding-bottom: 1pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; vertical-align: bottom; width: 88%">Description</TD></TR>

<TR>
    <TD STYLE="vertical-align: top">10.10**</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; vertical-align: bottom"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000114420418059004/tv505892_ex10-3.htm">Form of Non-Statutory Stock Option (Definitive/Contingent - Employees) (filed as Exhibit 10.3 on Form 10-Q on November 13, 2018)</A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">10.11**</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; vertical-align: bottom"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000114420418059004/tv505892_ex10-4.htm">Form of Non-Statutory Stock Option (Definitive/Contingent - Directors) (filed as Exhibit 10.4 on Form 10-Q on November 13, 2018)</A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">10.12**</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; vertical-align: bottom"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000114420419020345/tv519195_ex10-1.htm">Amended and Restated Employment Agreement between the Company and James Caruso, dated April 15, 2019 (filed as Exhibit 10.1 on Form 8-K on April 19, 2019)</A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">10.13**</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; vertical-align: bottom"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000114420419020345/tv519195_ex10-2.htm">Amended and Restated Employment Agreement between the Company and Jarrod Longcor, dated April 15, 2019 (filed as Exhibit 10.2 on Form 8-K on April 19, 2019)</A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">10.14</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; vertical-align: bottom"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000114420419027349/tv522073_ex4-1.htm">Form of Series F Common Stock Purchase Warrant (filed as Exhibit 4.1 on Form 8-K on May 20, 2019)</A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">10.15</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; vertical-align: bottom"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000114420419027349/tv522073_ex4-2.htm">Form of Series G Common Stock Purchase Warrant (filed as Exhibit 4.2 on Form 8-K on May 20, 2019)</A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">10.16</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; vertical-align: bottom"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000114420419027349/tv522073_ex10-3.htm">Registration Rights Agreement, dated as of May 16, 2019, by and among Cellectar Biosciences, Inc. and the Purchasers (filed as Exhibit 10.3 on Form 8-K on May 20, 2019)</A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">10.17**</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; vertical-align: bottom"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000110465921084900/tm2120575d1_ex10-1.htm">2021 Stock Incentive Plan (filed as Exhibit 10.1 on Form 8-K on June 24, 2021)</A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">10.18**</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; vertical-align: bottom"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000110465922074774/tm2219495d1_ex10-1.htm">Amendment 1 to the 2021 Stock Incentive Plan (filed as Exhibit 10.1 on Form 8-K on June 27, 2022)</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>10.19**</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000110465923075997/tm2319838d1_ex10-1.htm">2021 Stock Incentive Plan, as Amended (filed as Exhibit 10.1 on Form 8-K on June 29, 2023)</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>10.20**</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000110465924071822/tm2417372d1_ex10-1.htm">2021 Stock Incentive Plan, as Amended (filed as Exhibit 10.1 on Form 8-K on June 14, 2024)</A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">10.21**</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; vertical-align: bottom"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000110465919062109/tm1919524d1_ex10-2.htm">Amendment to Amended and Restated Employment Agreement between the Company and Jarrod Longcor dated November 10, 2019 (filed as Exhibit 10.2 on Form 10-Q on November 12, 2019)</A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">10.22</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; vertical-align: bottom"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000110465920093312/tm2027137d1_ex10-1.htm">Equity Distribution Agreement between Cellectar Biosciences, Inc. and Oppenheimer &amp; Co. Inc., dated August 11, 2020 (filed as Exhibit 10.1 on Form 8-K on August 11, 2020)</A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">10.23</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; vertical-align: bottom"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000110465924065163/tm2415389d1_ex1-2.htm"><FONT STYLE="color: blue">Equity Distribution Agreement, dated May 24, 2024, between the Company and Piper Sandler &amp; Co. (filed as Exhibit 1.2 on Form S-3 on May 24, 2024)</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">10.24</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; vertical-align: bottom"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000110465923099368/tm2325751d1_ex4-1.htm"><FONT STYLE="color: blue">Form of Tranche A Warrant (filed as Exhibit 4.1 on Form 8-K on September 8, 2023)</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">10.25</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; vertical-align: bottom"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000110465923099368/tm2325751d1_ex4-2.htm"><FONT STYLE="color: blue">Form of Tranche B Warrant (filed as Exhibit 4.2 on Form 8-K on September 8, 2023)</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">10.26</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; vertical-align: bottom"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000110465923099368/tm2325751d1_ex10-1.htm">Form of Securities Purchase Agreement (filed as Exhibit 10.1 on Form 8-K on September 8, 2023)</A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">10.27</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; vertical-align: bottom"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000110465920139761/tm2039355d1_ex10-2.htm">Form of Registration Rights Agreement (filed as Exhibit 10.2 on Form 8-K on December 28, 2020)</A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">10.28**</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; vertical-align: bottom"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000110465922027293/tm227716d1_ex10-1.htm">Employment Agreement between the Company and Chad Kolean, dated February 23, 2022 (filed as Exhibit 10.1 on Form 8-K on February 25, 2022)</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>10.29</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000141057823000224/clrb-20221231xex10d26.htm"><FONT STYLE="color: blue">Form of First Amendment of Lease, dated December 30, 2022 (filed as Exhibit 10.26 on Form 10-K on March 9, 2023)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>10.30</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000110465922111217/tm2228873d1_ex1-1.htm"><FONT STYLE="color: blue">Placement Agency Agreement, dated as of October 20, 2022, by and between Cellectar Biosciences, Inc. and Oppenheimer &amp; Co. Inc. (filed as Exhibit 1.1 on Form 8-K on October 25, 2022)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>10.31</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000110465922111217/tm2228873d1_ex4-1.htm"><FONT STYLE="color: blue">Form of Common Warrant (filed as Exhibit 4.1 on Form 8-K on October 25, 2022)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>10.32</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000110465922111217/tm2228873d1_ex4-2.htm"><FONT STYLE="color: blue">Form of Pre-Funded Warrant (filed as Exhibit 4.2 on Form 8-K on October 25, 2022)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>10.33</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000110465922111217/tm2228873d1_ex10-1.htm"><FONT STYLE="color: blue">Form of Hybrid Securities Purchase Agreement, dated as of October 20, 2022, by and between the Company and the purchasers named therein (filed as Exhibit 10.1 on Form 8-K on October 25, 2022)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>10.34</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000110465922111217/tm2228873d1_ex10-2.htm"><FONT STYLE="color: blue">Form of PIPE Securities Purchase Agreement, dated as of October 20, 2022, by and between the Company and the purchasers named therein (filed as Exhibit 10.2 on Form 8-K on October 25, 2022)</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">10.35</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; vertical-align: bottom"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000110465922111217/tm2228873d1_ex10-3.htm"><FONT STYLE="color: blue">Form of Registration Rights Agreement, dated as of October 20, 2022, by and between the Company and the purchasers named therein (filed as Exhibit 10.3 on Form 8-K on October 25, 2022)</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">10.36</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; vertical-align: bottom"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000110465922124193/tm2231728d1_ex10-1.htm"><FONT STYLE="color: blue">Form of Indemnification Agreement (filed as Exhibit 10.1 on Form 8-K on December 2, 2022)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>10.37</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000110465924081307/tm2419897d1_ex10-1.htm"><FONT STYLE="color: blue">Inducement Letter in consideration for Exercise of the Tranche B warrants (filed as Exhibit 10.1 on Form 8-K on July 22, 2024)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>10.38</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000110465924065163/tm2415389d1_ex4-7.htm"><FONT STYLE="color: blue">Form of Indenture (filed as Exhibit 4.7 on Form S-3 on May 24, 2024)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>10.39</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000110465924081307/tm2419897d1_ex4-1.htm"><FONT STYLE="color: blue">Form of Common Stock Purchase Warrant A (filed as Exhibit 4.1 on Form 8-K on July 22, 2024)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>10.40</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000110465924081307/tm2419897d1_ex4-2.htm"><FONT STYLE="color: blue">Form of Common Stock Purchase Warrant B (filed as Exhibit 4.2 on Form 8-K on July 22, 2024)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>10.41</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000110465924081307/tm2419897d1_ex4-3.htm"><FONT STYLE="color: blue">Form of Common Stock Purchase Warrant C (filed as Exhibit 4.3 on Form 8-K on July 22, 2024)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>10.42</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000110465925056697/tm2517243d1_ex10-1.htm"><FONT STYLE="color: blue">Inducement Letter in consideration for Exercise of the Common Stock Purchase Warrants issued on June 5, 2020, October 25, 2022 and July 21, 2024 (filed as Exhibit 10.1 on Form 8-K on June 5, 2025)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>10.43</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000110465925062834/tm2516057d3_ex1-1.htm"><FONT STYLE="color: blue">Form of Underwriting Agreement (filed as Exhibit 1.1 on Form S-1 on June 26, 2025)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>10.44</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000110465925063849/tm2516057d4_ex4-2.htm"><FONT STYLE="color: blue">Form of Common Warrant (filed as Exhibit 4.2 on Form S-1/A on June 30, 2025)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>10.45</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000110465925063849/tm2516057d4_ex4-3.htm"><FONT STYLE="color: blue">Form of Pre-Funded Warrant (filed as Exhibit 4.3 on Form S-1/A on June 30, 2025)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>10.46</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000110465925063849/tm2516057d4_ex4-4.htm"><FONT STYLE="color: blue">Form of Representative Warrant (filed as Exhibit 4.4 on Form S-1/A on June 30, 2025)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>10.47</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000110465925062834/tm2516057d3_ex4-5.htm"><FONT STYLE="color: blue">Form of Warrant Agency Agreement (filed as Exhibit 4.5 on Form S-1 on June 26, 2025)</FONT></A></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; width: 10%">Exhibit <BR>
No.</TD>
    <TD STYLE="padding-bottom: 1pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; vertical-align: bottom; width: 88%">Description</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%">10.48</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 88%"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000110465925098725/tm2528473d1_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="color: blue"><U>Inducement Letter in consideration for Exercise of the Common Stock Purchase Warrants issued on October 25, 2022, July 21, 2024 and July 2, 2025 (filed as Exhibit 10.1 on Form 8-K on October 10, 2025)</U></FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>16.1</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000110465924079262/tm2419333d1_ex16-1.htm"><FONT STYLE="color: blue">Letter Regarding Change in Certifying Accountant (filed as Exhibit 16.1 on Form 8-K on July 11, 2024)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>21.1</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1279704/000141057825000329/clrb-20241231xex21d1.htm"><FONT STYLE="color: blue">List of Subsidiaries (filed as Exhibit 21.1 on Form 10-K on March 13, 2025)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>23.1*</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="tm2529020d1_ex5-1.htm" STYLE="-sec-extract: exhibit">Consent of Sidley Austin LLP (included in Exhibit 5.1)</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>23.2*</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="tm2529020d1_ex23-2.htm" STYLE="-sec-extract: exhibit">Consent of Deloitte &amp; Touche LLP</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>24.1*</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="#v1">Powers of Attorney (included on signature page)</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>107*</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="tm2529020d1_ex-filingfees.htm" STYLE="-sec-extract: exhibit">Filing Fee Table</A></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">*</TD><TD STYLE="text-align: justify">Filed herewith.</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">**</TD><TD STYLE="text-align: justify">Management contract or compensatory plan or arrangement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 17. Undertakings.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
undersigned registrant hereby undertakes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;To
file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;To
include any prospectus required by section&nbsp;10(a)(3)&nbsp;of the Securities Act of 1933;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;To
reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective
amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration
statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities
offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range
may be reflected in the form of prospectus filed with the Commission pursuant to Rule&nbsp;424(b)&nbsp;if, in the aggregate, the changes
in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the &ldquo;Calculation of Registration
Fee&rdquo; table in the effective registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;To
include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any
material change to such information in the registration statement; provided, however, that the undertakings set forth in paragraphs&nbsp;(a)(1)(i),
(a)(1)(ii)&nbsp;and (a)(1)(iii)&nbsp;above do not apply if the information required to be included in a post-effective amendment by those
paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section&nbsp;13 or Section&nbsp;15(d)&nbsp;of
the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), that are incorporated by reference in this registration
statement or are contained in a form of prospectus filed pursuant to Rule&nbsp;424(b)&nbsp;that is part of this registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;That,
for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be
a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed
to be the initial bona fide offering thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;To
remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination
of the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;That,
for the purpose of determining liability under the Securities Act of 1933 to any purchaser, each prospectus filed pursuant to Rule&nbsp;424(b)&nbsp;as
part of a registration statement relating to the offering, other than registration statements relying on Rule&nbsp;430B or other than
prospectuses filed in reliance on Rule&nbsp;430A, shall be deemed to be part of and included in the registration statement as of the date
it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part
of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or
prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use,
supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement
or made in any such document immediately prior to such date of first use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing
of the registrant&rsquo;s annual report pursuant to section&nbsp;13(a)&nbsp;or section&nbsp;15(d)&nbsp;of the Securities Exchange Act
of 1934 (and, where applicable, each filing of an employee benefit plan&rsquo;s annual report pursuant to section&nbsp;15(d)&nbsp;of the
Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration
statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial
bona fide offering thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Insofar
as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons
of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such
indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification
against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling
person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling
person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been
settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against
public policy as expressed in the Act and will be governed by the final adjudication of such issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements
for filing on Form&nbsp;S-1 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly
authorized, in the City of Florham Park, State of New Jersey on October 20, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CELLECTAR BIOSCIENCES,&nbsp;INC.</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ James V. Caruso</I></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 6%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James V. Caruso</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="v1"></A>POWER OF ATTORNEY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We, the undersigned directors
and officers of Cellectar Biosciences,&nbsp;Inc. (the Company), hereby severally constitute and appoint James&nbsp;V.&nbsp;Caruso and
Chad&nbsp;J.&nbsp;Kolean, and each of them singly, our true and lawful attorneys, with full power to them, and to each of them singly,
to sign for us and in our names in the capacities indicated below, the registration statement on Form&nbsp;S-1 filed herewith, and any
and all pre-effective and post-effective amendments to said registration statement, and any registration statement filed pursuant to Rule&nbsp;462(b)&nbsp;under
the Securities Act of 1933, as amended, in connection with the registration under the Securities Act of 1933, as amended, of equity securities
of the Company, and to file or cause to be filed the same, with all exhibits thereto and other documents in connection therewith, with
the Securities and Exchange Commission, granting unto said attorneys, and each of them, full power and authority to do and perform each
and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as each of them
might or could do in person, and hereby ratifying and confirming all that said attorneys, and each of them, or their substitute or substitutes,
shall do or cause to be done by virtue of this Power of Attorney. This Power of Attorney does not revoke any power of attorney previously
granted by the undersigned, or any of them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities indicated
on October 20, 2025:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 49%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signature</B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 3%; border-bottom: white 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 48%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ James V. Caruso</I></FONT></TD>
    <TD STYLE="white-space: nowrap; border-bottom: white 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President, Chief Executive Officer and Director</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James V. Caruso</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(principal executive officer)</I></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Chad J. Kolean</I></FONT></TD>
    <TD STYLE="white-space: nowrap; border-bottom: white 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: white 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chad J. Kolean</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(principal financial officer and</I><BR>
<I>principal accounting officer)</I></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Douglas J. Swirsky</I></FONT></TD>
    <TD STYLE="white-space: nowrap; border-bottom: white 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: white 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the Board</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Douglas J. Swirsky</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Asher Alban Chanan-Khan</I></FONT></TD>
    <TD STYLE="white-space: nowrap; border-bottom: white 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: white 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Asher Alban Chanan-Khan</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Frederick W. Driscoll</I></FONT></TD>
    <TD STYLE="white-space: nowrap; border-bottom: white 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: white 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Frederick W. Driscoll</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Stefan D. Loren, Ph.D.</I></FONT></TD>
    <TD STYLE="white-space: nowrap; border-bottom: white 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: white 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stefan D. Loren, Ph.D.</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ John Neis</I></FONT></TD>
    <TD STYLE="white-space: nowrap; border-bottom: white 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: white 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John Neis</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 59; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>tm2529020d1_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 5.1</B></P>

<P STYLE="margin: 0; text-align: right"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 29%; padding-top: 12pt; font-size: 10pt"><IMG SRC="tm2529020d1_ex5-1img001.jpg" ALT=""></TD>
    <TD STYLE="text-align: left; width: 39%; padding-top: 0.15in; vertical-align: top">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase">Sidley Austin LLP</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase">2850 Quarry Lake Drive, Suite 301</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase">Baltimore, MD 21209</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase">+1 410 559 2880</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase">+1 202 736 8711 Fax</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase">&nbsp;&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase">AMERICA <FONT STYLE="font-family: Symbol">&middot;</FONT>
    ASIA PACIFIC <FONT STYLE="font-family: Symbol">&middot;</FONT> EUROPE</P></TD>
    <TD STYLE="width: 32%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: right">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase">&nbsp;</P></TD></TR>
  </TABLE>

<P STYLE="margin: 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">October 20, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cellectar Biosciences, Inc.<BR>
100 Campus Drive<BR>
Florham Park, New Jersey 07932</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">We refer to the Registration Statement on Form S-1
(the &ldquo;<U>Registration Statement</U>&rdquo;) being filed by Cellectar Biosciences, Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;),
with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the &ldquo;<U>Securities Act</U>&rdquo;), relating
to the registration under the Securities Act of 2,096,188 shares (the &ldquo;<U>Shares</U>&rdquo;) of common stock, $0.00001 par value
per share (the &ldquo;<U>Common Stock</U>&rdquo;), of the Company, which are issuable upon the exercise of inducement warrants (the &ldquo;<U>Warrants</U>&rdquo;).
The Shares may be offered and sold by the selling stockholders named in the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">This opinion letter is being delivered in accordance
with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">We have examined the Registration Statement, the
Company&rsquo;s Amended and Restated Certificate of Incorporation, as amended to the date hereof (the &ldquo;<U>Certificate of Incorporation</U>&rdquo;),
the Company&rsquo;s Amended and Restated Bylaws, the Warrants and the resolutions adopted by the board of directors of the Company relating
to the Registration Statement and the issuance of the Warrants and the Shares by the Company. We have also examined originals, or copies
of originals certified to our satisfaction, of such agreements, documents, certificates and statements of the Company and other corporate
documents and instruments, and have examined such questions of law, as we have considered relevant and necessary as a basis for this opinion
letter. We have assumed the authenticity of all documents submitted to us as originals, the genuineness of all signatures, the legal capacity
of all persons and the conformity with the original documents of any copies thereof submitted to us for examination. As to facts relevant
to the opinions expressed herein, we have relied without independent investigation or verification upon, and assumed the accuracy and
completeness of, certificates, letters and oral and written statements and representations of public officials and officers and other
representatives of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Based on the foregoing, and subject to the other
qualifications and limitations set forth herein, we are of the opinion that the Shares, when duly issued and delivered in accordance with
the terms of the Warrants (including the payment of the applicable exercise price), will be validly issued, fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Sidley Austin (DC) LLP is a Delaware limited liability partnership doing business as Sidley Austin LLP and practicing in affiliation
with other Sidley Austin partnerships.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><IMG SRC="tm2529020d1_ex5-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cellectar Biosciences, Inc.<BR>
October 20, 2025<BR>
Page 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">In rendering the opinion set forth above, we have
assumed that, at the time of the issuance of any Shares upon exercise of any Warrant there will be a sufficient number of shares of Common
Stock authorized and then available for issuance under the Company&rsquo;s Certificate of Incorporation as in effect at such time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">This opinion letter is limited to the General Corporation
Law of the State of Delaware. We express no opinion as to the laws, rules or regulations of any other jurisdiction, including, without
limitation, the federal laws of the United States of America or any state securities or blue sky laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">We hereby consent to the filing of this opinion letter
as an Exhibit to the Registration Statement and to all references to our Firm included in or made a part of the Registration Statement.
In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the
Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 50%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Very truly yours,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Sidley Austin LLP</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>3
<FILENAME>tm2529020d1_ex23-2.htm
<DESCRIPTION>EXHIBIT 23.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 23.2</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We consent to the incorporation by reference in this Registration Statement
on Form S-1 of our report dated March 12, 2025 relating to the financial statements of Cellectar Biosciences, Inc., appearing in the Annual
Report on Form 10-K of Cellectar Biosciences, Inc. for the year ended December 31, 2024. We also consent to the reference to us under
the heading &quot;Experts&quot; in such Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Deloitte &amp; Touche LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Morristown, New Jersey</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">October 20, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>4
<FILENAME>tm2529020d1_ex-filingfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:ffd="http://xbrl.sec.gov/ffd/2025">
  <head>
    <title>EX-FILING FEES</title>
  </head>
  <body>
    <div style="display: none">
      <ix:header>
        <ix:hidden>
          <ix:nonNumeric name="ffd:FormTp" contextRef="rc" id="ixv-331">S-1</ix:nonNumeric>
          <ix:nonNumeric name="ffd:SubmissnTp" contextRef="rc" id="ixv-332">S-1</ix:nonNumeric>
          <ix:nonNumeric name="ffd:FeeExhibitTp" contextRef="rc" id="ixv-333">EX-FILING FEES</ix:nonNumeric>
          <ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="rc" id="ixv-334">0001279704</ix:nonNumeric>
          <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="rc" id="ixv-335">Cellectar Biosciences, Inc.</ix:nonNumeric>
          <ix:nonNumeric name="ffd:OfferingTableNa" contextRef="rc" id="hiddenrcOfferingTableNa" xsi:nil="true"></ix:nonNumeric>
          <ix:nonNumeric name="ffd:OffsetTableNa" contextRef="rc" id="hiddenrcOffsetTableNa">N/A</ix:nonNumeric>
          <ix:nonNumeric name="ffd:CombinedProspectusTableNa" contextRef="rc" id="hiddenrcCombinedProspectusTableNa">N/A</ix:nonNumeric>
        </ix:hidden>
        <ix:references>
          <link:schemaRef xlink:href="https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd" xlink:type="simple"/>
        </ix:references>
        <ix:resources>
          <xbrli:context id="rc">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001279704</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-10-17</xbrli:startDate>
              <xbrli:endDate>2025-10-17</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="offrl_1">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001279704</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                  <dei:lineNo>1</dei:lineNo>
                </xbrldi:typedMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-10-17</xbrli:startDate>
              <xbrli:endDate>2025-10-17</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:unit id="USD">
            <xbrli:measure>iso4217:USD</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="pure">
            <xbrli:measure>xbrli:pure</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="Shares">
            <xbrli:measure>xbrli:shares</xbrli:measure>
          </xbrli:unit>
        </ix:resources>
      </ix:header>
    </div>
    <div>
      <table style="width: 99%; font-family: Arial, Helvetica, sans-serif; font-size: 20pt; text-align: center;">
        <tr>
          <td colspan="4" style="padding-bottom: .5em">
            <p>
              <b>Calculation of Filing Fee Tables</b>
            </p>
          </td>
        </tr>
        <tr>
          <td style="padding-bottom: .25em">
            <p>
              <b>
                <ix:nonNumeric name="ffd:FormTp" contextRef="rc" id="ixv-363">S-1</ix:nonNumeric>
              </b>
            </p>
          </td>
        </tr>
        <tr>
          <td style="padding-bottom: .25em">
            <p>
              <b>
                <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="rc" id="ixv-364">Cellectar Biosciences, Inc.</ix:nonNumeric>
              </b>
            </p>
          </td>
        </tr>
      </table>
    </div>
    <div style="padding-bottom: 20px;">
      <table style="float: center; width: 100%; text-align: left;  ">
        <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px">
          <th style="vertical-align: bottom; text-align: left; word-wrap: break-word">
            <b>Table 1: Newly Registered and Carry Forward Securities</b>
          </th>
          <th style="vertical-align: bottom; word-wrap: break-word; text-align: right;">
            <span style="-sec-ix-hidden: hiddenrcOfferingTableNa">&#9744;Not Applicable</span>
          </th>
        </tr>
      </table>
      <table style="font-family: Arial, Helvetica, sans-serif; float: center; width: 100%; text-align: center; border: 1px solid black; font-size: 16px;">
        <tr style="background-color:#9ADAF6">
          <th style="width: 12%;">
            <!-- BLANK -->
          </th>
          <th style="width: 2%;">
            <!-- BLANK -->
          </th>
          <th style="width: 12%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Security Type</b>
            </p>
          </th>
          <th style="width: 14%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Security Class Title </b>
            </p>
          </th>
          <th style="width: 2%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Fee Calculation or Carry Forward Rule</b>
            </p>
          </th>
          <th style="width: 5%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Amount Registered</b>
            </p>
          </th>
          <th style="width: 15%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Proposed Maximum Offering Price Per Unit</b>
            </p>
          </th>
          <th style="width: 10%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Maximum Aggregate Offering Price</b>
            </p>
          </th>
          <th style="width: 5%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Fee Rate</b>
            </p>
          </th>
          <th style="width: 6%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Amount of Registration Fee</b>
            </p>
          </th>
          <th style="width: 1%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Carry Forward Form Type</b>
            </p>
          </th>
          <th style="width: 7%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Carry Forward File Number</b>
            </p>
          </th>
          <th style="width: 6%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Carry Forward Initial Effective Date</b>
            </p>
          </th>
          <th style="width: 7%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward</b>
            </p>
          </th>
        </tr>
        <tr>
          <td colspan="14" style="text-align: center">
            <b>Newly Registered Securities</b>
          </td>
        </tr>
        <tr style="background-color:#E7E7E2">
          <td style="text-align: left;">
            <ix:nonNumeric name="ffd:PrevslyPdFlg" contextRef="offrl_1" format="ixt:booleanfalse" id="ixv-365">Fees to be Paid</ix:nonNumeric>
          </td>
          <td style="text-align: center;">
		1
	</td>
          <td style="text-align: left;">
            <ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="offrl_1" id="ixv-366">Equity</ix:nonNumeric>
          </td>
          <td style="text-align: left;">
            <ix:nonNumeric name="ffd:OfferingSctyTitl" contextRef="offrl_1" id="ixv-367">Common Stock, par value $0.00001 per share</ix:nonNumeric>
          </td>
          <td style="text-align: center;">
            <ix:nonNumeric name="ffd:Rule457aFlg" contextRef="offrl_1" format="ixt:booleantrue" id="ixv-368">457(a)</ix:nonNumeric>
          </td>
          <td style="text-align: right;">
            <ix:nonFraction name="ffd:AmtSctiesRegd" unitRef="Shares" decimals="0" format="ixt:numdotdecimal" contextRef="offrl_1" id="ixv-369">2,096,188</ix:nonFraction>
          </td>
          <td style="text-align: right;">
            <span>$</span>
            <ix:nonFraction name="ffd:MaxOfferingPricPerScty" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="offrl_1" id="ixv-370">4.86</ix:nonFraction>
          </td>
          <td style="text-align: right;">
            <span>$</span>
            <ix:nonFraction name="ffd:MaxAggtOfferingPric" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="offrl_1" id="ixv-371">10,187,473.68</ix:nonFraction>
          </td>
          <td style="text-align: right;">
            <ix:nonFraction name="ffd:FeeRate" unitRef="pure" decimals="INF" format="ixt:numdotdecimal" contextRef="offrl_1" id="ixv-372">0.0001381</ix:nonFraction>
          </td>
          <td style="text-align: right;">
            <span>$</span>
            <ix:nonFraction name="ffd:FeeAmt" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="offrl_1" id="ixv-373">1,406.89</ix:nonFraction>
          </td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: right;">

	</td>
        </tr>
        <tr style="background-color:#E7E7E2">
          <td style="text-align: left;">
		Fees Previously Paid
	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: left;">

	</td>
          <td style="text-align: left;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: right;">

	</td>
        </tr>
        <tr>
          <td colspan="14" style="text-align: center">
            <b>Carry Forward Securities</b>
          </td>
        </tr>
        <tr style="background-color:#E7E7E2">
          <td style="text-align: left;">
		Carry Forward Securities
	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: left;">

	</td>
          <td style="text-align: left;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: right;">

	</td>
        </tr>
        <tr>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td colspan="3" style="vertical-align: top">
            <p style="margin: 0pt; text-align: right">Total Offering Amounts:</p>
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td style="vertical-align: top; width: 16%;">
            <p id="MaxAggtOfferingPrice" style="margin: 0pt; text-align: right">
              <span>$</span>
              <ix:nonFraction name="ffd:TtlOfferingAmt" contextRef="rc" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="ixv-374">10,187,473.68</ix:nonFraction>
            </p>
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td style="vertical-align: top; border-bottom: 1px black; width: 16%;">
            <p id="TotalFeeAmt" style="margin: 0pt; text-align: right">
              <span>$</span>
              <ix:nonFraction name="ffd:TtlFeeAmt" contextRef="rc" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="ixv-375">1,406.89</ix:nonFraction>
            </p>
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
        </tr>
        <tr>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td colspan="3" style="vertical-align: top">
            <p style="margin: 0pt; text-align: right">
					Total Fees Previously Paid:
				</p>
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td style="vertical-align: top">
            <p id="TotalPreviouslyPaidAmt" style="margin: 0pt; text-align: right">
              <span>$</span>
              <ix:nonFraction name="ffd:TtlPrevslyPdAmt" contextRef="rc" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="ixv-376">0.00</ix:nonFraction>
            </p>
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
        </tr>
        <tr>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td colspan="3" style="vertical-align: top">
            <p style="margin: 0pt; text-align: right">
					Total Fee Offsets:
				</p>
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td style="vertical-align: top">
            <p id="TotalOffsetAmt" style="margin: 0pt; text-align: right">
              <span>$</span>
              <ix:nonFraction name="ffd:TtlOffsetAmt" contextRef="rc" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="ixv-377">0.00</ix:nonFraction>
            </p>
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
        </tr>
        <tr>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td colspan="3" style="vertical-align: top">
            <p style="margin: 0pt; text-align: right">
					Net Fee Due:
				</p>
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td style="vertical-align: top">
            <p id="NetFeeAmt" style="margin: 0pt; text-align: right">
              <span>$</span>
              <ix:nonFraction name="ffd:NetFeeAmt" contextRef="rc" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="ixv-378">1,406.89</ix:nonFraction>
            </p>
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
        </tr>
      </table>
    </div>
    <div>
      <table style="width: 100%; text-indent: 0px;">
        <tbody>
          <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px; vertical-align: top;">
            <td>
              <p style="margin:0pt;text-align:left; margin-bottom: 5px;">
                <b>Offering Note</b>
              </p>
            </td>
            <td/>
          </tr>
        </tbody>
      </table>
    </div>
    <div style="padding-bottom: 20px;">
      <table style="width: 100%; text-indent: 0px;">
        <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px; vertical-align: top;">
          <td style="width:10pt;">
            <p style="margin:0pt;text-align:left;">
              <sup style="vertical-align:top;line-height:120%;font-size:10px">1</sup>
            </p>
          </td>
          <td colspan="7" style="white-space: pre-line;">
            <ix:nonNumeric name="ffd:OfferingNote" escape="1" contextRef="offrl_1" id="ixv-379">(1) Consists of an aggregate of 2,096,188 shares of the registrant's common stock issuable upon the exercise of warrants, all of which were sold to the selling stockholders in private placements. Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), the shares of common stock being registered hereunder include such indeterminate number of shares of common stock as may be issuable with respect to the shares of common stock being registered hereunder as a result of stock splits, stock dividends or similar transactions.

(2) Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(c) of the Securities Act. The offering price per share and aggregate offering price are based upon the average of the high and low prices for the Registrant's Common Stock as reported on the Nasdaq Global Select Market on October 16, 2025, a date within five business days prior to the filing of this Registration Statement. </ix:nonNumeric>
          </td>
        </tr>
        <tr>
          <td colspan="7">
            <hr style="width:100%;text-align:left;margin-left:0"/>
          </td>
        </tr>
      </table>
    </div>
    <div style="padding-bottom: 20px;">
      <table style="float: center; width: 100%; text-align: left;  ">
        <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px">
          <th style="vertical-align: bottom; text-align: left; word-wrap: break-word">
            <b>Table 2: Fee Offset Claims and Sources</b>
          </th>
          <th style="vertical-align: bottom; word-wrap: break-word; text-align: right;">
            <span style="-sec-ix-hidden: hiddenrcOffsetTableNa">&#9745;Not Applicable</span>
          </th>
        </tr>
      </table>
      <table style="font-family: Arial, Helvetica, sans-serif; font-size: 16px; float: center; width: 100%; text-align: center;  border: 1px solid black;">
        <tr style="background-color:#9ADAF6">
          <th style="width: 10%; text-align: left;">
            <!-- BLANK -->
          </th>
          <th style="width: 8%; text-align: left;">
            <!-- BLANK -->
          </th>
          <th style="width: 16%;">
				Registrant or Filer Name
			</th>
          <th style="width: 6%;">
				Form or Filing Type
			</th>
          <th style="width: 7%;">
				File Number
			</th>
          <th style="width: 6%;">
				Initial Filing Date
			</th>
          <th style="width: 6%;">
				Filing Date
			</th>
          <th style="width: 6%;">
				Fee Offset Claimed
			</th>
          <th style="width: 6%;">
				Security Type Associated with Fee Offset Claimed
			</th>
          <th style="width: 8%;">
				Security Title Associated with Fee Offset Claimed
			</th>
          <th style="width: 6%;">
				Unsold Securities Associated with Fee Offset Claimed
			</th>
          <th style="width: 9%;">
				Unsold Aggregate Offering Amount Associated with Fee Offset Claimed
			</th>
          <th style="width: 6%;">
				Fee Paid with Fee Offset Source
			</th>
        </tr>
        <tr>
          <td colspan="14" style="text-align: center">
            <b>Rules 457(b) and 0-11(a)(2)</b>
          </td>
        </tr>
        <tr style="background-color:#E7E7E2">
          <td style="text-align: left;">
		Fee Offset Claims
	</td>
          <td>
		N/A
	</td>
          <td style="text-align: left;">
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: left;">
		N/A
	</td>
          <td style="text-align: left;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
        </tr>
        <tr style="background-color:#E7E7E2">
          <td style="text-align: left;">
		Fee Offset Sources
	</td>
          <td>
		N/A
	</td>
          <td style="text-align: left;">
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: left;">
		N/A
	</td>
          <td style="text-align: left;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
        </tr>
        <tr>
          <td colspan="14" style="text-align: center">
            <b>Rule 457(p)</b>
          </td>
        </tr>
        <tr style="background-color:#E7E7E2">
          <td style="text-align: left;">
		Fee Offset Claims
	</td>
          <td>
		N/A
	</td>
          <td style="text-align: left;">
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: left;">
		N/A
	</td>
          <td style="text-align: left;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
        </tr>
        <tr style="background-color:#E7E7E2">
          <td style="text-align: left;">
		Fee Offset Sources
	</td>
          <td>
		N/A
	</td>
          <td style="text-align: left;">
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: left;">
		N/A
	</td>
          <td style="text-align: left;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
        </tr>
      </table>
    </div>
    <div style="padding-bottom: 20px;">
      <table style="float: center; width: 100%; text-align: left;  ">
        <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px">
          <th style="vertical-align: bottom; text-align: left; word-wrap: break-word">
            <b>Table 3: Combined Prospectuses</b>
          </th>
          <th style="vertical-align: bottom; word-wrap: break-word; text-align: right;">
            <span style="-sec-ix-hidden: hiddenrcCombinedProspectusTableNa">&#9745;Not Applicable</span>
          </th>
        </tr>
      </table>
      <table style="font-family: Arial, Helvetica, sans-serif; font-size: 16px; float: center; width: 100%; border: 1px solid black;">
        <tr style="background-color:#9ADAF6">
          <th style="width: 4%">
            <!-- Note column -->
          </th>
          <th style="width: 14%">
            <p style="margin: 0pt; text-align: center;">
              <b>Security Type</b>
            </p>
          </th>
          <th style="width: 25%">
            <p style="margin: 0pt; text-align: center;">
              <b>Security Class Title</b>
            </p>
          </th>
          <th style="width: 14%">
            <p style="margin: 0pt; text-align: center;">
              <b>Amount of Securities Previously Registered</b>
            </p>
          </th>
          <th style="width: 18%">
            <p style="margin: 0pt; text-align: center;">
              <b>Maximum Aggregate Offering Price of Securities Previously Registered</b>
            </p>
          </th>
          <th style="width: 6%">
            <p style="margin: 0pt; text-align: center;">
              <b>Form Type</b>
            </p>
          </th>
          <th style="width: 10%">
            <p style="margin: 0pt; text-align: center;">
              <b>File Number</b>
            </p>
          </th>
          <th style="width: 8%">
            <p style="margin: 0pt; text-align: center;">
              <b>Initial Effective Date</b>
            </p>
          </th>
        </tr>
        <tr style="background-color:#E7E7E2;">
          <td style="text-align: center;">
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: center;">
		N/A
	</td>
          <td style="text-align: center;">
		N/A
	</td>
          <td style="text-align: center;">
		N/A
	</td>
        </tr>
      </table>
    </div>
  </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>tm2529020d1_ex5-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2529020d1_ex5-1img001.jpg
M_]C_X  02D9)1@ ! 0$       #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  G ) # 2(  A$! Q$!_\0
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M%WB"[^*ECXVN[[3;_P ,^)-+T:SM](;PIXP\,P):S6]]))<"[ANI3*B&.6-
M4/\ /2O_  >D_P#!1]46>3]E;]DTV^U9#(/#OQH1&B8 AUF/Q09 K @J^&4@
M@@$&O6/^#W[_ )./_80_[(E\6?\ U._#U?W/?\$^-/L)?V _V(!+96D@D_8_
M_9JWA[:%]^[X+^"RV[<AW;B23G.23F@#^,/]G/\ X/=;]M:TS2OVL?V([.+0
M;F\MX]6\;? /XCW#ZEI-F\H6YN+3X<>/M*,&L211LTJ0O\2])+>7Y08LX=?[
M@?V8?VK_ -G;]LWX3:%\;_V9/BSX0^+_ ,-M?BB\G7/"NHI<7&D:@]M!=S>'
M_%>B3B'6_"'BFPAN8#J?ACQ+I^EZYIYEC-U81++$S_F]_P %3/\ @AA^Q5_P
M4W^&>M6OB;X>>'/A9^T#INDZY+\-?C]\/]$T_P /^*M*\27=D?[-@\<KI5O:
MQ_$/P;_:4-J^H:!XB%U-;6LFH2^&]0T#5;Q]2'\(W_!M/^U9\5/^">7_  6$
M7]CSQY)+:^$?V@/'GB;]E#XR^$?M<TEAH_Q>\&ZQK^F> ?$MA"Q@BEUC1OB'
MI=UX,^TS1JQ\.>,M>(A:Y%H(P#^BS_@N[_P<>?M:?\$LOVY(?V8/@M\&OV?O
M'?@V7X+?#_XDMKGQ+T_X@77B0:OXLU/Q;97UD)?#7CGP]IO]GV\>@6K6JG3S
M<!Y9_-GE!0)_8]H&H2ZMH6BZI.D<<VI:3IVH31Q;A$DMY9PW,B1AV9O+5Y"J
M;F9MH&6)R:_RR/\ @\5_Y2\VG_9J7P6_]/\ \2O8?6O]2CP9_P B?X3_ .Q:
MT+_TUVM '2U_G,?M'_\ !XC^WU\'?VBOCW\'O#G[.?[*&J:'\*_C3\4_AMH=
M_JNC_%J75]0TCP+XXUWPQIMYJ1L_B?;6KZA<V.E0SWK6MK;V[7+RM#!#$5C7
M_1GK_)\_X)1?9/\ B*8\._;OL_V3_AMK]N#SOM?E?9\?\(Q^T9M\WSOW>-^W
M&[C=MQSB@#ZY_P"(U/\ X*,?]&P?LB_^"'XR_P#SU*_H!_X-]_\ @O1^U5_P
M5R^./[07PH^-OPI^!OPRT_X6_!NP\?\ AG5_AOHWCU;JYU[4/%^G>&U@UJ#Q
M/XYUB&\TJ""^:Z:UL7TR[FDC""_A5B1_5)GP>>_AH_CI?^>M:.GKHI,K:4-,
M+ *LSZ<+7(5B2BRM;<@,58J&/.TD<C- '\(OQ:_X.F/V^/V+/^"BNK_L>_MP
M_LV?LYZ!\/?AG\==/\!_%;QCX"T+XK:+XDOOA#J6LVR6'QA\ Q^(/'_B*RN-
M/UCP/J.G?$7P_87NFW;:EIL\>BSRV-_++<V?]WFCZQI/B+2-*\0:!J=AK6A:
MYIMCK&BZSI5W!J&EZMI.IVL5[IVIZ;?VLDMK>V%_9SPW5G=VTLD%S;RQS0R/
M&ZL?Y,_^#J#_ ((Y6'[9W[/6K?MV?!VTNX_VEOV5/AMJ-QXET&PMX98/BU\"
M/#EWJ'BCQ'I,T$5J^H3>,/A];7>O>*?"$EM,YU.PDU[PS-8WMWJ.A7&D?#O_
M  ;L_P#!P+X+\$?\$^?CW\#OVO=5@35/^"=OP'NOB5\*M7BNE@UWXI? O1;Z
MV\.Z1\-HFU&[:WN?&_A3Q?K_ (.\ >%/LX@AO_#WB?PS:RVD;>&M4U*_ /U-
M_P"#A+_@OIX@_P""1UY\!OA1\ O!OPQ^*?[07Q3BUSQUXNT#XC3Z]=:)X"^$
MVE%M%T34[_2O"^N>'=6_MCQ[XK?48/#-R^J&RAL/ WBP7EC++=:9/'^CW_!(
M#]I;]M/]L[]CKX:_M6?MA>"?A+\(]1^-%IK'BCP!\+/AWX/\<:1JEI\.;B\L
M;?P'XQ\0ZUXP\?\ B,L_C+3K/5_$VFZ7::'#%<>%M>\(ZHFJ0S&^L9OX(_\
M@G/^RI\3_P#@YE_X*U?'7]KG]J!;KPS\ _!VM>%OB!\7M*\/2W,E@F@6JP>'
MO@[^SCX2U#4$N!!:ZAX?\*S1>)=61%O7T'1O$6JJMAX@\1V%ZG^I-I]A8Z58
MV6F:99VVGZ;IUI;V&GZ?901VME8V5G"EO:VEI;0JD-O;6T$<<,$$2)%%$B)&
MJJH% 'X%_P#!93_@WY_9N_X*UW&A?$RX\27WP,_:5\*Z,WA^P^+OAO1['5+?
MQ;H$$4_]D>'OB/H<WD/XATS0[J=[C2;JTOM-UNPC>:QMM3CL)Y;9_P"+KXX?
M\&R'_!9G]BB\UGXC_L^^*+#XK:)\.X+OQ5H&O_ OXA:_X6^(+QZ.4,EWIW@J
M\-FUKK,=M<7-Y;V%AX@U&YG@MKN.V>6\:"UN/Z;=?_X.T/V0/AY_P4%^,/[,
M_P 4?!GCCPQ^SSX#;2O .A_&L^'[\:W_ ,+8T+7/$%A\0+SQ#X1O#:ZA9> )
M4ET"T\/W_E1ZC$NCZMJ]W;26VK6-K;?H/\3/^#D3_@CM\.O VK>,[/\ ;!\%
M_$*\T_0+K6[+P7X"T_7]5\7:S-#$C0:/86-UI5C;#4[N6011Q37<:1^7/([[
M8P' /P"_X-D_^"_O[17[0'[06F_\$\?VW/&&K_%7Q)XXT;Q'=_ 7XN>)=LGC
MBUU_P'X9U#Q-XA^'OCO4GCCO/$4>I>&] U[6=)U_6)9];M-6TV71[F>ZMM1L
M4T[\6O\ @X,_Y65_B!_V5+]AC_U37[/]:7_!MA\)O'W[7G_!=O1?VHO"G@JX
MT/X8_"_Q?^T'^T/\0Y].MGCT#P7:?$?PS\1M!\%>$(+R*-;1;JY\4^/=)L;#
M34*R3Z-I6K7$47D6<I7-_P"#@S_E97^('_94OV%__5-?L_T ?H3_ ,'OW_)Q
M_P"PA_V1+XL_^IWX>K^ZG_@GK_R8)^P[_P!F?_LT?^J7\%5_"M_P>_?\G'_L
M(?\ 9$OBS_ZG?A[\/\_2OV3_ &2?^#G_ /X)+_!S]D;]F'X7>-/B?\2(?&/P
MO_9T^"GP_P#%FGZ=\,[^_2#Q-X+^&OAGPWKUK:3KJ4:744&J:;=10S@(LT:+
M(H ;  /ZUJ_R(?AG?6?QM_X.C_#WB;X4/'J6@^(O^"ST_P 0=%O=,(:WU+P;
MX>_:QNO&^N:U;F+AK&_\*Z+JNKLZ_(;29F;Y2:_=+_@J7_P=[:=\1_A[J?P/
M_P""9/@_QII6O^/;'5?#.M?'#QYHITOQ-HMCK-H=,AB^&WA*VFO;BV\52O<3
M?9-9O)KE[*1K6?3(8[^))!;_ .#5/_@B5\;/ 'QN7_@I%^UU\.=7\!VWAWPC
MJ,/[,WA3QE#):>*]7\3>/=/N])U_XHZKHUR!>Z99Z=X0O]4T;0X]46.]O+[Q
M+>7[V]M-I$+R 'Y9_P#!XK_REZM/^S4O@M_Z?_B57^I1X,_Y$_PG_P!BUH7_
M *:[6O\ +7_X/%?^4O-H?^K4O@K_ .G_ .)77T/^>,5_6AX;_P"#LC_@CUIO
MAW0=.NOB'\8UN=/T72[*Y5/A'>N@GM+&""8*PUH!E$D;;6P,C!P,XH _I]K_
M !>++]DSXA_MS_\ !9_XR_LI_"CQ9IG@7X@?%W]L#]J[3O#GBO6);^#3=(F\
M.>)/BQXTO9;J73'COD6XTOPW?62&W=29;F,/F,N#_J'_ /!/[_@M_P#L%_\
M!3+XN^*O@C^RQXJ\?:[X\\'?#C4OBIK=IXK\"W'A>PB\(Z3XF\*>$;RX@OIM
M0NUGNUUGQGH<:6@C5FAEGFW@0E6_S<?V2_VI?A+^Q5_P<-^(OVGOCIJ&KZ7\
M*/A3^V;^V/J'B^_T'2GUO5K>V\0#XX^#]-:STN.:W>[9]:\1:;%*JS)Y4#RS
MDD1%2 ?K9_Q!V_\ !2?_ */#^%O_ (-_B!_\F5_2[_P;W?\ !(#]I#_@D]I?
M[5]E^T+\7_"_Q8E^.NH?!2Z\)OX:N]?NAH4?PWMOBI#K27AUV:8H=2;QQI1M
MQ:[0PL9O.SMBQS/_ !%J_P#!'/\ Z*+\9?\ PT-[_P#+JOLS]A/_ (+Q_P#!
M/C_@HS\<7_9Y_9E\6_$/6_B3'X+\0>/FLO$_@&Z\-:9_PCOAFYTFTU68:E+J
M-VAN8YM:L1#;^4#*K2,''ED$ _9*XMX+N":UNH8KBVN8I(+BWGC66&>"9#'+
M#+$X9)(I$9DD1P5=6*L""17^/K_P<7_\$\O"O_!-G_@I!XV\ ?"W5+2'X4?M
M!^#(?VC_  !X0TNTDTR#X>^%_'WC[QQHEY\-GCCF:"[TKP]XJ\":O-X?$4<$
M%OX?ET*R>W:YTY[F;_8/K_,6_P"#UO\ Y2;?LZ_]F)> ?_6@?VD: /[G/^".
M'_!.OP1_P3*_83^%/[/OA^32];\<:E:/\0_C/X^T_3Q8R^/?B9XM2.^U'4)0
MS23MIWA_2_[*\'^'8YY7DBT'0+ R$W$MQ))^IM<WX-_Y%#PK_P!BWH?_ *:[
M6NDH _#G_@H1_P &]O\ P3H_X*,>/=4^,/Q4\!:]X$^,^L6D4&K_ !%^%NL#
MPQ>>(;FW@6VM=2\5Z3';OI_B#4(+=(XA=3"WGF$:O<RS2YD/Y5^'?^#+O_@G
M_INKV]YXA^.OQ\\2:3'>)-/HZ/H>BM<6:EM]D-1M&GGA+@J/M*Q-(NW(0Y-%
M% ']*W[%/[!7[+/_  3X^%*_!W]E?X7Z5\._"UQ=QZEX@OT9M0\4>,-9BMH[
M--9\6^(;A?MNLZ@MM$D,;2&.W@7S#;VT3SSM+\#?M4?\&^W_  3U_;$_:_U7
M]N#XR:/\6KGXYZQK7PUUZ\N_#OQ*O-#\,G4/A1X?\+>&?";1^'X].GACBCTS
MP?HZW\8GQ>3+<2L4,Y"E% 'JO_!1W_@BU^Q/_P %3O%WPS\:_M5Z7\2=0UOX
M3>'-<\+>$F\"^/+KP?;1Z5XAU.UU;45O[>WL;L7L[7EG"89F9#%&&0 [LU^;
MH_X-!O\ @CQD9\-?M!D9&1_PNW4AD=QG^QN,^M%% 'WI^R-_P0(_X):_L7>*
M-,\=?"C]F_2->\=Z)()=$\9_%._E^(6NZ1-M*M/8MJT2:?'.P.1,^GR21NJR
M1-&ZAJ_9155%5$4*BJ%5% 5551A550   ,  <    444 ?BA^WY_P0$_X)]_
M\%)OCRG[1O[2^C_%B^^)$?@CP]\/UG\&?$B\\*Z./#WABZU>[TM#I<&G72&[
M6;6[XSW/F[IE:)2JB,9^)?\ B$&_X(\_]"W^T'_X>S4O_E-110!]]?\ !.W_
M ((5?L'?\$OOC'XL^.G[+>D_%&P\>>-/AGJGPFUJ;QO\0[OQ=I;>$=7\4^$?
M&%Y';:=/86B07YUGP3H;1WHD9H[=+J (1<%E^//B9_P:C?\ !)KXL_$CX@_%
M3Q=X>^/$OBOXF>-_%?Q \3R6'QCU"RL9/$/C/7K_ ,1ZT]E9KI#K:6CZEJ5R
MUM;*[K!"4B#,$R2B@#B/^(0;_@CS_P!"W^T'_P"'LU+_ .4U?;7[ ?\ P0$_
MX)^?\$V/CR_[1O[-&C_%>Q^)$G@CQ%\/VG\9_$B\\5:.?#WBBZTB[U1!I<^G
M6J"[:;1+$P7/F[H5650I\PX** /VQK\;?^"B7_!"G]@[_@J!\8_"?QT_:DTG
MXI:AX\\&?#/2_A-HDW@CXAW?A+2T\):1XI\7>,+..YTZWT^Z2>_&L^-]<:2]
M,BM);O:P; MLI8HH _8?3[*#3+"QTVU#"VT^SMK*W#MO<06D*01!W/+,(XUW
+,?O')[U;HHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>tm2529020d1_s1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2529020d1_s1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "? A,# 2(  A$! Q$!_\0
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MS2YJF=0M!<"(W$8D_ND\U9&#R.].S%<DHI!2T#"BBB@ HHHH **** "BBB@
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M7G25I:'?!WB)(0%)/85\U^/+@7?C.< Y ?;7T9>/MM)6/0*2:^:[^)[WQBY
MR&G_ *UOAG:[9S8J232/??!ML+7PU9QXQ\F<5T-4=)A\C3;>,=D'\JNDY%83
M=Y,ZJ=E% 3BN.\9^,K?P]:,JL&N6!"+4OC'Q?;>'-/9V8&X(^5*\%FN-0\7:
MSDEW>1_E _AKHHT=.:1C4J=$7-.U+6=>\2Q3Q22/(T@) )PHS7TE9+(EI$LA
MRX4 UR7@OP1!X>LU>10UT^"S>]=JHXYJ:LD]$5236XX4M%%8&X4444 %%%%
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M^;$4?C<M<C<?#G1[BY>9Q)ESEL4BG=&U_P )9HI!_P!/A_[ZI/\ A+-%R?\
M3H?^^JX[Q#\/]*L=$N+J'S ZKQ5+P;X&TS5M ANKCS"[$C]:OE1FYN]COU\5
M:,[;1?1$DX S6M'*DT8=&RIY!KC8_AKH\<JR@R;E.177VUNEM D4><*,#-9N
MQHB4MBH+N_M[&'S;F58T]6-2L0#UQZUY5XPN)O%7B./0K1R(4_UK"KBKBF['
MJ%G?V]]'YMM*LB'NIJUVKRCP;/+X7\1SZ#=R'RFYB8UZH&S2FK!"5T/JG>ZC
M::>F^ZG6)?4FK6:\X^*,7G+81L2$DD ;%**N.3L=?_PE.B_\_P##_P!]4?\
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1HHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>tm2529020d1_s1img002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2529020d1_s1img002.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "3 @X# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJC^*;M)+J_E60KYZ7$H1?G9B$C:)\G"C< "65@/\_P#8DR7S-,\I90N]SB/
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MOK?Q!^$7@+Q=XAMWMM5UW0[2[NDD4JQDE@B<MM[<N>O.:_-_X.?\$7OV.?A
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M" /J2,=C51:LHW][^7KOVW!M+=I>KL+O/H/U_P :4,QZ ?Y_&JR3PR E)$8
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MV>?;L,]*B3JJ4HQIU)*-K\L).UTGTB^Y,FH6YFHWVYFE?TO8N%^F,'UR#_\
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M>6HE!W?/D_H?_P %U/B;J_@G]EVR\*Z)J,UC>>//%%OX9E\F1XU:&\ET^/\
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M["I'"\82,YLW"B1U^\, G!K]C+2X,UM"X&S,2DJ1E@=SJ6+#*G>5R #E<<@
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M\'I(F20IHR6[,F25D2*+*/@97'8L #S@G!Q_F=RQF18Q&VPMN4R$$A68J%.
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MR">XK^Q3_@K1^PC>_'/PXWQ4\ VH'B[PU:RL]O:6BM/=VZ11&5]IV%V;R57
MW.2V0""<?R#:[X9U_P )W\FD>)M'NM&U.T<VM[;75O)%(LJ2RA7=<, )<DJ0
M2!SDC@'Y;'4:JG/]U4_\ EU3\C_+KQK\-<?E_%U;-Z6'Q,L+[:=1N-"JX03I
MQ=Y24'%*?Q)O=.ZT,<#*[^-OJ2![="0?TJ&1B40Q>6\SS110QN.9'D+<+GC
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M+LG?6S=G;JF>]R2H0<NO&1QD<GU)X^E?&'[>D(F_95^,GSMM'@O7&VH5!?\
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MJ.TFD_>J2EL_4E++"R8(!<D 9 )(&>@&< 9+,1M7H2-PS\6?MW?M,Z!^S/\
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MOIS*^[:Z]M?0\/)_#/@#*JT<7EN54XXQR;=2%*-W)2TU4>EDM]+6(((Q&(@
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M[O=V74_GM_X<)?"MXP[_ !?^)_F1YR6UBZ4HQX##9,2YX/3)7TYY^QOV-_\
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MN2I%M*_N\KB[NVRTW]3+,L#3S/ U,)4:2E&25^MT_P#/\$?Y;7[>7[*'BO\
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M;:,]B>2.W69#-)&Q0N$20*65<HV_!4L0#G;T!)'&['&?\P'X"_\ !1O]J'X
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MHROHXJVJ?9VU-/Q%J>H^)]:U#Q!JUY+K&LZM/-=2S7SD7+RE@^X/,PV;3(V
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MN#)/&LJG[O4.&ST'6O%O&7PF^&>J7CRZCX%\,7LDBG>UQI-K)NX&>&C(&>^
M,\9SBBBOHL)B,13KN-.O6A%.-E"K4BE=)NRC.*5WKMN?&YA"+IN\8O3K%/\
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$B@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Submission<br></strong></div></th>
<th class="th"><div>Oct. 17, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_SubmissionLineItems', window );"><strong>Submission [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Central Index Key</a></td>
<td class="text">0001279704<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Registrant Name</a></td>
<td class="text">Cellectar Biosciences, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FormTp', window );">Form Type</a></td>
<td class="text">S-1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_SubmissnTp', window );">Submission Type</a></td>
<td class="text">S-1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeExhibitTp', window );">Fee Exhibit Type</a></td>
<td class="text">EX-FILING FEES<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTableNa', window );">Offering Table N/A</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OffsetTableNa', window );">Offset Table N/A</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_CombinedProspectusTableNa', window );">Combined Prospectus Table N/A</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_CombinedProspectusTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_CombinedProspectusTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeExhibitTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeExhibitTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:feeExhibitTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FormTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FormTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OffsetTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OffsetTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_SubmissionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_SubmissionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_SubmissnTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_SubmissnTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Offerings - Offering: 1<br></strong></div></th>
<th class="th">
<div>Oct. 17, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_PrevslyPdFlg', window );">Fee Previously Paid</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_Rule457aFlg', window );">Rule 457(a)</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Common Stock, par value $0.00001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_AmtSctiesRegd', window );">Amount Registered | shares</a></td>
<td class="nump">2,096,188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxOfferingPricPerScty', window );">Proposed Maximum Offering Price per Unit</a></td>
<td class="nump">4.86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxAggtOfferingPric', window );">Maximum Aggregate Offering Price</a></td>
<td class="nump">$ 10,187,473.68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01381%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeAmt', window );">Amount of Registration Fee</a></td>
<td class="nump">$ 1,406.89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingNote', window );">Offering Note</a></td>
<td class="text">(1) Consists of an aggregate of 2,096,188 shares of the registrant's common stock issuable upon the exercise of warrants, all of which were sold to the selling stockholders in private placements. Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), the shares of common stock being registered hereunder include such indeterminate number of shares of common stock as may be issuable with respect to the shares of common stock being registered hereunder as a result of stock splits, stock dividends or similar transactions.

(2) Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(c) of the Securities Act. The offering price per share and aggregate offering price are based upon the average of the high and low prices for the Registrant's Common Stock as reported on the Nasdaq Global Select Market on October 16, 2025, a date within five business days prior to the filing of this Registration Statement. <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_AmtSctiesRegd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of securities being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_AmtSctiesRegd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegativeDecimal2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total amount of registration fee (amount due after offsets).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The rate per dollar of fees that public companies and other issuers pay to register their securities with the Commission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_MaxAggtOfferingPric">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum aggregate offering price for the offering that is being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_MaxAggtOfferingPric</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative100TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_MaxOfferingPricPerScty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum offering price per share/unit being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_MaxOfferingPricPerScty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegativeDecimal4lItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingSctyTitl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The title of the class of securities being registered (for each class being registered).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingSctyTitl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingSctyTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Type of securities: "Asset-backed Securities", "ADRs/ADSs", "Debt", "Debt Convertible into Equity", "Equity", "Face Amount Certificates", "Limited Partnership Interests", "Mortgage Backed Securities", "Non-Convertible Debt", "Unallocated (Universal) Shelf", "Exchange Traded Vehicle Securities", "Other"</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingSctyTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:securityTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_PrevslyPdFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_PrevslyPdFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_Rule457aFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Checkbox indicating whether filer is using Rule 457(a) to calculate the registration fee due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 457<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_Rule457aFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fees Summary<br></strong></div></th>
<th class="th">
<div>Oct. 17, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeesSummaryLineItems', window );"><strong>Fees Summary [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlOfferingAmt', window );">Total Offering</a></td>
<td class="nump">$ 10,187,473.68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlPrevslyPdAmt', window );">Previously Paid Amount</a></td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlFeeAmt', window );">Total Fee Amount</a></td>
<td class="nump">1,406.89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlOffsetAmt', window );">Total Offset Amount</a></td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_NetFeeAmt', window );">Net Fee</a></td>
<td class="nump">$ 1,406.89<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeesSummaryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeesSummaryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_NetFeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_NetFeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlFeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlFeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlOfferingAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlOfferingAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlOffsetAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlOffsetAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlPrevslyPdAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlPrevslyPdAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>2</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>1</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2529020d1_ex-filingfees.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995210 - Document - Submission</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/submissionTable</Role>
      <ShortName>Submission</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="tm2529020d1_ex-filingfees.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995211 - Document - Offerings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/feesOfferingTable</Role>
      <ShortName>Offerings</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="tm2529020d1_ex-filingfees.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995215 - Document - Fees Summary</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/feesSummaryTable</Role>
      <ShortName>Fees Summary</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="EX-FILING FEES" original="tm2529020d1_ex-filingfees.htm">tm2529020d1_ex-filingfees.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="3">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/ffd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tm2529020d1_ex-filingfees.htm": {
   "dts": {
    "inline": {
     "local": [
      "tm2529020d1_ex-filingfees.htm"
     ]
    },
    "schema": {
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/arcrole/deprecated-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 1,
   "memberCustom": 0,
   "hidden": {
    "total": 8,
    "http://xbrl.sec.gov/dei/2025": 2,
    "http://xbrl.sec.gov/ffd/2025": 6
   },
   "contextCount": 2,
   "entityCount": 1,
   "segmentCount": 1,
   "elementCount": 107,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/ffd/2025": 22,
    "http://xbrl.sec.gov/dei/2025": 3
   },
   "report": {
    "R1": {
     "role": "http://xbrl.sec.gov/ffd/role/document/submissionTable",
     "longName": "995210 - Document - Submission",
     "shortName": "Submission",
     "isDefault": "true",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R2": {
     "role": "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
     "longName": "995211 - Document - Offerings",
     "shortName": "Offerings",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "offrl_1",
      "name": "ffd:PrevslyPdFlg",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2529020d1_ex-filingfees.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "offrl_1",
      "name": "ffd:PrevslyPdFlg",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2529020d1_ex-filingfees.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable",
     "longName": "995215 - Document - Fees Summary",
     "shortName": "Fees Summary",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "3",
     "firstAnchor": {
      "contextRef": "rc",
      "name": "ffd:TtlOfferingAmt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2529020d1_ex-filingfees.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "rc",
      "name": "ffd:TtlOfferingAmt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2529020d1_ex-filingfees.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "ffd_AggtRedRpPricFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AggtRedRpPricFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Redeemed or Repurchased Price, Fiscal Year",
        "terseLabel": "Aggregate Redeemed or Repurchased, FY"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AggtRedRpPricPrrFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AggtRedRpPricPrrFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Redeemed or Repurchased Price, Prior Fiscal Year",
        "terseLabel": "Aggregate Redeemed or Repurchased, Prior FY"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AggtSalesPricFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AggtSalesPricFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Sales Price, Fiscal Year",
        "terseLabel": "Aggregate Sales Price"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AmtRedCdts": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AmtRedCdts",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Redemption Credits",
        "terseLabel": "Redemption Credits"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AmtSctiesRcvd": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AmtSctiesRcvd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Securities Received",
        "terseLabel": "Amount of Securities Received",
        "documentation": "Amount of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form)"
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ffd_AmtSctiesRegd": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AmtSctiesRegd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Securities Registered",
        "terseLabel": "Amount Registered",
        "documentation": "The amount of securities being registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CeasedOprsDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CeasedOprsDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ceased Operations Date",
        "terseLabel": "Ceased Operations Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CfwdFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Form Type",
        "terseLabel": "Carry Forward Form Type",
        "documentation": "The Form Type of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., \"Form S-3\" in the human-readable and \"S-3ASR\" in the XBRL)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CfwdPrevslyPdFee": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdPrevslyPdFee",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Previously Paid Fee",
        "terseLabel": "Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward",
        "documentation": "The fee previously paid in connection with the securities being brought forward from the prior shelf registration statement on which unsold securities are carried forward under 415(a)(6)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CfwdPrrFctvDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdPrrFctvDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Prior Effective Date",
        "terseLabel": "Carry Forward Initial Effective Date",
        "documentation": "The initial effective date of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CfwdPrrFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdPrrFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward File Number",
        "terseLabel": "Carry Forward File Number",
        "documentation": "The EDGAR File Number of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). If the prior registration statement has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CmbndPrspctsItemAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CmbndPrspctsItemAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus Item [Axis]",
        "terseLabel": "Combined Prospectus",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different references to earlier prospectuses on a single fee bearing submission."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CmbndPrspctsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CmbndPrspctsLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus [Line Items]",
        "terseLabel": "Combined Prospectus:"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CmbndPrspctsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CmbndPrspctsTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus [Table]",
        "terseLabel": "Combined Prospectus Table"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CombinedProspectusTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CombinedProspectusTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus Table [N/A]",
        "terseLabel": "Combined Prospectus Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CshPdByRegistrantInTx": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CshPdByRegistrantInTx",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Paid by Registrant in Transaction",
        "terseLabel": "Cash Consideration Paid",
        "documentation": "Amount of cash consideration paid by registrant in connection with the exchange or other transaction being registered (in a 457(f) calculation)."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "ffd_CshRcvdByRegistrantInTx": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CshRcvdByRegistrantInTx",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Received by Registrant in Transaction",
        "terseLabel": "Cash Consideration Received",
        "documentation": "Amount of cash consideration received by registrant in connection with the exchange or other transaction being registered (in a 457(f) calculation)."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "ffd_FeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Amount",
        "terseLabel": "Amount of Registration Fee",
        "documentation": "Total amount of registration fee (amount due after offsets)."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeExhibitTp": {
     "xbrltype": "feeExhibitTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeExhibitTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Exhibit Type",
        "terseLabel": "Fee Exhibit Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_FeeIntrstAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeIntrstAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Interest Amount",
        "terseLabel": "Interest Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Note",
        "terseLabel": "Fee Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeNoteMaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeNoteMaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Note Maximum Aggregate Offering Price",
        "terseLabel": "Fee Note MAOP"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeRate",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Rate",
        "terseLabel": "Fee Rate",
        "documentation": "The rate per dollar of fees that public companies and other issuers pay to register their securities with the Commission."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeesOthrRuleFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeesOthrRuleFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees, Other Rule [Flag]",
        "terseLabel": "Other Rule",
        "documentation": "Checkbox indicating whether filer is using a rule other than 457(a), 457(o), or 457(f) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeesSummaryLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeesSummaryLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees Summary [Line Items]",
        "terseLabel": "Fees Summary:"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FnlPrspctsFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FnlPrspctsFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Final Prospectus [Flag]",
        "terseLabel": "Final Prospectus"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FormTp": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Form Type",
        "terseLabel": "Form Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_GnlInstrIIhiFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "GnlInstrIIhiFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General Instruction II.H,I [Flag]",
        "terseLabel": "General Instruction II.H,I"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrCity": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrCity",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, City",
        "terseLabel": "City"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStatOrCtryCd": {
     "xbrltype": "stateOrCountryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrStatOrCtryCd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, State or Country Code",
        "terseLabel": "State or Country Code"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStrt1": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrStrt1",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Street 1",
        "terseLabel": "Street 1"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStrt2": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrStrt2",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Street 2",
        "terseLabel": "Street 2"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrZipCd": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrZipCd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Zip Code",
        "terseLabel": "Zip Code"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrNm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrNm",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Name",
        "terseLabel": "Issuer Name"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_MaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "MaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Aggregate Offering Price",
        "terseLabel": "Maximum Aggregate Offering Price",
        "documentation": "The maximum aggregate offering price for the offering that is being registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_MaxOfferingPricPerScty": {
     "xbrltype": "nonNegativeDecimal4lItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "MaxOfferingPricPerScty",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Offering Price per Security",
        "terseLabel": "Proposed Maximum Offering Price per Unit",
        "documentation": "The maximum offering price per share/unit being registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NetFeeAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NetFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Fee Amount",
        "terseLabel": "Net Fee"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NetSalesAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NetSalesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Sales Amount",
        "terseLabel": "Net Sales"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NrrtvDsclsr": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NrrtvDsclsr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure",
        "terseLabel": "Narrative Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NrrtvMaxAggtAmt": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NrrtvMaxAggtAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure, Maximum Aggregate Offering Amount",
        "terseLabel": "Narrative - Max Aggregate Offering Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NrrtvMaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NrrtvMaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure, Maximum Aggregate Offering Price",
        "terseLabel": "Narrative - Max Aggregate Offering Price"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Axis]",
        "terseLabel": "Offering",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different security offerings on a single fee bearing submission."
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Line Items]",
        "terseLabel": "Offering:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Note",
        "terseLabel": "Offering Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingSctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingSctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Security Title",
        "terseLabel": "Security Class Title",
        "documentation": "The title of the class of securities being registered (for each class being registered)."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingSctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingSctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Security Type",
        "terseLabel": "Security Type",
        "documentation": "Type of securities: \"Asset-backed Securities\", \"ADRs/ADSs\", \"Debt\", \"Debt Convertible into Equity\", \"Equity\", \"Face Amount Certificates\", \"Limited Partnership Interests\", \"Mortgage Backed Securities\", \"Non-Convertible Debt\", \"Unallocated (Universal) Shelf\", \"Exchange Traded Vehicle Securities\", \"Other\""
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Table]",
        "terseLabel": "Offering:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Table [N/A]",
        "terseLabel": "Offering Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OffsetAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset [Axis]",
        "terseLabel": "Offset",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different offsets as applied to a fee bearing submission."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetClmInitlFilgDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetClmInitlFilgDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claim Initial Filing Date",
        "terseLabel": "Initial Filing Date",
        "documentation": "The initial filing date of the earlier registration statement with which the earlier (offsetting) fee was paid for a claimed offset. If the offset fee was paid with an amendment, do not provide the amendment date under this element; instead, provide the date of the initial filing (i.e. the \"parent\" filing) ."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetClmdAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetClmdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claimed Amount",
        "terseLabel": "Fee Offset Claimed",
        "documentation": "The amount of offsetting fees being claimed."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetClmdInd": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetClmdInd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claimed Indicator",
        "terseLabel": "Offset Claimed"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetExpltnForClmdAmt": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetExpltnForClmdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Explanation for Claimed Amount",
        "terseLabel": "Explanation for Claimed Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetLineItems",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset:",
        "label": "Offset [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Note",
        "terseLabel": "Offset Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetPrrFeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Fee Amount",
        "terseLabel": "Fee Paid with Fee Offset Source",
        "documentation": "The fee previously paid from which an offset is being derived."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior File Number",
        "terseLabel": "File Number",
        "documentation": "The EDGAR File Number of the earlier registration statement with which the earlier (offsetting) fee was paid. If the offset filing for the offset has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrFilerNm": {
     "xbrltype": "filerNameItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFilerNm",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Filer Name",
        "terseLabel": "Registrant or Filer Name",
        "documentation": "The name of the registrant that filed the earlier registration statement with which the earlier (offsetting) fee was paid."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Form Type",
        "terseLabel": "Form or Filing Type",
        "documentation": "The Form Type of the offset filing."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrNbOfUnsoldScties": {
     "xbrltype": "nonNegativeIntegerItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrNbOfUnsoldScties",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Unsold Number of Securities",
        "terseLabel": "Unsold Securities Associated with Fee Offset Claimed",
        "documentation": "The number of unsold securities registered on the prior registration statement that are associated with the claimed offset."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrSctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrSctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Security Title",
        "terseLabel": "Security Title Associated with Fee Offset Claimed",
        "documentation": "The title of the class of securities from which offset fees were derived."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrSctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrSctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Security Type",
        "terseLabel": "Security Type Associated with Fee Offset Claimed",
        "documentation": "Type of securities: \"Asset-backed Securities\", \"ADRs/ADSs\", \"Debt\", \"Debt Convertible into Equity\", \"Equity\", \"Face Amount Certificates\", \"Limited Partnership Interests\", \"Mortgage Backed Securities\", \"Non-Convertible Debt\", \"Unallocated (Universal) Shelf\", \"Exchange Traded Vehicle Securities\", \"Other\""
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrUnsoldOfferingAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrUnsoldOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Unsold Offering Amount",
        "terseLabel": "Unsold Aggregate Offering Amount Associated with Fee Offset Claimed",
        "documentation": "The aggregate offering amount of unsold securities registered on the prior registration statement that are associated with the claimed offset."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetSrcFilgDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetSrcFilgDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Source Filing Date",
        "terseLabel": "Filing Date",
        "documentation": "The filing date of the earlier registration statement with which the earlier (offsetting) fee was paid in an offset."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset Payment:",
        "label": "Offset [Table]"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Table [N/A]",
        "terseLabel": "Offset Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_PrevslyPdFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "PrevslyPdFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Previously Paid [Flag]",
        "terseLabel": "Fee Previously Paid"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_RegnFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "RegnFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration File Number",
        "terseLabel": "Registration File Number"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_RptgFsclYrEndDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "RptgFsclYrEndDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reporting Fiscal Year End Date",
        "terseLabel": "Reporting FY End Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule011Flg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule011Flg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 0-11 [Flag]",
        "terseLabel": "Rule 0-11"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule011a2OffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule011a2OffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 0-11(a)(2) Offset",
        "label": "Rule 0-11(a)(2) Offset [Flag]"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule415a6Flg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule415a6Flg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 415(a)(6) [Flag]",
        "terseLabel": "Rule 415(a)(6)",
        "documentation": "Checkbox indicating whether filer is claiming a 415(a)(6) carryforward."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_Rule429AggtOfferingAmt": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429AggtOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Aggregate Offering Amount",
        "terseLabel": "Maximum Aggregate Offering Price of Securities Previously Registered",
        "documentation": "The maximum aggregate offering amount of unsold securities registered on the prior registration statement that are carried forward under Rule 429. Only applicable if 457(o) was used in the fee calculation for the prior registration statement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429CmbndPrspctsFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429CmbndPrspctsFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Combined Prospectus [Flag]",
        "terseLabel": "Rule 429",
        "documentation": "Checkbox indicating whether filer is using a combined prospectus under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429EarlierFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429EarlierFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Earlier File Number",
        "terseLabel": "File Number",
        "documentation": "The Securities Act File Number of the earlier effective registration statement(s) from which securities may be offered and sold using the combined prospectus pursuant to Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429EarlierFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429EarlierFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Earlier Form Type",
        "terseLabel": "Form Type",
        "documentation": "The Form Type of the earlier registration statement from which unsold securities are carried forward under Rule 429. This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., \"Form S-3\" in the human-readable and \"S-3ASR\" in the XBRL)."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429InitlFctvDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429InitlFctvDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Initial Effective Date",
        "terseLabel": "Initial Effective Date",
        "documentation": "The filing date of the earlier registration statement from which unsold securities are carried forward under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429NbOfUnsoldScties": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429NbOfUnsoldScties",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Number Of Unsold Securities",
        "terseLabel": "Amount of Securities Previously Registered",
        "documentation": "The number of securities registered on the prior registration statement that are carried forward under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429PrspctsNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429PrspctsNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Prospectus Note",
        "terseLabel": "Combined Prospectus Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Rule429SctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429SctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Security Title",
        "terseLabel": "Security Class Title"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Rule429SctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429SctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Security Type",
        "terseLabel": "Security Type"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Rule457aFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457aFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(a) [Flag]",
        "terseLabel": "Rule 457(a)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(a) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ffd_Rule457bOffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457bOffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(b) Offset [Flag]",
        "terseLabel": "Rule 457(b) Offset",
        "documentation": "Checkbox indicating whether filer is claiming an offset under Rule 457(b) or 0-11(a)(2)."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ffd_Rule457fFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457fFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(f) [Flag]",
        "terseLabel": "Rule 457(f)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(f) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ffd_Rule457oFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457oFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(o) [Flag]",
        "terseLabel": "Rule 457(o)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(o) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ffd_Rule457pOffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457pOffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(p) Offset [Flag]",
        "terseLabel": "Rule 457(p) Offset",
        "documentation": "Checkbox indicating whether filer is claiming an offset under Rule 457(p)."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "ffd_Rule457rFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457rFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(r) [Flag]",
        "terseLabel": "Rule 457(r)"
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "ffd_Rule457sFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457sFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(s) Flag",
        "terseLabel": "Rule 457(s)"
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "ffd_Rule457uFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457uFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(u) [Flag]",
        "terseLabel": "Rule 457(u)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(u) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "ffd_Scties424iAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Scties424iAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Axis]",
        "terseLabel": "Securities, 424I"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Scties424iLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Scties424iLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Line Items]",
        "terseLabel": "Securities, 424I:"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Scties424iTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Scties424iTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Table]",
        "terseLabel": "Securities, 424I Table"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Securities424iTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Securities424iNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities 424I [N/A]",
        "terseLabel": "Securities 424I N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_SubmissionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "SubmissionLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Submission [Line Items]",
        "terseLabel": "Items"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_SubmissnTp": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "SubmissnTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Submission Type",
        "terseLabel": "Submission Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TermntnCmpltnWdrwl": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TermntnCmpltnWdrwl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination / Completion / Withdrawal Statement",
        "terseLabel": "Termination / Withdrawal Statement"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TtlFeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fee Amount",
        "terseLabel": "Total Fee Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlFeeAndIntrstAmt": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlFeeAndIntrstAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fee and Interest Amount",
        "terseLabel": "Total Fee and Interest Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlOfferingAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Offering Amount",
        "terseLabel": "Total Offering"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlOffsetAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlOffsetAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Offset Amount",
        "terseLabel": "Total Offset Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlPrevslyPdAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlPrevslyPdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Previously Paid Amount",
        "terseLabel": "Previously Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlTxValtn": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlTxValtn",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Transaction Valuation",
        "terseLabel": "Total Transaction Valuation"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TxValtn": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TxValtn",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction Valuation",
        "terseLabel": "Transaction Valuation"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_ValSctiesRcvd": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "ValSctiesRcvd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of Securities Received",
        "terseLabel": "Value of Securities Received",
        "documentation": "Value of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form)"
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ffd_ValSctiesRcvdPerShr": {
     "xbrltype": "nonNegativeDecimal4lItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "ValSctiesRcvdPerShr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of Securities Received, Per Share",
        "terseLabel": "Value of Securities Received, Per Share",
        "documentation": "Value per share of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form). This is included in the explanation of 457(f) fee calculation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "415",
   "Subsection": "a"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "429"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "f"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "o"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "p"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "r"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "s"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "u"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Subsection": "f",
   "Section": "457"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001104659-25-100854-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-25-100854-xbrl.zip
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M@H@1TVFEWJ@T6BDD%4'-#"+XNSKV'M?B.:N<Z!&>!8EG.<7AH2$2,0I6I!^
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MJA;GHH;_/Y'>_P%02P$"% ,4    " #6@U1;Y!NB*](,  "A9   '0
M        @ $     =&TR-3(Y,#(P9#%?97@M9FEL:6YG9F5E<RYH=&U02P4&
2      $  0!+    #0T

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>tm2529020d1_ex-filingfees_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ffd="http://xbrl.sec.gov/ffd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef
      xlink:href="https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd"
      xlink:type="simple"/>
    <context id="rc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
        </entity>
        <period>
            <startDate>2025-10-17</startDate>
            <endDate>2025-10-17</endDate>
        </period>
    </context>
    <context id="offrl_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>1</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-17</startDate>
            <endDate>2025-10-17</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <ffd:FormTp contextRef="rc" id="ixv-331">S-1</ffd:FormTp>
    <ffd:SubmissnTp contextRef="rc" id="ixv-332">S-1</ffd:SubmissnTp>
    <ffd:FeeExhibitTp contextRef="rc" id="ixv-333">EX-FILING FEES</ffd:FeeExhibitTp>
    <dei:EntityCentralIndexKey contextRef="rc" id="ixv-334">0001279704</dei:EntityCentralIndexKey>
    <dei:EntityRegistrantName contextRef="rc" id="ixv-335">Cellectar Biosciences, Inc.</dei:EntityRegistrantName>
    <ffd:OfferingTableNa contextRef="rc" id="hiddenrcOfferingTableNa" xsi:nil="true"/>
    <ffd:OffsetTableNa contextRef="rc" id="hiddenrcOffsetTableNa">N/A</ffd:OffsetTableNa>
    <ffd:CombinedProspectusTableNa contextRef="rc" id="hiddenrcCombinedProspectusTableNa">N/A</ffd:CombinedProspectusTableNa>
    <ffd:FormTp contextRef="rc" id="ixv-363">S-1</ffd:FormTp>
    <dei:EntityRegistrantName contextRef="rc" id="ixv-364">Cellectar Biosciences, Inc.</dei:EntityRegistrantName>
    <ffd:PrevslyPdFlg contextRef="offrl_1" id="ixv-365">false</ffd:PrevslyPdFlg>
    <ffd:OfferingSctyTp contextRef="offrl_1" id="ixv-366">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="offrl_1" id="ixv-367">Common Stock, par value $0.00001 per share</ffd:OfferingSctyTitl>
    <ffd:Rule457aFlg contextRef="offrl_1" id="ixv-368">true</ffd:Rule457aFlg>
    <ffd:AmtSctiesRegd
      contextRef="offrl_1"
      decimals="0"
      id="ixv-369"
      unitRef="Shares">2096188</ffd:AmtSctiesRegd>
    <ffd:MaxOfferingPricPerScty
      contextRef="offrl_1"
      decimals="INF"
      id="ixv-370"
      unitRef="USD">4.86</ffd:MaxOfferingPricPerScty>
    <ffd:MaxAggtOfferingPric
      contextRef="offrl_1"
      decimals="INF"
      id="ixv-371"
      unitRef="USD">10187473.68</ffd:MaxAggtOfferingPric>
    <ffd:FeeRate
      contextRef="offrl_1"
      decimals="INF"
      id="ixv-372"
      unitRef="pure">0.0001381</ffd:FeeRate>
    <ffd:FeeAmt
      contextRef="offrl_1"
      decimals="INF"
      id="ixv-373"
      unitRef="USD">1406.89</ffd:FeeAmt>
    <ffd:TtlOfferingAmt contextRef="rc" decimals="INF" id="ixv-374" unitRef="USD">10187473.68</ffd:TtlOfferingAmt>
    <ffd:TtlFeeAmt contextRef="rc" decimals="INF" id="ixv-375" unitRef="USD">1406.89</ffd:TtlFeeAmt>
    <ffd:TtlPrevslyPdAmt contextRef="rc" decimals="INF" id="ixv-376" unitRef="USD">0.00</ffd:TtlPrevslyPdAmt>
    <ffd:TtlOffsetAmt contextRef="rc" decimals="INF" id="ixv-377" unitRef="USD">0.00</ffd:TtlOffsetAmt>
    <ffd:NetFeeAmt contextRef="rc" decimals="INF" id="ixv-378" unitRef="USD">1406.89</ffd:NetFeeAmt>
    <ffd:OfferingNote contextRef="offrl_1" id="ixv-379">(1) Consists of an aggregate of 2,096,188 shares of the registrant's common stock issuable upon the exercise of warrants, all of which were sold to the selling stockholders in private placements. Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), the shares of common stock being registered hereunder include such indeterminate number of shares of common stock as may be issuable with respect to the shares of common stock being registered hereunder as a result of stock splits, stock dividends or similar transactions.

(2) Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(c) of the Securities Act. The offering price per share and aggregate offering price are based upon the average of the high and low prices for the Registrant's Common Stock as reported on the Nasdaq Global Select Market on October 16, 2025, a date within five business days prior to the filing of this Registration Statement. </ffd:OfferingNote>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
